UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
Filed
by the Registrant [X]
|
Filed
by a Party other than the Registrant [ ]
|
Check
the appropriate box:
|
[ ]
|
Preliminary
Proxy Statement
|
[ ]
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
[X]
|
Definitive
Proxy Statement
|
[ ]
|
Definitive
Additional Materials
|
[ ]
|
Soliciting
Material Pursuant to §240.14a-12
|
INSPIREMD,
INC.
|
(Name
of Registrant as Specified In Its Charter)
|
|
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment
of Filing Fee (Check the appropriate box):
|
[X]
|
No
fee required.
|
[ ]
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
[ ]
|
Fee
paid previously with preliminary materials.
|
|
|
[ ]
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11 and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date
of its filing.
|
|
|
|
(1)
|
Amount
Previously Paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
(4)
|
Date
Filed:
|
|
|
|
InspireMD,
Inc.
4
Menorat Hamaor St.
Tel
Aviv, Israel 6744832
Telephone:
(888) 776-6804
September
11, 2018
Dear
Stockholder:
You
are cordially invited to attend the annual meeting of stockholders of InspireMD, Inc. to be held at 11:30 a.m., New York time,
on October 24, 2018, at the offices of Haynes and Boone, LLP, located at 30 Rockefeller Plaza, 26th Floor, New York, New York
10112.
Please
note that in order to gain admission to the site of our annual meeting, all attendees will need to present a photo identification
card and have their name previously provided to building security. As such, in order to facilitate your attendance at the annual
meeting, we strongly encourage you to advise Craig Shore by email at craigs@inspiremd.com or phone at (888) 776-6804 if you plan
to attend the meeting prior to 5:00 p.m., New York time, on October 23, 2018, so that we can timely provide your name to building
security. In the event that you do not advise us ahead of time that you will be attending the annual meeting, we encourage you
to arrive at the meeting no later than 11:00 a.m., New York time, in order to ensure that you are able to pass through security
prior to the start of the meeting.
Your
vote is very important, regardless of the number of shares of our voting securities that you own. I encourage you to vote by telephone,
over the Internet, or by marking, signing, dating and returning your proxy card so that your shares will be represented and voted
at the annual meeting, whether or not you plan to attend. If you attend the annual meeting, you will, of course, have the right
to revoke the proxy and vote your shares in person.
If
your shares are held in the name of a broker, trust, bank or other intermediary, and you receive notice of the annual meeting
through your broker or through another intermediary, please vote or return the materials in accordance with the instructions provided
to you by such broker or other intermediary or contact your broker directly in order to obtain a proxy issued to you by your intermediary
holder to attend the meeting and vote in person. Failure to do so may result in your shares not being eligible to be voted by
proxy at the meeting.
On
behalf of the board of directors, I urge you to submit your proxy as soon as possible, even if you currently plan to attend the
meeting in person.
Thank
you for your support of our company. I look forward to seeing you at the annual meeting.
|
Sincerely,
|
|
|
|
/s/
Paul Stuka
|
|
Paul
Stuka
|
|
Chairman
|
IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR
THE STOCKHOLDER MEETING TO BE HELD ON
October 24, 2018
:
|
|
Our
official Notice of Annual Meeting of Stockholders, Proxy Statement, Proxy Card and
2017 Annual Report to Stockholders are available at:
|
|
www.proxyvote.com
|
InspireMD,
Inc.
4
Menorat Hamaor St.
Tel
Aviv, Israel 6744832
Telephone:
(888) 776-6804
NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS
To
Be Held October 24, 2018
The
2018 Annual Meeting of Stockholders of InspireMD, Inc., a Delaware corporation (the “Company”), will be held at 11:30
a.m., New York time, on October 24, 2018, at the offices of Haynes and Boone, LLP, located at 30 Rockefeller Plaza, 26th Floor,
New York, New York 10112. We will consider and act on the following items of business at the Annual Meeting:
|
(1)
|
Election
of one Class 1 director to serve on our board of directors for a term of three years or until his successor is elected and
qualified, for which Paul Stuka is the nominee.
|
|
|
|
|
(2)
|
Approval
of the Fourth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to (i) increase the number of shares of common
stock of the Company available for issuance pursuant to awards under such plan by 8,900,000 shares, to a total of 8,919,737
shares of common stock, and (ii) remove the cap on the number of shares of common stock with respect to which stock options
or stock appreciation rights may be granted to certain executive officers of the Company during any calendar year (the “Plan
Amendment Proposal”)
|
|
|
|
|
(3)
|
An
advisory vote on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying
this notice.
|
|
|
|
|
(4)
|
An
advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.
|
|
|
|
|
(5)
|
Ratification
of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International
Limited, as our independent registered public accounting firm for the year ending December 31, 2018.
|
|
|
|
|
(6)
|
Such
other business as may properly come before the Annual Meeting.
|
Stockholders
are referred to the Proxy Statement accompanying this notice for more detailed information with respect to the matters to be considered
at the Annual Meeting. After careful consideration,
the board of directors recommends a vote FOR the election of the nominee
as Class 1 director (Proposal 1), FOR the Plan Amendment Proposal (Proposal 2), FOR the approval of the executive compensation
as disclosed in the Proxy Statement accompanying this notice (Proposal 3), FOR holding an advisory vote every three years regarding
approval of the compensation of the Company’s named executive officers (Proposal 4), and, and FOR the ratification of the
appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited,
as our independent registered public accounting firm for the year ending December 31, 2018 (Proposal 5)
.
The
board of directors has fixed the close of business on September 10, 2018, as the record date (the “Record Date”).
Only holders of record of shares of our common stock are entitled to receive notice of the Annual Meeting and to vote at the Annual
Meeting or at any postponement(s) or adjournment(s) of the Annual Meeting. A complete list of registered stockholders entitled
to vote at the Annual Meeting will be available for inspection at the office of the Company during regular business hours for
the 10 calendar days prior to and during the Annual Meeting.
Please
note that in order to gain admission to the site of our annual meeting, all attendees will need to present a photo identification
card and have their name previously provided to building security. As such, in order to facilitate your attendance at the annual
meeting, we strongly encourage you to advise Craig Shore by email at craigs@inspiremd.com or phone at 972-3-6917691 if you plan
to attend the meeting prior to 5:00 p.m., New York time, on October 23, 2018, so that we can timely provide your name to building
security. In the event that you do not advise us ahead of time that you will be attending the annual meeting, we encourage you
to arrive at the meeting no later than 11:00 a.m., New York time, in order to ensure that you are able to pass through security
prior to the start of the meeting.
YOUR
VOTE AND PARTICIPATION IN THE COMPANY’S AFFAIRS ARE IMPORTANT.
If
your shares are registered in your name
, even if you plan to attend the Annual Meeting or any postponement or adjournment
of the Annual Meeting in person, we request that you vote by telephone, over the Internet, complete, sign and mail your proxy
card to ensure that your shares will be represented at the Annual Meeting.
If
your shares are held in the name of a broker, trust, bank or other intermediary
, and you receive notice of the Annual Meeting
through your broker or through another intermediary, please vote or complete and return the materials in accordance with the instructions
provided to you by such broker or other intermediary or contact your broker directly in order to obtain a proxy issued to you
by your intermediary holder to attend the Annual Meeting and vote in person. Failure to do so may result in your shares not being
eligible to be voted by proxy at the Annual Meeting.
|
By
Order of The Board of Directors,
|
|
|
|
/s/
Paul Stuka
|
|
Paul
Stuka
|
|
Chairman
|
|
|
September
11, 2018
|
|
Table
of Contents
InspireMD,
Inc.
4
Menorat Hamaor St.
Tel
Aviv, Israel 6744832
Telephone:
(888) 776-6804
PROXY
STATEMENT
FOR
ANNUAL
MEETING OF STOCKHOLDERS
To
Be Held October 24, 2018
Unless
the context otherwise requires, references in this Proxy Statement to “we,” “us,” “our,” the
“Company,” or “InspireMD” refer to InspireMD, Inc., a Delaware corporation, and its direct and indirect
subsidiaries. In addition, unless the context otherwise requires, references to “stockholders” are to the holders
of our voting securities, which consist of our common stock, par value $0.0001 per share.
All
amounts set forth in this proxy statement are adjusted for the 1-for-35 reverse stock split of our common stock that occurred
on February 7, 2018.
The
accompanying proxy is solicited by the board of directors on behalf of InspireMD, Inc., a Delaware corporation, to be voted at
the annual meeting of stockholders of the Company (the “Annual Meeting”) to be held on October 24, 2018, at the time
and place and for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders (the “Notice”)
and at any adjournment(s) or postponement(s) of the Annual Meeting. This Proxy Statement and accompanying form of proxy are expected
to be first sent or given to stockholders on or about September 13, 2018.
The
executive office of the Company is located at, and the mailing address of the Company is, 4 Menorat Hamaor St., Tel Aviv, Israel
6744832.
IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY
MATERIALS
FOR
THE STOCKHOLDER MEETING TO BE HELD ON
October 24, 2018
:
Our
official Notice of Annual Meeting of Stockholders, Proxy Statement, Proxy Card and
2017
Annual Report to Stockholders are available at:
www.proxyvote.com
ABOUT
THE ANNUAL MEETING
What
is a proxy?
A
proxy is another person that you legally designate to vote your stock. If you designate someone as your proxy in a written document,
that document is also called a “proxy” or a “proxy card.” If you are a street name holder, you must obtain
a proxy from your broker or intermediary in order to vote your shares in person at the Annual Meeting.
What
is a proxy statement?
A
proxy statement is a document that regulations of the Securities and Exchange Commission (the “SEC”) require that
we give to you when we ask you to sign a proxy card to vote your stock at the Annual Meeting.
What
is the purpose of the Annual Meeting?
At
our Annual Meeting, stockholders will act upon the matters outlined in the Notice, including the following:
|
(1)
|
Election
of one Class 1 director to serve on our board of directors for a term of three years or until his successor is elected and
qualified, for which Paul Stuka is the nominee.
|
|
|
|
|
(2)
|
Approval
of the Fourth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “2013 Plan”) to (i) increase
the number of shares of common stock of the Company available for issuance pursuant to awards under such plan by 8,900,000
shares, to a total of 8,919,737 shares of common stock, and (ii) remove the cap on the number of shares of common stock with
respect to which stock options or stock appreciation rights may be granted to certain executive officers of the Company during
any calendar year (the “Plan Amendment Proposal”)
|
|
|
|
|
(3)
|
An
advisory vote on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
|
|
|
|
|
(4)
|
An
advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.
|
|
|
|
|
(5)
|
Ratification
of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International
Limited, as our independent registered public accounting firm for the year ending December 31, 2018.
|
|
|
|
|
(6)
|
Such
other business as may properly come before the Annual Meeting.
|
What
is “householding” and how does it affect me?
With
respect to eligible stockholders who share a single address, we may send only one Proxy Statement to that address unless we receive
instructions to the contrary from any stockholder at that address. This practice, known as “householding,” is designed
to reduce our printing and postage costs. However, if a stockholder of record residing at such address wishes to receive a separate
notice or proxy statement in the future, he or she may contact InspireMD, Inc., 4 Menorat Hamaor St., Tel Aviv, Israel 6744832,
Attn: Investor Relations or call (888) 776-6804 and ask for Investor Relations. Eligible stockholders of record receiving multiple
copies of our Notice or Proxy Statement can request householding by contacting us in the same manner. Stockholders who own shares
through a bank, broker or other intermediary can request householding by contacting the intermediary.
We
hereby undertake to deliver promptly, upon written or oral request, a copy of the Notice or Proxy Statement to a stockholder at
a shared address to which a single copy of the document was delivered. Requests should be directed to Investor Relations at the
address or phone number set forth above.
What
should I do if I receive more than one set of voting materials?
You
may receive more than one set of voting materials, including multiple copies of the Notice or this Proxy Statement and multiple
proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you may receive
a separate notice or voting instruction card for each brokerage account in which you hold shares. Similarly, if you are a stockholder
of record and hold shares in a brokerage account, you will receive a Notice for shares held in your name and a notice or voting
instruction card for shares held in street name. Please follow the directions provided in the Notice and each additional notice
or voting instruction card you receive to ensure that all your shares are voted.
What
is the record date and what does it mean?
The
record date to determine the stockholders entitled to notice of and to vote at the Annual Meeting is the close of business on
September 11, 2018 (the “Record Date”). The Record Date is established by the board of directors as required by Delaware
law. On the Record Date, 23,784,784 of common stock were issued and outstanding.
Who
is entitled to vote at the Annual Meeting?
Holders
of common stock at the close of business on the Record Date may vote at the Annual Meeting.
What
are the voting rights of the stockholders?
On
each matter to be voted upon at the Annual Meeting, you have one vote for each share of common stock you own as of the Record
Date.
What
is the quorum requirement?
The
presence, in person or by proxy, of the holders of a majority of the shares of the stock entitled to vote at the Annual Meeting
is necessary to constitute a quorum to transact business. If a quorum is not present or represented at the Annual Meeting, the
stockholders entitled to vote at the Annual Meeting, present in person or by proxy, may adjourn the Annual Meeting from time to
time without notice or other announcement until a quorum is present or represented.
What
is the difference between a stockholder of record and a “street name” holder?
If
your shares are registered directly in your name with Action Stock Transfer Corporation, our stock transfer agent, you are considered
the stockholder of record with respect to those shares. The Notice has been sent directly to you by us.
If
your shares are held in a stock brokerage account or by a bank or other intermediary, the intermediary is considered the record
holder of those shares. You are considered the beneficial owner of those shares, and your shares are held in “street name.”
A notice or Proxy Statement and voting instruction card have been forwarded to you by your intermediary. As the beneficial owner,
you have the right to direct your intermediary concerning how to vote your shares by using the voting instructions they included
in the mailing or by following their instructions for voting.
What
is a broker non-vote?
A
broker non-vote occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the
broker does not have discretionary voting power with respect to that item and has not received voting instructions from the beneficial
owner. Your broker does not have discretionary authority to vote your shares with respect to the election of the nominee as Class
1 director (Proposal 1), the Plan Amendment Proposal (Proposal 2), the advisory vote on executive compensation (Proposal 3) or
the advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers
(Proposal 4) in the absence of specific instructions from you.
With
respect to the proposal to ratify the appointment of the independent registered public accounting firm (Proposal 5), your broker
will have the discretion to vote your shares and, therefore, will be able to vote your shares with respect to such proposal even
if you do not provide your broker with instructions on that proposal.
How
do I vote my shares?
Your
vote is very important to us and we hope that you will attend the Annual Meeting. However, whether or not you plan to attend the
Annual Meeting, please vote by proxy in accordance with the instructions on your proxy card or voting instruction card (from your
broker or other intermediary). There are three convenient ways of submitting your vote:
|
●
|
By
Telephone or Internet
- All record holders can vote by touchtone telephone from the United States using the toll free
telephone number on the proxy card, or over the Internet, using the procedures and instructions described on the proxy card.
“Street name” holders may vote by telephone or Internet if their bank, broker or other intermediary makes those
methods available, in which case the bank, broker or other intermediary will enclose the instructions with the proxy materials.
The telephone and Internet voting procedures are designed to authenticate stockholders’ identities, to allow stockholders
to vote their shares, and to confirm that their instructions have been recorded properly.
|
|
|
|
|
●
|
In
Person
- All record holders may vote in person at the Annual Meeting. “Street name” holders may vote in
person at the Annual Meeting if their bank, broker or other intermediary has furnished a legal proxy. If you are a “street
name” holder and would like to vote your shares by proxy, you will need to ask your bank, broker or other intermediary
to furnish you with an intermediary issued proxy. You will need to bring the intermediary issued proxy with you to the Annual
Meeting and hand it in with a signed ballot that will be provided to you at the Annual Meeting. You will not be able to vote
your shares without a intermediary issued proxy. Note that a broker letter that identifies you as a stockholder is not the
same as a intermediary issued proxy.
|
|
|
|
|
●
|
By
Written Proxy
- All record holders can vote by written proxy card, if they have requested to receive printed proxy
materials. If you are a “street name” holder and you request to receive printed proxy materials, you will receive
a written proxy card and a voting instruction card from your bank, broker or other intermediary.
|
The
board of directors has appointed Craig Shore, chief financial officer, chief administrative officer, treasurer and secretary,
and James Barry, Ph.D., president, chief executive officer and director, to serve as the proxies for the Annual Meeting.
If
you complete all of the proxy card except one or more of the voting instructions, then the designated proxies will vote your shares
as to which you provide no voting instructions in the manner described under “What if I do not specify how I want my shares
voted?” below. We do not anticipate that any other matters will come before the Annual Meeting, but if any other matters
properly come before the meeting, then the designated proxies will vote your shares in accordance with applicable law and their
judgment.
If
you hold your shares in “street name,” and complete the voting instruction card provided by your broker or other intermediary
except with respect to one or more of the voting instructions, then your broker may be unable to vote your shares with respect
to the proposal as to which you provide no voting instructions. See “What is a broker non-vote?” above.
Even
if you currently plan to attend the Annual Meeting, we recommend that you vote by telephone or Internet or return your proxy card
or voting instructions as described above so that your votes will be counted if you later decide not to attend the Annual Meeting
or are unable to attend.
Who
counts the votes?
All
votes will be tabulated by James Barry, Ph.D., the inspector of election appointed for the Annual Meeting. Each proposal will
be tabulated separately.
What
are my choices when voting?
In
the election of the nominee as Class 1 director (Proposal 1), stockholders may vote for the director nominee or may withhold their
votes to the director nominee. With respect to the advisory vote on the frequency of future advisory votes on the compensation
of the Company’s named executive officers (Proposal 4), stockholders may vote to choose an advisory vote on executive compensation
every one, two or three years or to abstain from voting on the proposal. With respect to the Plan Amendment Proposal (Proposal
2), the advisory vote on executive compensation (Proposal 3) and the ratification of the independent registered public accounting
firm (Proposal 5), stockholders may vote for the proposal, against the proposal, or abstain from voting on the proposal.
What
are the board of directors’ recommendations on how I should vote my shares?
The
board of directors recommends that you vote your shares as follows:
Proposal
1—
FOR
the election of the nominee as Class 1 director.
Proposal
2—
FOR
the Plan Amendment Proposal.
Proposal
3—
FOR
the approval of the executive compensation as disclosed in these materials.
Proposal
4—
FOR
an advisory vote on executive compensation every
three
years.
Proposal
5—
FOR
the ratification of the appointment of the independent registered public accounting firm.
What
if I do not specify how I want my shares voted?
If
you are a record holder who returns a completed proxy card that does not specify how you want to vote your shares on one or more
proposals, the proxies will vote your shares for each proposal as to which you provide no voting instructions, and such shares
will be voted in the following manner:
Proposal
1—
FOR
the election of the nominee as Class 1 director.
Proposal
2—
FOR
the Plan Amendment Proposal.
Proposal
3—
FOR
the approval of the executive compensation as disclosed in these materials.
Proposal
4—
FOR
an advisory vote on executive compensation every
three
years.
Proposal
5—
FOR
the ratification of the appointment of the independent registered public accounting firm.
If
you are a street name holder and do not provide voting instructions on one or more proposals, your bank, broker or other intermediary
may be unable to vote those shares. See “What is a broker non-vote?” above.
Can
I change my vote?
Yes.
If you are a record holder, you may revoke your proxy at any time by any of the following means:
|
●
|
Attending
the Annual Meeting and voting in person. Your attendance at the Annual Meeting will not by itself revoke a proxy. You must
vote your shares by ballot at the Annual Meeting to revoke your proxy.
|
|
|
|
|
●
|
Voting
again by telephone or over the Internet (only your latest telephone or Internet vote submitted prior to the Annual Meeting
will be counted).
|
|
●
|
If
you requested and received written proxy materials, completing and submitting a new valid proxy bearing a later date.
|
|
|
|
|
●
|
Giving
written notice of revocation to the Company addressed to Craig Shore, chief financial officer, chief administrative officer,
treasurer and secretary, at the Company’s address above, which notice must be received before noon, New York time on
October 23, 2018.
|
If
you are a street name holder, your bank, broker or other intermediary should provide instructions explaining how you may change
or revoke your voting instructions.
What
percentage of the vote is required to approve each proposal?
Since
there is only one nominee for Class 1 director this year, assuming the presence of a quorum, the director nominee will be elected
as a Class 1 director if he receives at least one “FOR” vote (Proposal 1).
Pursuant
to Section 711 of the NYSE MKT Company Guide, the Plan Amendment Proposal (Proposal 2) will require approval by a majority of
votes cast, including abstentions.
Assuming
the presence of a quorum, the approval of the executive compensation (Proposal 3), and the ratification of the independent registered
public accounting firm (Proposal 5) will require the affirmative vote of the holders of a majority of the shares of our common
stock represented in person or by proxy at the Annual Meeting entitled to vote on such proposal that voted for or against such
proposal. For the advisory vote on how frequently our stockholders should vote on the compensation of our named executive officers
in (Proposal 4), the number of years (1, 2 or 3) that receives the highest number of votes will be deemed to be preferred by our
stockholders. Please note that the vote on executive compensation (Proposal 3) and the vote on the frequency of future advisory
votes on the compensation of the Company’s named executive officers (Proposal 4) are non-binding advisory votes.
How
are abstentions and broker non-votes treated?
Abstentions
are included in the determination of the number of shares present at the Annual Meeting for determining a quorum at the meeting.
Abstentions will have no effect with respect to the election of the nominee as Class 1 director (Proposal 1), the advisory vote
on executive compensation (Proposal 3), the advisory vote on the frequency of future advisory votes on the compensation of the
Company’s named executive officers (Proposal 4) or the ratification of the independent registered public accounting firm
(Proposal 5). Abstentions will have the same effect as a vote against the Plan Amendment Proposal (Proposal 2).
Broker
non-votes are included in the determination of the number of shares present at the Annual Meeting for determining a quorum at
the meeting. Broker non-votes will have no effect upon the election of the nominee as Class 1 director (Proposal 1), the approval
of the Plan Amendment (Proposal 2), the advisory vote on executive compensation (Proposal 3), and the advisory vote on the frequency
of future advisory votes on the compensation of the Company’s named executive officers (Proposal 4). With respect to the
proposal to ratify the appointment of the independent registered public accounting firm (Proposal 5), broker-non-votes are not
applicable because such proposal is considered a routine matter and therefore a broker holding shares for a beneficial owner will
have discretionary authority to vote those shares for such proposal in the absence of voting instructions from the beneficial
owner.
Do
I have any dissenters’ or appraisal rights with respect to any of the matters to be voted on at the Annual Meeting?
No.
None of our stockholders has any dissenters’ or appraisal rights with respect to the matters to be voted on at the Annual
Meeting.
When
will the next stockholder advisory vote on executive compensation occur?
At
our 2012 Annual Meeting of stockholders, we submitted to stockholders an advisory vote on whether an advisory vote on executive
compensation should be held every one, two or three years. “Three years” was the frequency that received the highest
number of votes. In light of such outcome, we held an advisory vote on executive compensation every three years (including this
year). As further described in “Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation,”
the board of directors is asking the Company’s stockholders in to vote at the Annual Meeting on a proposal regarding the
frequency of the vote on future Say-on-Pay proposals as required by Section 14A. Subject to adoption by the board of directors
of a different frequency for an advisory vote on executive compensation in accordance with the recommendation of the Company’s
stockholders pursuant to “Proposal No. 4 - Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation”
or otherwise, we currently expects to hold future advisory votes on executive compensation every three years, and the next “say-on-pay”
vote is expected to occur at the annual meeting of our stockholders in 2021.
What
are the solicitation expenses and who pays the cost of this proxy solicitation?
Our
board of directors is asking for your proxy and we will pay all of the costs of asking for stockholder proxies. We will reimburse
brokerage houses and other custodians, intermediaries and fiduciaries for their reasonable out-of-pocket expenses for forwarding
solicitation material to the beneficial owners of common stock and collecting voting instructions. We may use officers and employees
of the Company to ask for proxies, as described below. In addition, we have retained Kingsdale Advisors (“Kingsdale”)
to assist in the solicitation of proxies for a fee of $8,500 plus telephone solicitation fees and reimbursement of expenses.
Is
this Proxy Statement the only way that proxies are being solicited?
No.
In addition to the solicitation of proxies by use of the mail, officers and employees of the Company, as well as Kingsdale, the
proxy solicitation firm hired by the Company, may solicit the return of proxies, either by mail, telephone, fax, e-mail or through
personal contact. These officers and employees will not receive additional compensation for their efforts but will be reimbursed
for out-of-pocket expenses. The fees of Kingsdale as well as the reimbursement of expenses of Kingsdale will be borne by us. Brokerage
houses and other custodians, intermediaries and fiduciaries, in connection with shares of the common stock registered in their
names, will be requested to forward solicitation material to the beneficial owners of shares of common stock.
Are
there any other matters to be acted upon at the Annual Meeting?
Management
does not intend to present any business at the Annual Meeting for a vote other than the matters set forth in the Notice and has
no information that others will do so. If other matters requiring a vote of the stockholders properly come before the Annual Meeting,
it is the intention of the persons named in the accompanying form of proxy to vote the shares represented by the proxies held
by them in accordance with applicable law and their judgment on such matters.
Where
can I find voting results?
The
Company expects to publish the voting results in a Current Report on Form 8-K, which it expects to file with the SEC within four
business days following the Annual Meeting.
Who
can help answer my questions?
The
information provided above in this “Question and Answer” format is for your convenience only and is merely a summary
of the information contained in this Proxy Statement. We urge you to carefully read this entire Proxy Statement, including the
documents we refer to in this Proxy Statement. If you have any questions, or need additional material, please feel free to contact
the firm assisting us in the solicitation of proxies, Kingsdale. Banks and brokers and shareholders may call Kingsdale at 1-888-518-1561
(North American toll free number) or 416-867-2272 (call collect outside North America).
CORPORATE
GOVERNANCE AND BOARD OF DIRECTORS MATTERS
Director
Independence
The
board of directors has determined that Dr. Rogers and Messrs. Stuka, Berman and Kester, and our former directors, Dr. Sol Barer,
who resigned from our board as of June 2, 2017, and Mr. Isaac Blech who resigned from our board as of June 29, 2017, satisfy the
requirement for independence set out in Section 803 of the NYSE American rules and that each of these directors has no material
relationship with us (other than being a director and/or a stockholder). In making its independence determinations, the board
of directors sought to identify and analyze all of the facts and circumstances relating to any relationship between a director,
his immediate family or affiliates and our company and our affiliates and did not rely on categorical standards other than those
contained in the NYSE American rule referenced above.
Board
Committees
Our
board of directors has established an audit committee, a nominating and corporate governance committee and a compensation committee,
each of which has the composition and responsibilities described below.
Audit
Committee.
Our audit committee is currently comprised of Messrs. Berman, Stuka and Kester, each of whom our board has determined
to be financially literate and qualify as an independent director under Section 803(B)(2) of the NYSE American rules. Mr. Kester
is the chairman of our audit committee and qualifies as a financial expert, as defined in Item 407(d)(5)(ii) of Regulation S-K.
The audit committee’s duties are to recommend to our board of directors the engagement of independent auditors to audit
our financial statements and to review our accounting and auditing principles. The audit committee will review the scope, timing
and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent public
accountants, including their recommendations to improve the system of accounting and internal controls. The audit committee held
a total of 4 meetings during the twelve months ended December 31, 2017. The audit committee operates under a formal charter adopted
by the board of directors that governs its duties and conduct. Copies of the charter can be obtained free of charge from the Company’s
web site, www.inspiremd.com, by contacting the Company at the address appearing on the first page of this Proxy Statement to the
attention of Investor Relations, or by telephone at (888) 776-6804.
Nominating
and Corporate Governance Committee.
Our nominating and corporate governance committee is currently comprised of Messrs. Berman
and Stuka, each of whom qualify as an independent director under Section 803(A) of the NYSE American rules. Mr. Berman is the
chairman of our nominating and corporate governance committee. The nominating and corporate governance committee identifies and
recommends to our board of directors individuals qualified to be director nominees. In addition, the nominating and corporate
governance committee recommends to our board of directors the members and chairman of each board committee who will periodically
review and assess our code of business conduct and ethics and our corporate governance guidelines. The nominating and corporate
governance committee also makes recommendations for changes to our code of business conduct and ethics and our corporate governance
guidelines to our board of directors, reviews any other matters related to our corporate governance and oversees the evaluation
of our board of directors and our management. The nominating and corporate governance committee did not hold any meetings during
the twelve months ended December 31, 2017. The nominating and corporate governance committee operates under a formal charter adopted
by the board of directors that governs its duties and conduct. Copies of the charter can be obtained free of charge from the Company’s
web site, www.inspiremd.com, by contacting the Company at the address appearing on the first page of this Proxy Statement to the
attention of Investor Relations, or by telephone at (888) 776-6804.
Compensation
Committee.
Our compensation committee is currently comprised of Messrs. Stuka and Kester, each of whom qualify as an independent
director under Sections 803(A) and 805(c)(1) of the NYSE American rules. Mr. Stuka is the chairman of our compensation committee.
The compensation committee reviews and approves our salary and benefits policies, including compensation of executive officers
and directors. The compensation committee also administers our stock option plans and recommends and approves grants of stock
options under such plans. The compensation committee held 1 meeting during the twelve months ended December 31, 2017. The compensation
committee operates under a formal charter adopted by the board of directors that governs its duties and conduct. Copies of the
charter can be obtained free of charge from the Company’s web site, www.inspiremd.com, by contacting the Company at the
address appearing on the first page of this Proxy Statement to the attention of Investor Relations, or by telephone at (888) 776-6804.
Meetings
and Attendance
The
board of directors held a total of 15 meetings during the twelve months ended December 31, 2017, and each director attended at
least 75 percent of the aggregate number of all (i) board meetings held during the period for which he was a director and (ii)
committee meetings held during the period for which he was a committee member. We do not have a policy requiring director attendance
at stockholder meetings, but members of our board of directors are encouraged to attend. One of five directors attended our 2017
Annual Meeting of Stockholders.
Board
Leadership Structure
The
board of directors is committed to promoting effective, independent governance of the Company. Our board believes it is in the
best interests of the stockholders and the Company for the board to have the flexibility to select the best director to serve
as chairman at any given time, regardless of whether that director is an independent director or the chief executive officer.
Consequently, we do not have a policy governing whether the roles of chairman of the board and chief executive officer should
be separate or combined. This decision is made by our board of directors, based on the best interests of the Company considering
the circumstances at the time.
Currently,
the offices of the chairman of the board and the chief executive officer are held by two different people. Mr. Stuka is our independent,
non-executive chairman of the board of directors and Dr. Barry is our chief executive officer. The chief executive officer is
responsible for the day to day leadership and performance of the Company, while the chairman of the board of directors provides
guidance to the chief executive officer and sets the agenda for board meetings and presides over meetings of the board. We believe
that separation of the positions reinforces the independence of the board in its oversight of the business and affairs of the
Company, and creates an environment that is more conducive to objective evaluation and oversight of management’s performance,
increasing management accountability and improving the ability of the board to monitor whether management’s actions are
in the best interests of the Company and its stockholders. Furthermore, we believe that Mr. Stuka is especially suited to serve
as our chairman of the board, in light of his significant strategic and investment management experience in the U.S. healthcare
industry, which provide him with a unique perspective on the best methods of growth for a life sciences company.
Role
in Risk Oversight
Our
board of directors oversees an enterprise-wide approach to risk management, designed to support the achievement of business objectives,
including organizational and strategic objectives, to improve long-term organizational performance and enhance stockholder value.
The involvement of our board of directors in setting our business strategy is a key part of its assessment of management’s
plans for risk management and its determination of what constitutes an appropriate level of risk for the company. The participation
of our board of directors in our risk oversight process includes receiving regular reports from members of senior management on
areas of material risk to our company, including operational, financial, legal and regulatory, and strategic and reputational
risks.
While
our board of directors has the ultimate responsibility for the risk management process, senior management and various committees
of our board of directors also have responsibility for certain areas of risk management.
Our
senior management team is responsible for day-to-day risk management and regularly reports on risks to our full board of directors
or a relevant committee. Our finance and regulatory personnel serve as the primary monitoring and evaluation function for company-wide
policies and procedures, and manage the day-to-day oversight of the risk management strategy for our ongoing business. This oversight
includes identifying, evaluating and addressing potential risks that may exist at the enterprise, strategic, financial, operational,
compliance, cybersecurity and reporting levels.
The
audit committee focuses on monitoring and discussing our major financial risk exposures and the steps management has taken to
monitor and control such exposures, including our risk assessment and risk management policies. As appropriate, the audit committee
provides reports to and receives direction from the full board of directors regarding our risk management policies and guidelines,
as well as the audit committee’s risk oversight activities.
In
addition, the compensation committee assesses our compensation policies to confirm that the compensation policies and practices
do not encourage unnecessary risk taking. The compensation committee regularly reviews and discusses the relationship between
risk management policies and practices, corporate strategy and senior executive compensation and, when appropriate, reports on
the findings from the discussions with our board of directors. Our compensation committee intends to set performance metrics that
will create incentives for our senior executives that encourage an appropriate level of risk-taking that is commensurate with
our short-term and long-term strategies.
Code
of Ethics
We
have adopted a code of ethics and business conduct that applies to our officers, directors and employees, including our principal
executive officer, principal financial officer and principal accounting officer, which is posted on our website at www.inspiremd.com.
We intend to disclose future amendments to certain provisions of the code of ethics, or waivers of such provisions granted to
executive officers and directors, on this website within four business days following the date of such amendment or waiver.
Communications
with the Board of Directors
A
stockholder who wishes to communicate with our board of directors, any committee of our board of directors, the non-management
directors or any particular director, may do so by writing to such director or directors in care of the Secretary, c/o InspireMD,
Inc., 4 Menorat Hamaor St., Tel Aviv, Israel 6744832. Our secretary will forward such communication to the full board of directors,
to the appropriate committee or to any individual director or directors to whom the communication is addressed, unless the communication
is unrelated to the duties and responsibilities of our board of directors (such as spam, junk mail and mass mailings, ordinary
course disputes over fees or services, personal employee complaints, business inquiries, new product or service suggestions, resumes
and other forms of job inquiries, surveys, business solicitations or advertisements) or is unduly hostile, threatening, illegal,
or harassing, in which case our secretary has the authority to discard the communication or take appropriate legal action regarding
the communication.
Director
Nomination Policies
We
have a standing nominating and corporate governance committee consisting entirely of independent directors. The director nominee
was recommended to the board by the nominating and corporate governance committee for selection.
The
nominating and corporate governance committee will consider all proposed nominees for the board of directors, including those
properly put forward by stockholders. Stockholder nominations should be addressed to the nominating and corporate governance committee
in care of the Secretary, c/o InspireMD, Inc., 4 Menorat Hamaor St., Tel Aviv, Israel 6744832, in accordance with the provisions
of the Company’s amended and restated bylaws. The nominating and corporate governance committee annually reviews with the
board the applicable skills and characteristics required of board nominees in the context of current board composition and our
circumstances. In making its recommendations to the board, the nominating and corporate governance committee considers all factors
it considers appropriate, which may include experience, accomplishments, education, understanding of the business and the industry
in which we operate, specific skills, general business acumen and the highest personal and professional integrity. Generally,
the nominating and corporate governance committee will first consider current board members because they meet the criteria listed
above and possess an in depth knowledge of us, our history, strengths, weaknesses, goals and objectives. This level of knowledge
has proven very valuable to us. In determining whether to recommend a director for re-election, the nominating and corporate governance
committee also considers the director’s past attendance at meetings and participation in and contributions to the activities
of the board.
The
board and the nominating and corporate governance committee aim to assemble a diverse group of board members and believe that
no single criterion such as gender or minority status is determinative in obtaining diversity on the board. The board defines
diversity as differences of viewpoint, professional experience, education and skills such as a candidate’s range of experience
serving on other public company boards, the balance of the business interest and experience of the candidate as compared to the
incumbent or other nominated directors, and the need for any particular expertise on the board or one of its committees.
Certain
Related Transactions and Relationships
We
effected a 1-for-35 reverse stock split of our outstanding common stock on February 7, 2018. Unless otherwise indicated, the share
numbers and prices described below have been adjusted to give effect to the reverse stock split.
On
March 21, 2016, we closed a private placement of 1,183 shares of our common stock and warrants to purchase up to 592 shares of
our common stock with certain of our officers and directors. The purchasers in the private placement included: Dr. Barer, the
chairman of our board of directors, who purchased 969 shares of common stock and warrants to purchase 485 shares of common stock,
for a purchase price of $500,000, Osiris Investment Partners, L.P., of which Mr. Stuka, our director, is the principal and managing
member, which purchased 146 shares of common stock and warrants to purchase 73 shares of common stock, for a purchase price of
$75,000, Mr. Loughlin, who served as our director until May 24, 2016, purchased 58 shares of common stock and warrants to purchase
29 shares of common stock, for a purchase price of $29,500 and Dr. Rogers, our director, who purchased 10 shares of common stock
and warrants to purchase 5 shares of common stock, for a purchase price of $5,000.
On
July 7, 2016, we closed a public offering of 442,424 shares of Series B Convertible Preferred Stock (the “Series B Preferred
Stock”) and accompanying warrants to purchase up to 50,620 shares of common stock at a price of $33.00 per share of Series
B Preferred Stock and the accompanying warrant, for gross proceeds of approximately $14.6 million, before deducting placement
agent fees and offering expenses payable by us. Each share of Series B Preferred Stock was convertible into 0.114 shares of common
stock reflecting a conversion price equal to $288.75 per share. In accordance with the anti-dilution price protection contained
in the certificate of designation for the Series B Preferred Stock, the conversion price for the Series B Preferred Stock was
adjusted, and each share of Series B Preferred Stock is currently convertible into 4.714 shares of common stock at $7.00 per share.
The holders of Series B Preferred Stock are entitled to receive cumulative dividends at the rate per share of 15% per annum of
the stated value for five years, payable in cash or common stock, at our discretion. The warrants are exercisable immediately
and have a term of exercise of five years from the date of issuance and have an exercise price of $175.00 per share of common
stock. The purchasers in the offering included: Dr. Barer, the then chairman of our board of directors, who purchased 33,333 shares
of Series B Preferred Stock and warrants to purchase 3,810 shares of common stock, for a purchase price of $1,099,989, Osiris
Investment Partners, L.P., of which Mr. Stuka, our director, is the principal and managing member, which purchased 1,515 shares
of Series B Preferred Stock and warrants to purchase 174 shares of common stock, for a purchase price of $49,995 and Mr. Stuka,
who purchased 3,030 shares of Series B Preferred Stock and warrants to purchase 347 shares of common stock, for a purchase price
of $99,990.
On
December 1, 2017, as part of a planned recapitalization, we sold 750 shares of Series D Convertible Preferred Stock (the “Series
D Preferred Stock”) to Sabby Healthcare Master Fund, Ltd., who is a beneficial owner of more than 5% of our common stock
(the “Series D Investor”) in a private placement (the “Series D Private Placement”) pursuant to a securities
purchase agreement (the “Series D Purchase Agreement”), dated November 28, 2017, for aggregate gross proceeds of $750,000.
The stated value of each share of Series D Preferred Stock is $1,000, and the Series D Preferred Stock is convertible, at the
option of the holder, into shares of our common stock (subject to the beneficial ownership limitation set forth in the certificate
of designation for the Series D Preferred Stock (“Series D Certificate of Designation”)), at a conversion price of
$7.00 per share, subject to adjustment as provided in the Series D Certificate of Designation. Pursuant to the Series D Purchase
Agreement and the Series D Certificate of Designation, the purchasers of Series D Preferred Stock have the option, subject to
certain limitations, to exchange their Series D Preferred Stock into the securities issued in a subsequent offering (the “Series
D Exchange Right”) or into the securities we sell in an offering of our common stock or common stock equivalents for gross
proceeds of at least $8 million (a “Qualified Offering”) upon consummation of a Qualified Offering on a $1.00 per
stated value for $1.00 new subscription amount basis. In addition, in accordance with the Series D Purchase Agreement, the certificate
of designation for the Series B Preferred Stock was amended to provide that each share of outstanding Series B Preferred Stock
will be automatically exchanged into the securities we sell in a Qualified Offering on a $1.00 per stated value for $1.00 new
subscription amount basis. As a result of the issuance and sale of the Series D Preferred Stock, the conversion price of our outstanding
shares of Series B Preferred Stock was reduced to $7.00 pursuant to the anti-dilution adjustment provisions of the Series B Preferred
Stock. There was no change to the conversion price of our outstanding Series C Convertible Preferred Stock (the “Series
C Preferred Stock”) as a result of an amendment made to the terms of the Series C Preferred Stock exempting the issuance
of the Series D Preferred Stock from the anti-dilution adjustment provisions of the Series C Preferred Stock. The conversion price
for each of our Series B Preferred Stock, our Series C Preferred Stock and our Series D Preferred was subsequently reduced to
$3.00 per share and to $1.75 as described below.
On
February 21, 2018, the Series D Purchase Agreement was amended to require us (i) to use 15% of the proceeds from any subsequent
offering of our securities that is not a Qualified Offering to redeem the outstanding shares of the Series C Preferred Stock held
by the Series D Investor at a per share purchase price equal to the stated value of the Series C Preferred Stock, and (ii) upon
closing of any subsequent offering that is a Qualified Offering, to exchange all remaining outstanding shares of Series C Preferred
Stock held by the Series D Investor for any securities issued in such Qualified Offering on a $1.00 per stated value for $1.00
new subscription amount basis (subject to the beneficial ownership limitation set forth in the certificate of designation for
the Series C Preferred Stock). In the event that we fail, or are unable, to issue securities issued in the Qualified Offering
to the Series D Investor in exchange for such investor’s remaining Series C Preferred Stock due to limitations mandated
by the NYSE American, the Securities and Exchange Commission, or for any other reason, we are required to offer to purchase from
such investor those shares of Series C Preferred Stock not exchanged for the securities sold in the Qualified Offering at a per
share purchase price equal to the stated value of Series C Preferred Stock.
On
February 26, 2018, we and the Series D Investor entered into a waiver agreement which provided that (i) the Series D Exchange
Right would not be applicable to an offering of up to $7,000,000 which occurred no later than March 9, 2017, (ii) we shall reduce
the conversion price of the Series D Preferred Stock to the public offering price of our common stock in such offering, (iii)
instead of using 15% of the proceeds from such offering to redeem shares of Series C Preferred Stock held by the Series D Investor,
we shall use 15% of the proceeds from such offering to redeem a portion of the outstanding shares of Series D Preferred Stock
held by the Series D Investor at a per share purchase price equal to the stated value of the Series D Preferred Stock, and (iv)
we shall file a registration statement with the SEC under the Securities Act of 1933, as amended, in order to register the resale
of the shares of common stock issuable upon the conversion of the Series D Preferred Stock as soon as practicable following the
closing of such offering, but in no event later than seven days following such closing and to cause such registration statement
to become effective as soon as practical after its filing.
On
March 1, 2018, we closed an underwritten public offering of 1,000,000 shares of our common stock at a price to the public of $3.00
per share, thus triggering the rights under the above described February 26, 2018 agreement. Upon closing of the offering, we
used 15% of the proceeds from the offering to redeem 450 shares of Series D Preferred Stock. As a result of such offering, the
conversion price for each of our Series B Preferred Stock, our Series C Preferred Stock and our Series D Preferred Stock was reduced
to $3.00 per share.
On
March 28, 2018, we and the Series D Investor entered into the second waiver agreement which provides that (i) the Series D Exchange
Right would not be applicable to a subsequent financing consisting solely of shares of common stock, which shall be publicly registered
on Form S-3 for gross proceeds to us of up to $5,000,000, to be consummated by not later than April 3, 2018 (the “Planned
April 2018 Offering”), (ii) our obligation to use 15% of the proceeds from any subsequent offering of our securities that
is not a Qualified Offering to redeem the outstanding shares of the Series C Preferred Stock held by the Series D Investor would
not be applicable to the Planned April 2018 Offering, (iii) we shall reduce the conversion price of the Series D Preferred Stock
to the public offering price of our common stock sold in the Planned April 2018 Offering, and (iv) we shall use $300,000 of the
proceeds from the Planned April 2018 Offering to redeem outstanding shares of Series C Preferred Stock held by the Series D Investor
at a per share purchase price equal to the stated value of the Series C Preferred Stock.
On
April 2, 2018, we closed an underwritten public offering of 2,857,143 shares of our common stock at a price to the public of $1.75
per share, thus triggering the rights under the above described March 28, 2018 second waiver agreement. Upon closing of the offering,
we used $300,000 of the proceeds from the offering to redeem 46,875 shares of our Series C Preferred Stock held by the Series
D Investor. As a result of such offering, the conversion price for each of our Series B Preferred Stock, our Series C Preferred
Stock and our Series D Preferred Stock was reduced to $1.75 per share.
On
June 28, 2018, we and the Series D Investor entered into a letter agreement (the “Letter Agreement”) which further
amended the Series D Purchase Agreement to provide that, notwithstanding anything to the contrary in the prior agreements, in
the event we consummate a Qualified Offering in which the Series D Investor and its affiliates invest at least $3 million, (i)
instead of an automatic exchange of all outstanding shares of Series C Preferred Stock held by the Series D Investor into securities
issued in a Qualified Offering on a $1.00 per stated value for $1.00 new subscription amount basis, all outstanding shares of
Series C Preferred Stock held by the Series D Investor will be redeemed at a per share purchase price equal to the stated value
of the Series C Preferred Stock, and (ii) all outstanding shares of Series D Preferred Stock will be redeemed at a per share purchase
price equal to the stated value of the Series D Preferred Stock.
On
July 3, 2018, we closed an underwritten public offering of (i) 10,851,417 common units, with each common unit being comprised
of one share of our common stock, and one Series D warrant to purchase one share of common stock and (ii) 22,481,916 pre-funded
units, with each pre-funded unit being comprised of one pre-funded warrant to purchase one share of common stock and one Series
D warrant. The underwriter exercised its option to purchase an additional 4,999,999 Series D warrants to purchase 4,999,999 shares
of common stock. Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation
for the Series B Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B
Preferred Stock and the Series C Preferred Stock was reduced to $0.30 per share.
Pursuant
to the Letter Agreement, on July 3, 2018, upon closing of the public offering that was a Qualified Offering, we used $2,264,269
of the net proceeds of the offering to redeem 306,917 shares of Series C Preferred Stock and 300 shares of Series D Preferred
Stock held by the Series D Investor.
In
accordance with our audit committee charter, the audit committee is required to approve all related party transactions. In general,
the audit committee will review any proposed transaction that has been identified as a related party transaction under Item 404
of Regulation S-K, which means a transaction, arrangement or relationship in which we and any related party are participants in
which the amount involved exceeds $120,000. A related party includes (i) a director, director nominee or executive officer of
us, (ii) a security holder known to be an owner of more than 5% of our voting securities, (iii) an immediate family member of
the foregoing or (iv) a corporation or other entity in which any of the foregoing persons is an executive, principal or similar
control person or in which such person has a 5% or greater beneficial ownership interest.
REPORT
OF THE AUDIT COMMITTEE
The
audit committee has reviewed and discussed the Company’s audited financial statements and related footnotes for the year
ended December 31, 2017, and the independent auditor’s report on those financial statements, with management and with our
independent auditor, Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International
Limited (“Kesselman”). The audit committee has also discussed with Kesselman the matters required to be discussed
by the statement on Auditing Standards No. 61, as amended, as adopted by the Public Company Accounting Oversight Board in Rule
3200T. The audit committee has also received the written disclosures and the letter from Kesselman required by applicable requirements
of the Public Company Accounting Oversight Board regarding Kesselman’ s communications with the audit committee concerning
independence, and has discussed with Kesselman that firm’s independence.
Based
on the review and the discussions referred to in the preceding paragraph, the audit committee determined that the Company’s
audited financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017,
that was filed with the SEC.
|
The
Audit Committee:
|
|
|
|
Michael
Berman
|
|
Thomas
J. Kester (Chairman)
|
|
Paul
Stuka
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth information with respect to the beneficial ownership of our common stock as of September 6, 2018 by:
|
●
|
each
person known by us to beneficially own more than 5.0% of our common stock;
|
|
|
|
|
●
|
each
of our directors;
|
|
|
|
|
●
|
each
of the named executive officers; and
|
|
|
|
|
●
|
all
of our directors and executive officers as a group.
|
The
percentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchange Commission
governing the determination of beneficial ownership of securities. Under the rules of the Securities and Exchange Commission,
a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power
to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the
disposition of the security.
Except
as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment
power with respect to all shares beneficially owned and each person’s address is c/o InspireMD, Inc., 4 Menorat Hamaor St.,
Tel Aviv, Israel 6744832. As of September 6, 2018, we had 23,784,784 shares outstanding.
Name of Beneficial Owner
|
|
Number of Shares
Beneficially
Owned
(1)
|
|
|
Percentage
Beneficially
Owned
(1)
|
|
5% Owners
|
|
|
|
|
|
|
|
|
Sol J. Barer, Ph.D.
|
|
|
2,624,856
|
(2)
|
|
|
9.99
|
%
|
Intracoastal Capital, LLC
|
|
|
2,573,885
|
(4)
|
|
|
9.99
|
%
|
Anson Funds Management LP
|
|
|
2,446,945
|
(5)
|
|
|
9.99
|
%
|
Sabby Management, LLC
|
|
|
2,379,467
|
(3)
|
|
|
9.99
|
%
|
Officers and Directors
|
|
|
|
|
|
|
|
|
Craig Shore
|
|
|
1,928
|
(6)
|
|
|
*
|
|
James Barry, Ph.D.
|
|
|
3,397
|
(7)
|
|
|
*
|
|
Michael Berman
|
|
|
272
|
(8)
|
|
|
*
|
|
Campbell Rogers, M.D.
|
|
|
260
|
(9)
|
|
|
*
|
|
Paul Stuka
|
|
|
38,775
|
(10)
|
|
|
*
|
|
Thomas Kester
|
|
|
223
|
(11)
|
|
|
*
|
|
Agustin V. Gago
|
|
|
1,300
|
(12)
|
|
|
*
|
|
All directors and executive officers as a group (7 persons)
|
|
|
46,156
|
|
|
|
*
|
|
*
|
Represents
ownership of less than one percent.
|
|
|
(1)
|
Shares
of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assumes the exercise
of all options, warrants and other securities convertible into common stock beneficially owned by such person or entity currently
exercisable or exercisable within 60 days of September 6, 2018. Shares issuable pursuant to the exercise of stock options
and warrants exercisable within 60 days are deemed outstanding and held by the holder of such options or warrants for computing
the percentage of outstanding common stock beneficially owned by such person, but are not deemed outstanding for computing
the percentage of outstanding common stock beneficially owned by any other person.
|
(2)
|
Includes
(i) options to purchase 818 shares of common stock that are currently exercisable or exercisable within 60 days of September
6, 2018, (ii) warrants to purchase 4,592 shares of common stock that are currently exercisable or exercisable within 60 days
of September 6, 2018, (iii) 133,631 shares of common stock and (iv) includes 2,485,828 shares of common stock issuable upon
conversion of Series B Preferred Stock that are currently convertible within 60 days of September 6, 2018. Does not include
845,000 shares of common stock issuable upon conversion of Series B Preferred Stock, which shares were excluded because the
certificate of designation for the Series B Preferred Stock contain provisions that block conversion if such conversion will
result in the holder having beneficial ownership of more than 9.99% of our common stock.
|
|
|
(3)
|
Based
on our knowledge based on the representation by the reporting person to the management of the Company on September 5, 2018,
comprised of (i) 1,718,430 shares of common stock owned directly by Sabby Healthcare Master Fund, Ltd., (ii) 633,037
shares of common stock owned directly by Sabby Volatility Warrant Master Fund, Ltd., and (iii) 28,000 shares
of common stock issuable upon exercise of pre-funded warrants that are currently exercisable or exercisable within 60 days
of September 6, 2018, owned directly by Sabby Volatility Warrant Master Fund, Ltd. Does not include 9,372,000 shares
of common stock issuable upon exercise of pre-funded warrants held directly by Sabby Volatility Warrant Master Fund, Ltd.,
which shares were excluded because the pre-funded warrants contain provisions that block exercise of the warrants if such
exercise will result in the holder having beneficial ownership of more than 9.99% of our common stock. Sabby Management, LLC
serves as the investment manager of Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. Hal
Mintz serves as manager of Sabby Management, LLC. As such, Sabby Management, LLC and Hal Mintz may be deemed to beneficially
own these securities. Sabby Management LLC’s address is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey
07458.
|
|
|
(4)
|
Consists
of (i) 581,885 shares of common stock and (ii) 1,992,000 shares of common stock issuable upon exercise of pre-funded warrants.
Does not include 1,324,666 shares of common stock issuable upon exercise of pre-funded warrants, which shares were excluded
because the pre-funded warrants contain provisions that block exercise of the warrants if such exercise will result in the
holder having beneficial ownership of more than 9.99% of our common stock. Intracoastal Capital, LLC’s address is 245
Palm Trail, Delray Beach, Florida 33483.
|
|
|
(5)
|
Consists
of (i) 1,731,945 shares of common stock and (ii) 715,000 shares of common stock issuable upon exercise of pre-funded warrants.
Does not include 2,118,334 shares of common stock issuable upon exercise of pre-funded warrants, which shares were excluded
because the pre-funded warrants contain provisions that block exercise of the warrants if such exercise will result in the
holder having beneficial ownership of more than 9.99% of our common stock. Anson Funds Management LP’s address is 5950
Berkshire Lane, Suite 210, Dallas, Texas 75225.
|
|
|
(6)
|
Consists
of (i) 532 shares of common stock, (ii) options to purchase 336 shares of common stock that are currently exercisable or exercisable
within 60 days of September 6, 2018, and (iii) 1,060 shares of restricted stock granted to employees under the Israeli Appendix
of the 2013 Plan held in trust, and with respect to which Mr. Shore was granted a proxy with the right to vote such shares
at his discretion.
|
|
|
(7)
|
Consists
of (i) 1,382 shares of common stock and (ii) options to purchase 2,015 shares of common stock that are currently exercisable
or exercisable within 60 days of September 6, 2018.
|
|
|
(8)
|
Includes
options to purchase 267 shares of common stock that are currently exercisable or exercisable within 60 days of September 6,
2018.
|
|
|
(9)
|
Includes
options to purchase 244 shares of common stock and warrants to purchase 5 shares of common stock that are currently exercisable
or exercisable within 60 days of September 6, 2018.
|
(10)
|
Paul
Stuka is the principal and managing member of Osiris Investment Partners, L.P., and, as such, has beneficial ownership of
(A) (i) 12,811 shares of common stock, (ii) warrants to purchase 319 shares of common stock that are currently exercisable
or exercisable within 60 days of September 6, 2018 in addition to (B) personally holding (i) options to purchase 299 shares
of common stock that are currently exercisable or exercisable within 60 days of September 6, 2018, (ii) warrants to purchase
347 shares of common stock that are currently exercisable or exercisable within 60 days of September 6, 2018, and (iii) 24,999
shares of common stock.
|
|
|
(11)
|
Consists
of (i) 8 shares of common stock and (ii) options to purchase 215 shares of common stock that are currently exercisable or exercisable
within 60 days of September 6, 2018.
|
|
|
(12)
|
Includes
options to purchase 1,300 shares of common stock that are currently exercisable or exercisable within 60 days of September
6, 2018.
|
SECTION
16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section
16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and officers, and persons who own more than ten
percent of our common stock, to file with the Securities and Exchange Commission initial reports of ownership and reports of changes
in ownership of our common stock. Directors, officers and persons who own more than ten percent of our common stock are required
by Securities and Exchange Commission regulations to furnish us with copies of all Section 16(a) forms they file.
To
our knowledge, based solely on a review of the copies of such reports furnished to us, during the twelve months ended December
31, 2017, each of our directors, officers and greater than ten percent stockholders complied with all Section 16(a) filing requirements
applicable to our directors, officers and greater than ten percent stockholders, except for one late report on Form 4 for Dr.
Barry, with respect to a payment of tax liability by withholding securities in connection with vesting of restricted stock.
PROPOSAL
1: ELECTION OF CLASS 1 DIRECTOR
The
board of directors currently consists of five members and is classified into three classes of similar size. The members of each
class are elected in different years, so that only one-third of the board is elected in any single year. As indicated below, we
currently have one director in Class 1 (with a term of office expiring this year), two directors in Class 2 (with a term of office
expiring in 2019), and two directors in Class 3 (with a term of office expiring in 2020). Sol Barer, Ph.D., our former chairman
of the board of directors, and Isaac Blech, one of our former directors, resigned from the board of directors in June 2017, and,
in an effort to reduce costs, we have determined not to fill his position and instead reduce the size of the board to five directors.
Accordingly, this year, the board of directors has nominated only one nominee for re-election as Class 1 director, Paul Stuka,
whose term will expire at the Annual Meeting.
Mr.
Stuka has been nominated to serve for a term of office to expire at the Annual Meeting of Stockholders in 2021, to hold office
until his successor has been duly elected and qualified. Stockholders will be unable to vote for more than one person. Directors
are elected by a plurality of the votes present in person or represented by proxy and entitled to vote at the Annual Meeting.
Since there is only one nominee for Class 1 director, assuming the presence of a quorum, the director nominee will be elected
as a Class 1 director if he receives at least one “FOR” vote. Should the director nominee become unable or unwilling
to accept nomination or election, the proxy holders may vote the proxies for the election, in his stead, of any other person the
board of directors may nominate or designate. The director nominee has expressed his intention to serve the entire term for which
election is sought.
Directors
and Nominee
The
following table and text set forth the name, age and positions of the director nominee and each director currently serving on
our board of directors:
Name
|
|
Age
|
|
Director
Class
|
|
Position
|
|
Term
Expiration
|
Paul
Stuka
|
|
63
|
|
Class
1
|
|
Chairman
of the Board of Directors
|
|
2018Annual
Meeting
|
Michael
Berman
|
|
60
|
|
Class
2
|
|
Director
|
|
2019
Annual Meeting
|
Campbell
Rogers, M.D.
|
|
57
|
|
Class
2
|
|
Director
|
|
2019
Annual Meeting
|
James
Barry, Ph.D.
|
|
59
|
|
Class
3
|
|
President,
Chief Executive Officer and Director
|
|
2020
Annual Meeting
|
Thomas
J. Kester
|
|
71
|
|
Class
3
|
|
Director
|
|
2020
Annual Meeting
|
Biographies
Paul
Stuka
has served as a director since August 8, 2011 and has served as our chairman since June 2, 2017. Mr. Stuka has served
as the managing member of Osiris Partners, LLC, an investment fund, since 2000. Prior to forming Osiris Partners, LLC, Mr. Stuka,
with 35 years of experience in the investment industry, was a managing director of Longwood Partners, managing small cap institutional
accounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds.
From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership.
Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a wide
array of industries including healthcare, energy, transportation, and lodging and gaming. Early in his career he became the assistant
portfolio manager for three Fidelity Funds, including the Select Healthcare Fund which was recognized as the top performing fund
in the United States for the five-year period ending December 31, 1985. Mr. Stuka has been serving as a director of Caliber Imaging
& Diagnostics, Inc. (formerly Lucid, Inc.) since June 2013. Mr. Stuka’s qualifications to serve on the board include
his significant strategic and business insight from his years of experience investing in the healthcare industry.
Michael
Berman
has served as our director since February 7, 2013. Mr. Berman is a medical device entrepreneur who works with high-potential
development and early-stage commercial companies. From 2005 to 2012, when the company was sold to Boston Scientific, Mr. Berman
was a co-founder and the chairman of BridgePoint Medical, Inc., which developed technology to treat coronary and peripheral vascular
chronic total occlusions. Mr. Berman was also a member of the board of Lutonix, Inc. from 2007 until 2011, when the company was
sold to C.R. Bard, Inc. From 2011 to 2018, Mr. Berman served as a co-founder and director of Rebiotix Inc., a company developing
an innovative treatment for C Diff colitis. Rebiotix was sold to Ferring Pharmaceuticals in 2018. Mr. Berman has served (i) since
2011 as an advisor to, and since 2012 as a director of, Cardiosonic, Inc., a company developing a system for hypertension reduction
via renal denervation, (ii) since 2005 as a director of PharmaCentra, LLC, which creates customizable marketing programs that
help pharmaceutical companies communicate with physicians and patients, (iii) since 2018 as a Director of STMedical, a medical
device company that has developed a temporary stent for the treatment of chronic sinusitis, (iv) since 2011 as a director of AngioSlide
Ltd., a medical device company that has developed an embolic capture angioplasty device, (v) since 2017 as a Director of Owlytics
Healthcare, (vi) since 2013 as a Director of ClearCut Inc., a medical device company that has developed an MRI system for tumor
margin assessment, (vii) since 2013 as a director of PulmOne Ltd., a medical device company developing an innovative Pulmonary
Function Testing system, (viii) since 2014 as a director of Mazor Robotics, Inc., a publicly held company that has developed and
markets an innovative system for robotic surgery, (ix) since 2014 as a director of SoniVie, a medical device company, (x) since
2014 as a venture partner at RiverVest Ventures and (xi) since 2017 as a Director of Truleaf Medical. Mr. Berman brings to the
board his extensive executive and entrepreneurial experiences in the field of medical devices and vascular intervention, which
should assist in strengthening and advancing our strategic focus.
Campbell
Rogers, M.D.
has served as a director since September 3, 2013. Dr. Rogers is the executive vice president and chief medical
officer of HeartFlow, Inc., a cardiovascular diagnostics company, since March 2012. Prior to joining HeartFlow, Inc., he was the
chief scientific officer and global head of research and development at Cordis Corporation (currently part of Cardinal Health,
Inc.), Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to
that, he was associate professor of medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and
Technology and director of the cardiac catheterization and experimental cardiovascular interventional laboratories at Brigham
and Women’s Hospital. He served as principal investigator for numerous interventional cardiology device, diagnostic, and
pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other
cardiovascular diseases and was the recipient of research grant awards from the National Institute of Health and the American
Heart Association. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr. Rogers’ qualifications
to serve on the board include his significant experience in cardiovascular devices, as well as his familiarity with the operations
of medical device companies.
James
Barry, Ph.D.
has served as our president and chief executive officer since June 6, 2016, and as a director since January 30,
2012. Prior to becoming our president and chief executive officer, Dr. Barry served as our executive vice president and chief
operating officer from July 14, 2014. Dr. Barry served as president and chief executive officer and executive vice president and
chief operating officer at Arsenal Medical Inc., a medical device company focused on local therapy, from September 2011 to December
2013. Dr. Barry also heads his own consulting firm, Convergent Biomedical Group LLC, advising medtech companies on product development,
strategy, regulatory compliance and fund raising. Until June 2010, he was senior vice president, corporate technology development
at Boston Scientific Corporation, where he was in charge of the corporate research and development and pre-clinical science functions
and was also a member of the operating committee and corporate portfolio committee. Dr. Barry joined Boston Scientific in 1992
and oversaw its efforts in the identification and development of drug device combinations for both implantable and catheter-based
delivery systems. He currently serves on a number of advisory boards including the College of Biomedical Engineering at Yale University,
the College of Sciences at University of Massachusetts-Lowell where he is chairman emeritus and the Massachusetts Life Science
Center.). Dr. Barry received his Ph.D. in Biochemistry from the University of Massachusetts-Lowell and holds a B.A. degree in
Chemistry from Saint Anselm College. Dr. Barry brings to the board over 25 years of experience in leadership roles in the medical
device industry and significant medical technology experience, in particular with respect to interventional cardiology products,
and as chief executive officer, Dr. Barry’s position on the board ensures a unity of vision between the broader goals of
our company and our day-to-day operations.
Dr.
Barry is a party to an agreement related to his service as president, chief executive officer and director described under “Executive
Compensation – Agreements with Executive Officers.”
Thomas
J. Kester
has served as a director since September 6, 2016. Mr. Kester has been serving as the chief financial officer of
Kester Search Group, Inc., a private executive search firm specializing in sales force placement for medical, dental and diagnostic
device companies, since October 2014. From 2004 to 2010, Mr. Kester served as a director of Orthofix International, NV (NASDAQ:
OFIX), a global medical device company. Mr. Kester’s experience includes 28 years at KPMG LLP, including 18 years as an
audit partner, advising public and private companies in connection with annual audit and financings. Mr. Kester’s qualifications
to serve on the board include his significant strategic and business insight from his years of experience auditing global companies
and serving on the boards of several public and not-for-profit organizations. Mr. Kester received his B.S. in mechanical engineering
from Cornell University and an M.B.A. from Harvard University.
Family
Relationships
There
are no family relationships amongst our directors and executive officers.
Vote
Required
Directors
will be elected by a plurality of the votes cast by the holders of our common stock voting in person or by proxy at the Annual
Meeting. Since there is only one nominee for Class 1 director, the nominee will be elected as a Class 1 director if he receives
at least one “FOR” vote.
|
The
board of directors recommends a vote
FOR
the Class 1 director nominee.
|
|
EXECUTIVE
OFFICERS
In
addition to James Barry, Ph.D. whose information is set forth above under the caption “Proposal 1: Election of Class 1 Director
– Directors and Nominee” and “– Biographies,” below is certain information with respect to our other
executive officers.
Name
|
|
Age
|
|
Position(s)
|
Craig
Shore
|
|
57
|
|
Chief
Financial Officer, Chief Administrative Officer, Secretary
and
Treasurer
|
Agustin
V. Gago
|
|
59
|
|
Executive
Vice President, Chief Commercial Officer
|
Our
officers hold office until the earlier of their death, resignation or removal by our board of directors or until their successors
have been selected. They serve at the pleasure of our board of directors.
Craig
Shore
has served as our chief financial officer, secretary and treasurer since March 31, 2011 and as our chief administrative
officer since May 3, 2013. In addition, from November 10, 2010 through March 31, 2011, Mr. Shore served as InspireMD Ltd.’s
vice president of business development. Mr. Shore has over 30 years of experience in financial management in the United States,
Europe and Israel for companies such as Pfizer Pharmaceuticals, Bristol Myers Squibb and General Electric. His experience includes
raising capital both in the private and public markets. Mr. Shore graduated with honors and received a B.Sc. in Finance from Pennsylvania
State University and an M.B.A. from George Washington University.
Mr.
Shore is a party to an agreement related to his service as chief financial officer described under “Executive Compensation
– Agreements with Executive Officers.”
Agustin
V. Gago
has served as our executive vice president and chief commercial officer since October 24, 2016. Mr. Gago has over
25 years of experience in building profitable international commercial, sales and marketing organizations. Prior to joining us,
Mr. Gago served as a principal at Dash International, LLC, a consulting firm he founded in 2013, advising senior management of
major medical device companies on business strategy. From 2009 to 2013, Mr. Gago served as chief commercial officer at Delcath
Systems, Inc. (NASDAQ: DCTH), an interventional oncology company, creating its direct and contract sales forces as well as a distributor
infrastructure serving Europe, Asia and South America. From 2011 to 2013, Mr. Gago also served as a director of Delcath Systems,
Inc.’s subsidiary in Galway, Ireland. From 2008 to 2009, Mr. Gago was vice president of international oncology surgery sales
at AngioDynamics, Inc. (NASDAQ: ANGO), a provider of minimally invasive medical devices for cardiology vascular disease and oncology.
Mr. Gago also worked from 1998 to 2008 in various leadership roles at E-Z-EM, Inc. (acquired by Bracco Diagnostics Inc.), a global
manufacturer of medical devices and contrast agents for gastrointestinal imaging, and served as a director of E-Z-EM, Inc.’s
subsidiaries in the United Kingdom and the Netherlands, eventually being appointed as vice president of global gastrointestinal
business and vice president of international operations of E-Z EM, Inc. Mr. Gago received a B.S. degree in business management
from Hofstra University.
Mr.
Gago is a party to an agreement related to his service as chief financial officer described under “Executive Compensation
– Agreements with Executive Officers.”
EXECUTIVE
COMPENSATION
Compensation
Philosophy and Process
The
responsibility for establishing, administering and interpreting our policies governing the compensation and benefits for our executive
officers lies with our compensation committee and our board of directors. During the review of named executive officer compensation
for 2017, the compensation committee did not retain the services of any compensation consultants.
The
goals of our compensation policy are to ensure that executive compensation rewards management for helping us achieve our financial
goals (increased sales, profitability, etc.) and meet our clinical trial milestones and aligns management’s overall goals
and objectives with those of our stockholders. In 2017, we designed our executive compensation program to achieve the following
objectives:
|
●
|
provide
a competitive compensation package that enables us to attract and retain superior management personnel;
|
|
|
|
|
●
|
provide
incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value
and facilitate executive retention;
|
|
|
|
|
●
|
reward
our officers fairly for their role in our achievements; and
|
|
|
|
|
●
|
align
executives’ interests with those of stockholders through long-term incentives linked to specific performance.
|
We
have determined that in order to best meet these objectives, our executive compensation program should balance fixed and bonus
compensation, as well as cash and equity compensation. Historically, there has been no pre-established policy or target for the
allocation between either cash and non-cash or short-term and long-term incentive compensation for our executive officers.
Summary
Compensation Table
The
table below sets forth the compensation earned by our named executive officers for the twelve month period ended December 31,
2017 and 2016.
Name and Principal Position
|
|
Year
|
|
|
Salary
($)
|
|
|
Bonus ($)
|
|
|
Restricted
Stock
Awards ($)
(1)
|
|
|
Option
Awards ($)
(1)
|
|
|
All Other
Compensation ($)
|
|
|
Total
($)
|
|
James Barry, Ph.D.
|
|
|
2017
|
|
|
|
365,000
|
|
|
|
25,000
|
(2)
|
|
|
-
|
|
|
|
-
|
|
|
|
50,319
|
(3)
|
|
|
440,319
|
|
President and Chief Executive Officer
|
|
|
2016
|
|
|
|
288,958
|
|
|
|
106,458
|
(4)
|
|
|
334,871
|
|
|
|
235,783
|
|
|
|
25,820
|
(3)
|
|
|
991,890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Craig Shore
|
|
|
2017
|
|
|
|
267,106
|
(5)
|
|
|
25,000
|
(2)(5)
|
|
|
-
|
|
|
|
-
|
|
|
|
98,181
|
(5)(6)
|
|
|
370,286
|
(5)
|
Chief Financial Officer, Secretary and Treasurer
|
|
|
2016
|
|
|
|
290,341
|
(5)(7)
|
|
|
50,000
|
(5)(8)
|
|
|
83,718
|
|
|
|
60,711
|
|
|
|
95,343
|
(5)(6)
|
|
|
580,113
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agustin Gago
|
|
|
2017
|
|
|
|
275,000
|
|
|
|
75,000
|
(9)
|
|
|
-
|
|
|
|
-
|
|
|
|
28,334
|
(3)
|
|
|
378,334
|
|
Executive Vice President And Chief Commercial Officer
|
|
|
2016
|
|
|
|
51,225
|
|
|
|
25,000
|
(10)
|
|
|
-
|
|
|
|
61,241
|
|
|
|
-
|
|
|
|
137,466
|
|
(1)
|
The
amounts reflect the dollar amounts recognized for financial statement reporting purposes with respect to the twelve month
periods ended December 31, 2017 and 2016 in accordance with FASB ASC Topic 718. Fair value is based on the Black-Scholes option
pricing model using the fair value of the underlying shares at the measurement date. For additional discussion of the valuation
assumptions used in determining stock-based compensation and the grant date fair value for stock options, see “Management’s
Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies — Share-based
compensation” and Note 2-”Significant Accounting Policies” and Note 10-”Equity” to the Consolidated
Financial Statements for the Twelve Months Ended December 31, 2017 included in the 2017 Annual Report.
|
(2)
|
Cash
bonus awards for the 2017 calendar year were approved by the compensation committee in
May 2018.
|
(3)
|
Dr.
Barry’s and Mr. Gago’s other compensation consisted solely of benefits related to health insurance.
|
|
|
(4)
|
Pursuant
to the fourth amendment of Dr. Barry’s employment agreement dated June 6, 2016.
|
|
|
(5)
|
Compensation
amounts received in non-U.S. currency have been converted into U.S. dollars using the average exchange rate for the applicable
period, except for (i) 2016 bonus amounts which have been converted into U.S. dollars using 3.846 NIS per dollar which was
the exchange rate as of June 30, 2016, and (ii) for 2017 bonus amounts which have been converted into U.S. dollars using 3.6
NIS per dollar which was the exchange rate as of May 9, 2018. The average exchange rate for the twelve month period ended
December 31, 2017 and 2016 were 3.5997 NIS per dollar and 3.8409 NIS per dollar, respectively.
|
|
|
(6)
|
Mr.
Shore’s other compensation consisted solely of benefits in the twelve months ended December 31, 2017 and 2016. In each
of the periods reported, Mr. Shore’s benefits included our contributions to his severance, pension, vocational studies
and disability funds, an annual recreation payment, a company car or car allowance and cell phone, and a daily food allowance.
|
|
|
(7)
|
Mr.
Shore’s salary for 2016 includes cash paid in lieu of accrued vacation of $51,678.
|
|
|
(8)
|
Bonuses
for the 2016 calendar year were approved by the compensation committee in July 2016.
|
|
|
(9)
|
$50,000
of cash bonus earned by Mr. Gago in the 2017 calendar year was approved by the compensation committee in May 2017. $25,000
of cash bonus earned by Mr. Gago in the 2017 calendar year was approved by the compensation committee in May 2018.
|
|
|
(10)
|
Pursuant
to Mr. Gago’s employment agreement, dated October 24, 2016.
|
Agreements
with Executive Officers
James
Barry, Ph.D.
On
July 14, 2014, we entered into an employment agreement with James Barry to serve as our executive vice president and chief operating
officer, which was first amended on January 5, 2015, and further amended on February 22, 2015, and March 28, 2016, and on June
6, 2016, our board of directors appointed Dr. Barry as our president and chief executive officer and further amended the employment
agreement. On September 5, 2017, we entered into the Fifth Amendment to Dr. Barry’s employment agreement. Dr. Barry was
previously a director and continues his role as a director. The term of Dr. Barry’s employment will continue until July
31, 2018, with Dr. Barry resigning as a member of the board of directors at the end of such term if requested by us. In the event
that the term is not extended beyond July 31, 2018 by mutual agreement of the parties and we do not offer Dr. Barry a position
as chief executive officer on the same or more favorable terms with an annual base salary that is at least $400,000, Dr. Barry’s
termination will be deemed a termination without cause.
Under
the employment agreement, as amended, Dr. Barry is entitled to an annual base salary of at least $365,000. Such amount may be
reduced only as part of an overall cost reduction program that affects all of our senior executives and does not disproportionately
affect Dr. Barry, so long as such reductions do not reduce the base salary to a rate that is less than 90% of the amount set forth
above (or 90% of the amount to which it has been increased). Notwithstanding the foregoing, in the event of the closing of a transaction
or series of related transactions with investors where we raise an aggregate of $7 million from such investors, Dr. Barry’s
annual base salary shall increase to $400,000, commencing on the pay period immediately following the applicable closing for the
remainder of the term of his employment under the employment agreement. The base salary will be reviewed annually by the board
for increase as part of its annual compensation review.
In
November 2015, due to our efforts to preserve cash, Dr. Barry agreed to temporarily forego, in exchange for a corresponding reduced
time commitment to us, 50% of his base salary. We formalized such voluntarily agreement by entering into an amendment to Dr. Barry’s
employment agreement, dated March 28, 2016. The foregoing amendment to Dr. Barry’s employment agreement provides that, until
the earlier of (1) the end of the term of his employment, and (2) we raise an aggregate of $5 million from investors, Dr. Barry
shall receive 50% of his base salary and shall be eligible for 50% of any annual bonus or other incentive compensation, during
which period Dr. Barry shall devote 50% less business time than he ordinarily has devoted or would devote to us for the performance
of his services under his employment agreement.
On
June 6, 2016, in connection with Dr. Barry’s appointment as our president and chief executive officer, we further amended
Dr. Barry’s employment agreement to provide that, for the period beginning on June 1, 2016 and ending on the earlier of
(i) the closing of a transaction with investors where we raise an aggregate of $5 million and (ii) March 15, 2017, Dr. Barry would
receive 50% of his base salary in cash payments, payable in accordance with our regular payroll practices, with the remaining
50% of his base salary paid in a lump-sum payment on the first to occur of (a) the first payroll period that is on or after the
20th business day following such transaction or (b) March 15, 2017.
Pursuant
to the June 6, 2016, amendment, Dr. Barry became eligible to receive annual bonus compensation in an amount equal to 100% of his
base salary upon the achievement of reasonable target objectives and performance goals as may be determined by the board of directors
in consultation with Dr. Barry. In addition, on the first to occur of (a) the first payroll period that is on or after the 20th
business day following closing of a transaction with investors where we raise an aggregate of $5 million or (b) March 15, 2017,
Dr. Barry would receive a lump-sum retention bonus in an amount equal to $106,458, subject to Dr. Barry’s continued employment
through such date, which amount was paid on July 14, 2016. Dr. Barry is also eligible to receive such additional bonus or incentive
compensation as the board may establish from time to time in its sole discretion.
Pursuant
to the June 6, 2016, amendment, within 20 business days of the closing of the transaction with investors where we raise an aggregate
of $5 million, Dr. Barry was to be granted, subject to the board’s approval and Dr. Barry’s continued employment through
the applicable grant date, (i) a nonqualified stock option relating to the number of shares of our common stock equal to 2% of
outstanding common stock on the date of the closing of such transaction and (ii) an award of a number of restricted shares of
our common stock equal to 2% of outstanding common stock on the date of the closing of such transaction, in each case, subject
to the terms and conditions of the 2013 Plan and a nonqualified stock option agreement and a restricted stock award agreement
to be entered into by us and Dr. Barry. Such transaction occurred on July 7, 2016, and following the closing of the transaction,
Dr. Barry was granted an option to purchase 2,015 shares of common stock and 2,015 shares of restricted shares. The fifth amendment
to Dr. Barry’s employment agreement, dated September 5, 2017, amended this provision to provide that Dr. Barry will be eligible
to receive, subject to Dr. Barry’s continued employment through the applicable grant date, (i) a nonqualified stock option
relating to the number of shares of the our common stock equal to 2% of the Company’s outstanding common stock on the date
of the closing of the Financing (the “Financing Option”) and (ii) an award of a number of restricted shares of our
common stock equal to 2% of our outstanding common stock on the date of the closing of the Financing (the “Financing Restricted
Stock Award” and together with the Financing Option, the “Financing Equity Grant”), in each case, subject to
the availability of shares for grant under the 2013 Plan. To the extent shares are not available for grant under the 2013 Plan
for the full amount of the Financing Equity Grant on the date of grant, the Financing Option will be for 50% of the maximum number
of shares that remain available on the date of grant for grant under the 2013 Plan, and the Financing Restricted Stock Award will
be for 50% of the maximum number of shares that remain available on the date of grant for grant under the 2013 Plan. The Financing
Equity Grant is subject to the terms and conditions of separate award agreements between us and Dr. Barry and the terms and conditions
of the 2013 Plan.
Pursuant
to Dr. Barry’s employment agreement, if Dr. Barry’s employment is terminated upon his death or disability, by Dr.
Barry for good reason (as such term is defined in Dr. Barry’s employment agreement), or by us without cause (as such term
is defined in Dr. Barry’s employment agreement), Dr. Barry will be entitled to receive, in addition to other unpaid amounts
owed to him (e.g., for base salary and accrued vacation): (i) the pro rata amount of any bonus for the fiscal year of such termination
(assuming full achievement of all applicable goals under the bonus plan) that he would have received had his employment not been
terminated; (ii) a one-time lump sum severance payment equal to 200% of his base salary, calculated with a base salary amount
at the annual rate of $425,000, provided that he executes a release relating to employment matters and the circumstances surrounding
his termination in favor of us, our subsidiaries and our officers, directors and related parties and agents, in a form reasonably
acceptable to us at the time of such termination; (iii) vesting of 100% of all unvested stock options, restricted stock, stock
appreciation rights or similar stock based rights granted to Dr. Barry, and lapse of any forfeiture included in such restricted
or other stock grants; (iv) an extension of the term of any outstanding stock options or stock appreciation rights until the earlier
of (a) eighteen months from the date of termination, or (b) the latest date that each stock option or stock appreciation right
would otherwise expire by its original terms; (v) to the fullest extent permitted by our then-current benefit plans, continuation
of health, dental, vision and life insurance coverage for the lesser of 18 months after termination or until Dr. Barry obtains
coverage from a new employer; and (vi) a cash payment of $25,000, which Dr. Barry may use for executive outplacement services
or an education program. The payments described above will be reduced by any payments received by Dr. Barry pursuant to any of
our employee welfare benefit plans providing for payments in the event of death or disability. If Dr. Barry continues to be employed
by us after the term of his employment agreement, unless otherwise agreed by the parties in writing, and Dr. Barry’s employment
is terminated upon his death or disability, by Dr. Barry for good reason, or by us without cause, Dr. Barry will be entitled to
receive, in addition to other unpaid amounts owed to him, the payments set forth in (i), (ii) and (iv) above. If, during the term
of his employment agreement, we terminate Dr. Barry’s employment for cause or by Dr. Barry voluntarily, Dr. Barry will only
be entitled to unpaid amounts owed to him and whatever rights, if any, are available to him pursuant to our stock-based compensation
plans or any award documents related to any stock-based compensation.
Dr.
Barry has no specific right to terminate the employment agreement or right to any severance payments or other benefits solely
as a result of a change in control. However, if within 24 months following a change in control, (a) Dr. Barry terminates his employment
for good reason, or (b) we terminate his employment without cause, Dr. Barry will receive the same payments he would receive if
his employment is terminated upon his death or disability, by Dr. Barry for good reason (as such term is defined in Dr. Barry’s
employment agreement), or by us without cause (as such term is defined in Dr. Barry’s employment agreement).
Dr.
Barry’s employment agreement also contains certain noncompetition, no solicitation, confidentiality, and assignment of inventions
requirements for Dr. Barry.
Pursuant
to an option cancellation and release agreement, dated January 26, 2016, between us and Dr. Barry, Dr. Barry agreed to cancel
options to purchase 78 shares of our common stock at exercise prices ranging from $6,300 to $68,250 previously granted to him.
In exchange for the cancellation of Dr. Barry’s options, we granted to Dr. Barry, pursuant to the 2013 Plan and the 2013
Employee Stock Incentive Plan, which is a sub-plan to the 2013 Plan, one share of our common stock as of January 26, 2016.
Craig
Shore
We
have been a party to an employment agreement with Craig Shore since November 28, 2010. On May 5, 2014, we entered into an amended
and restated employment agreement with Mr. Shore, which was amended on January 5, 2015 and on July 25, 2016. The employment agreement,
as amended, has an initial term that ends on April 20, 2020 and will automatically renew for additional one-year periods on April
21, 2020 and on each April 21
st
thereafter unless either party gives the other party written notice of its election
not to extend such employment at least six months prior to the next April 21
st
renewal date. If a change in control
occurs when less than two full years remain in the initial term or during any renewal term, the employment agreement will automatically
be extended for two years from the change in control date and will terminate on the second anniversary of the change in control
date.
Mr.
Shore was initially entitled to a monthly gross salary of $8,750, which amount had increased to $10,620 by 2012. In addition,
Mr. Shore’s annual base salary was increased to $175,000 on April 22, 2013, retroactive to January 1, 2013, and to $220,200
in May 2014, retroactive to January 1, 2014. Under the terms of the employment agreement, as amended by the second amendment to
the amended and restated employment agreement, dated July 25, 2016, Mr. Shore is entitled to an annual base salary of at least
$250,000. Such amount may be reduced only as part of an overall cost reduction program that affects all of our senior executives
and does not disproportionately affect Mr. Shore, so long as such reduction does not reduce the base salary to a rate that is
less than 90% of the amount set forth above (or 90% of the amount to which it has been increased). The base salary will be reviewed
annually by our chief executive officer for increase (but not decrease, except as permitted as part of an overall cost reduction
program) as part of our annual compensation review. Mr. Shore is also eligible to receive an annual bonus in an amount equal to
60% of his then-annual salary upon the achievement of reasonable target objectives and performance goals, to be determined by
the board of directors in consultation with Mr. Shore. On January 5, 2015, we amended Mr. Shore’s amended and restated employment
agreement to remove from the amended and restated employment agreement the provision disallowing payment of annual bonus compensation
if Mr. Shore achieved less than 70% of the target objectives and performance goals determined by our board of directors in consultation
with him. Pursuant to such amendment, Mr. Shore is eligible to receive the percentage of his annual bonus corresponding to the
percentage of his achievement of such target objectives and performance goals. The annual bonus will be reviewed annually by our
chief executive officer for increase in the amount of the percentage of his then-base salary (but not decrease), as well as the
criteria and the goals, as part of our annual compensation review. In addition, Mr. Shore is eligible to receive such additional
bonus or incentive compensation as the board may establish from time to time in its sole discretion. Mr. Shore will also be considered
for grants of equity awards each year as part of the board’s annual compensation review, which will be made at the sole
discretion of the board of directors. Each grant will, with respect to any awards that are options, have an exercise price equal
to the fair market value of our common stock as of the date of grant, and will be subject to a three-year vesting period subject
to Mr. Shore’s continued service with us, with one-third of each additional grant vesting equally on the first, second,
and third anniversary of the date of grant for such awards.
The
second amendment to the amended and restated employment agreement provides a grant of equity awards to Mr. Shore on or within
10 business days of July 25, 2016 (the “Date of Grant”), with respect to an aggregate number of shares of our common
stock equal to 1% of our outstanding common stock and common stock issuable upon the conversion of our outstanding Series B Preferred
Stock on the Date of Grant, 50% of which shall be granted as restricted stock and 50% of which shall be granted as nonqualified
stock options, which will be subject to the terms and conditions of the 2013 Plan and a nonqualified stock option agreement and
a restricted stock award agreement to be entered into by us and Mr. Shore and a one-time lump-sum cash bonus in an amount equal
to $50,000, payable on or before September 1, 2016.
If
during the term of the employment agreement, Mr. Shore’s employment is terminated upon his death or disability, by us without
cause (as such term is defined in Mr. Shore’s employment agreement), or upon his resignation for “good reason”
(as such term is defined in Mr. Shore’s employment agreement), Mr. Shore will be entitled to receive, in addition to any
amounts he is entitled to receive under the manager’s insurance policy: (i) any unpaid base salary and accrued unpaid vacation
or earned incentive compensation and the pro rata amount of any bonus plan incentive compensation for the fiscal year of such
termination (based on the number of business days he was actually employed by us during the fiscal year of such termination and
based on the percentage of the goals that he actually achieved under the bonus plan) that he would have received had his employment
not been terminated; (ii) a one-time lump sum severance payment equal to 100% of his base salary, provided that he executes a
release relating to employment matters and the circumstances surrounding his termination in favor of us, our subsidiaries and
our officers, directors and related parties and agents, in a form reasonably acceptable to us at the time of such termination;
(iii) vesting of all unvested stock options, stock appreciation rights or similar stock-based rights granted to him and immediate
lapse of any risk of forfeiture included in restricted or other stock grants previously made to Mr. Shore; (iv) an extension of
the exercise period of all vested stock options granted to Mr. Shore until the earlier of (a) two years from the date of termination
or (b) the latest date that each stock option would otherwise expire by its original terms; (v) to the fullest extent permitted
by our then-current benefit plans, continuation of health, dental, vision and life insurance coverage for the lesser of 12 months
after termination or until Mr. Shore obtains coverage from a new employer; and (vi) reimbursement of up to $30,000 for executive
outplacement services, subject to certain restrictions. The severance payment described in (ii) of the foregoing sentence upon
Mr. Shore’s death or disability will be reduced by any payments received by Mr. Shore pursuant to any of our employee welfare
benefit plans providing for payments in the event of death or disability. If, during or after the term of his employment agreement,
Mr. Shore’s employment is terminated by us for cause or by Mr. Shore voluntarily, Mr. Shore will only be entitled to unpaid
amounts owed to him (e.g., base salary, accrued vacation and earned incentive compensation through the date of such termination)
and whatever rights, if any, are available to him pursuant to our stock-based compensation plan or any award documents related
to any stock-based compensation.
Mr.
Shore may terminate his employment for good reason by delivering a notice of termination to us 30 days in advance of the date
of termination; provided, however, that Mr. Shore agreed to not terminate his employment for good reason until he has given us
at least 30 days’ notice from which to cure the circumstances set forth in the notice of termination constituting good reason,
and if such circumstances are not cured by the 30th day, Mr. Shore’s employment shall terminate on such date.
Pursuant
to terms contained in Mr. Shore’s stock option and restricted stock award agreements, in the event of a change of control
of our company, the stock options and restricted stock granted to Mr. Shore that were unvested will vest immediately upon such
change of control, in the case of stock options, if such stock options are not assumed or substituted by the surviving company.
If
we terminate Mr. Shore’s employment without cause, Mr. Shore will be entitled, under Israeli law, to severance payments
equal to his last month’s salary multiplied by the number of years Mr. Shore has been employed with us. In order to finance
this obligation, we make monthly contributions equal to 8.33% of Mr. Shore’s salary to a severance payment fund. The total
amount accumulated in Mr. Shore’s severance payment fund as of December 31, 2017 was $122,220, as adjusted for conversion
from New Israeli Shekels to U.S. Dollars. However, if Mr. Shore’s employment is terminated without cause, on account of
a disability or upon his death, as of December 31, 2017, Mr. Shore would have been entitled to receive $164,151 in severance under
Israeli law, thereby requiring us to pay Mr. Shore $41,931, in addition to releasing the $122,220 in Mr. Shore’s severance
payment fund. On the other hand, pursuant to his employment agreement, Mr. Shore is entitled to the total amount contributed to
and accumulated in his severance payment fund in the event of the termination of his employment as a result of his voluntary resignation.
In addition, Mr. Shore would be entitled to receive his full severance payment under Israeli law, including the total amount contributed
to and accumulated in his severance payment fund, if he retires from our company at or after age 67.
We
are entitled to terminate Mr. Shore’s employment immediately at any time for “cause” (as such term is defined
in the agreement and the Israeli Severance Payment Act 1963), upon which, after meeting certain requirements under the applicable
law and recent Israeli Labor court requirements, we believe we will have no further obligation to compensate Mr. Shore.
Also,
upon termination of Mr. Shore’s employment for any reason, we will compensate him for all unused or previously uncompensated
vacation days accrued.
The
employment agreement also contains certain standard noncompetition, non-solicitation, confidentiality, and assignment of inventions
requirements for Mr. Shore.
Mr.
Shore is also entitled to participate in or receive benefits under our social insurance and benefits plans, including but not
limited to our manager’s insurance policy and education fund, which are customary benefits provided to executive employees
in Israel. A management insurance policy is a combination of severance savings (in accordance with Israeli law), defined contribution
tax-qualified pension savings and disability pension payments. An education fund is a savings fund of pre-tax contributions to
be used after a specified period of time for advanced educational training and other permitted purposes, as set forth in the by-laws
of the education fund. We will make periodic contributions to these insurance and social benefits plans based on certain percentages
of Mr. Shore’s base salary, including (i) 7.5% to the education fund and (ii) 15.83% to the manager’s insurance policy,
of which 8.33% will be allocated to severance pay, 5% to pension fund payments and 2.5% to disability pension payments. Upon the
termination of Mr. Shore’s employment for any reason other than for cause, Mr. Shore will be entitled to receive the total
amount contributed to and accumulated in his manager insurance policy fund.
Pursuant
to an option cancellation and release agreement, dated January 26, 2016, between us and Mr. Shore, Mr. Shore agreed to cancel
options to purchase 51 shares of our common stock at exercise prices ranging from $6,300 to $43,124.20 previously granted to him.
In exchange for the cancellation of Mr. Shore’s options, we granted to Mr. Shore, pursuant to the 2013 Plan and the 2013
Employee Stock Incentive Plan, which is a sub-plan to the 2013 Plan, one share of our common stock as of January 26, 2016.
Agustin
V. Gago
On
October 24, 2016, we entered into an employment agreement with Agustin V. Gago to serve as our executive vice president and chief
commercial officer. The initial term of Mr. Gago’s employment ends on October 23, 2018, unless earlier terminated or extended
for additional one-year periods on October 23, 2018, and on each and every October 23 thereafter, provided that either party may
elect not to extend the term of the employment by prior written notice at least two months prior to the expiration date or the
next renewal date.
Pursuant
to Mr. Gago’s employment agreement, Mr. Gago is entitled to an annual base salary of $275,000, which shall automatically
increase to $300,000, effective as of January 1, 2018. Mr. Gago is eligible to receive an annual bonus in an amount up to 50%
of his then-base salary, commencing in 2017, based upon the achievement of reasonable target objectives and performance goals
as may be determined by our president and chief executive officer and subject to approval of the board of directors after consultation
with Mr. Gago. The target objectives shall be based 60% on revenue achievement, 20% on marketing objectives, and 20% on corporate
objectives. In addition, in the event that Mr. Gago and his team shall exceed quarterly revenue targets determined by our president
and chief executive officer and subject to approval of the board of directors after consultation with Mr. Gago, Mr. Gago may receive
additional escalating amounts included as part of the annual bonus based upon the payment scales determined by our president and
chief executive officer and approved by the board of directors after consultation with Mr. Gago. Mr. Gago will receive a one-time
bonus of $25,000 in the event that our net sales for the fourth quarter of 2016 exceed our forecast by at least 20%. Mr. Gago
is also entitled to a one-time bonus of $25,000, payable on or before November 15, 2016, which was paid on October 31, 2016. In
addition, pursuant to Mr. Gago’s employment agreement, on October 24, 2016, Mr. Gago was granted (i) a stock option to purchase
385 shares of our common stock at an exercise price of $65.10, vesting on the first anniversary of the date of grant (subject
to forfeiture upon termination of employment); and (ii) a stock option to purchase 915 shares of our common stock at an exercise
price of $65.10, vesting in equal installments on the first and second anniversary of the date of grant, each subject to the terms
and conditions of the 2013 Plan, and our form of option award agreement. Mr. Gago may also be eligible to receive certain stock
options or similar stock-based rights as set forth separately in those certain agreements and subject to the terms and conditions
of the 2013 Plan.
Either
party may terminate the agreement at any time, provided that Mr. Gago provides 90 day’s prior written notice to us of his
voluntary resignation and we provide 90 days’ prior written notice of termination by us without cause (as defined in Mr.
Gago’s employment agreement) to Mr. Gago. In addition, we may terminate Mr. Gago’s employment for cause, after a 30
day cure period, if the circumstances are curable. If we terminate Mr. Gago’s employment without cause or Mr. Gago’s
death, Mr. Gago is entitled to (A) any unpaid base salary accrued through the termination date, any accrued and unpaid vacation
pay and any unreimbursed expenses properly incurred prior to the termination date; (B) a severance pay equal to Mr. Gago’s
base salary for 12 months; (C) any earned but unpaid annual bonus relating to the calendar year prior to the calendar year in
which the termination date occurs; and (D) to the fullest extent permitted by our then-current benefit plans, continuation of
certain insurance benefits for the lesser of 12 months after termination of employment or until Mr. Gago secures coverage from
new employment. Mr. Gago has no specific right to terminate Mr. Gago’s employment agreement as a result of a change in control
(as defined in the 2013 Plan); however, if following a change in control, during the term of Mr. Gago’s employment, if we
terminate Mr. Gago without cause, or the purchaser or surviving entity following the change in control does not offer Mr. Gago
a comparable offer of employment, all stock options or similar stock-based rights granted to Mr. Gago shall vest in full and become
immediately exercisable.
Mr.
Gago’s employment agreement also contains certain noncompetition, non-solicitation, non-disparagement, confidentiality and
assignment of work product requirements for Mr. Gago.
Outstanding
Equity Awards at December 31, 2017
The
following table shows information concerning unexercised options and unvested restricted shares outstanding as of December 31,
2017 for each of our named executive officers.
Option Awards
|
|
Stock Awards
|
|
Name
|
|
Number of securities underlying unexercised options (#)
exercisable
|
|
|
Number of securities underlying unexercised options (#)
unexercisable
|
|
|
Option exercise
price ($)
|
|
|
Option expiration
date
|
|
|
Number of shares of stock that have not vested (#)
|
|
|
Market value of shares of stock that have not vested ($)
|
|
James Barry, Ph.D.
|
|
|
2,015
|
|
|
|
-
|
|
|
|
166.25
|
|
|
|
07/25/2026
|
|
|
|
1
|
(1)
|
|
$
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Craig Shore
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
(1)
|
|
$
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
336
|
(2)
|
|
$
|
1,509
|
|
|
|
|
168
|
|
|
|
336
|
(3)
|
|
|
166.25
|
|
|
|
07/25/2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agustin V. Gago
|
|
|
458
|
|
|
|
457
|
(4)
|
|
|
65.10
|
|
|
|
10/24/2026
|
|
|
|
|
|
|
|
|
|
|
|
|
385
|
|
|
|
-
|
|
|
|
65.10
|
|
|
|
10/24/2026
|
|
|
|
|
|
|
|
|
|
(1)
|
These
restricted shares vested on January 26, 2018.
|
|
|
(2)
|
These
restricted shares vest annually, with one-half vesting on each of July 25, 2018 and July 25, 2019.
|
|
|
(3)
|
These
options vest annually, with one-half vesting on each of July 25, 2018 and July 25, 2019.
|
|
|
(4)
|
These
options will vest on October 24, 2018.
|
Option
Exercises and Stock Vested
There
were no stock options exercised by our named executive officers during the twelve months ended December 31, 2017.
2011
UMBRELLA Option Plan
On
March 28, 2011, our board of directors and stockholders adopted and approved the InspireMD, Inc. 2011 UMBRELLA Option Plan, which
was subsequently amended on October 31, 2011 and December 21, 2012. Under the InspireMD, Inc. 2011 UMBRELLA Option Plan, we have
reserved 571 shares of our common stock as awards to the employees, consultants, and service providers to InspireMD, Inc. and
its subsidiaries and affiliates worldwide.
The
InspireMD, Inc. 2011 UMBRELLA Option Plan currently consists of three components, the primary plan document that governs all awards
granted under the InspireMD, Inc. 2011 UMBRELLA Option Plan, and two appendices: (i) Appendix A, designated for the purpose of
grants of stock options and restricted stock awards to Israeli employees, consultants, officers and other service providers and
other non-U.S. employees, consultants, and service providers, and (ii) Appendix B, which is the 2011 U.S. Equity Incentive Plan,
designated for the purpose of grants of stock options and restricted stock awards to U.S. employees, consultants, and service
providers who are subject to the U.S. income tax. On December 21, 2012, the stockholders approved the awarding of “incentive
stock options” pursuant to the U.S. portion of the plan.
The
purpose of the InspireMD, Inc. 2011 UMBRELLA Option Plan is to provide an incentive to attract and retain employees, officers,
consultants, directors, and service providers whose services are considered valuable, to encourage a sense of proprietorship and
to stimulate an active interest of such persons in our development and financial success. The InspireMD, Inc. 2011 UMBRELLA Option
Plan is administered by our compensation committee. Unless terminated earlier by the board of directors, the InspireMD, Inc. 2011
UMBRELLA Option Plan will expire on March 27, 2021. We have 291 shares of common stock available for future issuance under our
2011 UMBRELLA Option Plan.
2013
Long-Term Incentive Plan
On
December 16, 2013, our stockholders approved the 2013 Plan, which was adopted by our board of directors on October 25, 2013.
The
purpose of the 2013 Plan is to provide an incentive to attract and retain employees, officers, consultants, directors, and service
providers whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of
such persons in our development and financial success. The 2013 Plan provides for the granting of incentive stock options, nonqualified
stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights,
and other awards, which may be granted singly, in combination, or in tandem. The 2013 Plan is administered by our compensation
committee.
The
2013 Plan is intended to serve as an “umbrella” plan for us and our subsidiaries worldwide. Therefore, if so required,
appendices may be added to the 2013 Plan in order to accommodate local regulations that do not correspond to the scope of the
2013 Plan. Attached as Appendix A to the 2013 Plan is the InspireMD, Inc. 2013 Employee Stock Incentive Plan, for the purpose
of making grants of stock options, restricted stock, and other stock incentive awards pursuant to Sections 102 and 3(i) of the
Israeli Income Tax Ordinance (New Version), 1961 to Israeli employees and officers and any other service providers or control
holders of us who are subject to Israeli Income Tax.
When
the 2013 Plan was adopted, a total of 571 shares of common stock were reserved for awards under the 2013 Plan.
On
September 9, 2015, our stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available
for issuance pursuant to awards under the 2013 Plan by 537 shares of common stock, to a total of 1,108 shares of common stock.
On
May 24, 2016, our stockholders approved the second amendment to the 2013 Plan to increase the number of shares of common stock
available for issuance pursuant to awards under the 2013 Plan by 11,429 shares of common stock, to a total of 12,537 shares of
common stock.
On
September 28, 2016, our stockholders approved the third amendment to the 2013 Plan to increase the number of shares of common
stock available for issuance pursuant to awards under the 2013 Plan by 7,200 shares of common stock, to a total of 19,737 shares
of common stock.
We
have 8,983 shares of common stock available for future issuance under our 2013 Long-Term Incentive Plan.
Equity
Compensation Plan Information
The
following table provides certain information as of December 31, 2017, with respect to our equity compensation plans under which
our equity securities are authorized for issuance:
Plan Category
|
|
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants and
rights
|
|
|
Weighted-
average
exercise price of
outstanding
options,
warrants and
rights
|
|
|
Number of
securities
remaining
available for
future issuance
under equity
compensation
plans
(excluding
securities
reflected in
column (a))
|
|
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
Equity compensation
plans approved by
security holders
|
|
|
8,114
|
|
|
|
316.84
|
|
|
|
8,888
|
|
Equity compensation
plans not approved
by security holders
|
|
|
102
|
(1)
|
|
|
59,895
|
|
|
|
—
|
|
Total
|
|
|
8,216
|
|
|
|
1,047.17
|
|
|
|
—
|
|
(1)
|
Comprised
of awards made to individuals outside the InspireMD, Inc. 2011 UMBRELLA Option Plan and 2013 Long Term Incentive Plan, as
described below:
|
|
●
|
Options
issued to current director: in November 2011, we issued options to purchase an aggregate of 84 shares of common stock to Dr.
Barer, the chairman of our board of directors. The exercise price of these options is $68,250 per share. An option to purchase
21 shares of common stock vested on April 11, 2013, when our common stock was first listed on a national securities exchange.
An option to purchase 21 shares of common stock vested on May 10, 2013, after we received research coverage from a second
investment bank that ranked in the top twenty investment banks in terms of life science underwritings. The option to purchase
42 shares of common stock vested in substantially equal monthly installments (with any fractional shares vesting on the last
vesting date) on the last business day of each calendar month over a two year period from the date of grant, with the first
installment having vested on November 30, 2011, provided that Dr. Barer was still providing services to us in some capacity
as of each such vesting date.
|
|
|
|
|
●
|
Options
issued to our former vice president of global marketing and strategy: in September 2013, we issued options to purchase 18
shares of common stock to David Blossom. The exercise price of these options was $19,512.50 per share. The options vest annually
with one-third vesting on September 16, 2014, September 16, 2015 and September 16, 2016. The options expire on December 16,
2018.
|
Change
of Control Agreements
We
do not currently have any plans providing for the payment of retirement benefits to our officers or directors, other than as described
under “Agreements with Executive Officers” above.
We
do not currently have any change-of-control or severance agreements with any of our executive officers or directors, other than
as described under “Agreements with Executive Officers” above. In the event of the termination of employment of the
named executive officers, any and all unexercised stock options shall expire and no longer be exercisable after a specified time
following the date of the termination, other than as described under “Agreements with Executive Officers” above.
Director
Compensation
The
following table shows information concerning our directors, other than James Barry, Ph.D., during the twelve months ended December
31, 2017.
Name
|
|
Fees
Earned
or
Paid in Cash
($)
|
|
|
Stock
Awards
($)
|
|
|
Option
Awards
($)
|
|
|
All Other
Compensation
($)
|
|
|
Total
($)
|
|
Sol J. Barer, Ph.D.
(1)
|
|
|
13,917
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13,917
|
|
Isaac Blech
(2)
|
|
|
12,500
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
12,500
|
|
Paul Stuka
|
|
|
39,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
39,000
|
|
Michael Berman
|
|
|
37,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
37,000
|
|
Campbell Rogers, M.D.
|
|
|
26,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
26,000
|
|
Thomas Kester
|
|
|
39,333
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
39,333
|
|
(1)
|
Dr.
Barer resigned from our board as of June 2, 2017.
|
|
|
(2)
|
Mr.
Blech resigned from our board as of June 29, 2017.
|
In
connection with Dr. Barer’s resignation from the Board, on June 2, 2017, we amended (i) the nonqualified stock option agreement
we entered into with Dr. Barer on December 7, 2016, to accelerate the vesting of the option to purchase 572 shares of common stock
so that the option are fully vested as of June 2, 2017, and to permit Dr. Barer to exercise such option at any time prior to the
tenth anniversary of the grant date, and (ii) the nonqualified stock option agreements we entered into with Dr. Barer on November
16, 2011, March 31, 2015, June 30, 2015, September 30, 2015, and June 30, 2016, to permit Dr. Barer to exercise the fully vested
options to purchase an aggregate of 243 shares of common stock at any time prior to the tenth anniversary of the grant date.
For
the 2017 calendar year, our board approved the following compensation for our independent directors: (i) a $25,000 stipend, payable
quarterly; (ii) annual committee chair compensation (effective April 1, 2014) of $12,000 for the chairman of the audit committee,
$8,000 for the chairman of the compensation committee and $5,000 for the chairmen of the nominating and corporate governance committee
and the research and development committee; (iii) annual committee membership compensation (effective April 1, 2014) of $4,000
for members of the audit committee and the compensation committee and $2,000 for members of the nominating and corporate governance
committee and the research and development committee; (iv) an option to purchase 358 shares of our common stock for each board
member; and (v) an option to purchase an additional 215 shares of our common stock for the chairman of the board. The research
and development committee was dissolved following the second quarter of 2017.
Directors’
and Officers’ Liability Insurance
We
currently have directors’ and officers’ liability insurance insuring our directors and officers against liability
for acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance also insures
us against losses which we may incur in indemnifying our officers and directors. In addition, we have entered into indemnification
agreements with key officers and directors and such persons shall also have indemnification rights under applicable laws, and
our certificate of incorporation and bylaws.
PROPOSAL
2: APPROVAL OF THE PLAN AMENDMENT PROPOSAL
Our
board of directors is seeking the approval of our stockholders of an amendment to the 2013 Plan, which was adopted by our board
of directors on May 23, 2018, subject to stockholder approval (the “Fourth Amendment”). The 2013 Plan was originally
approved by our board of directors on October 25, 2013, and by our stockholders at our annual meeting held on December 16, 2013.
Under the 2013 Plan as originally adopted, we reserved a total of 5,000,000 shares of our common stock for issuance pursuant to
awards under the 2013 Plan. Our board of directors subsequently amended the 2013 Plan on July 16, 2015, which amendment was approved
by our stockholders on September 9, 2015, to increase the number of shares of common stock available for issuance pursuant to
awards under the 2013 Plan by 4,700,000 shares, to a total of 9,700,000 shares of our common stock. On October 1, 2015, we effected
a 1-for-10 reverse stock split such that, after giving effect to the reverse stock split, there were 970,000 shares of our common
stock reserved for issuance pursuant to awards under the 2013 Plan. On May 24, 2016, our stockholders approved the second amendment
to the 2013 Plan to increase the number of shares of common stock available for issuance pursuant to awards under the 2013 Plan
by 10,000,000 shares of common stock, to a total of 10,970,000 shares of common stock. On September 28, 2016, our stockholders
approved the third amendment to the 2013 Plan to further increase the number of shares of common stock available for issuance
pursuant to awards under the 2013 Plan by an additional 6,300,000 shares of common stock, to a total of 17,270,000 shares of common
stock. On October 7, 2016, we effected a 1-for-25 reverse stock split of our common stock such that, after giving effect to the
reverse stock split, there were 690,800 shares of our common stock reserved for issuance pursuant to awards under the 2013 Plan.
On February 7, 2018, we effected a 1-for-35 reverse stock split of our common stock such that, after giving effect to the reverse
stock split, there were 19,737 shares of our common stock reserved for issuance pursuant to awards under the 2013 Plan. When adjusted
to give effect to the 1-for-10 reverse stock split, the 1-for-25 reverse stock split and the 1-for-35 reverse stock split, as
applicable, the first, second and third amendments to the 2013 Plan increased the number of shares of common stock available for
issuance pursuant to awards under the 2013 Plan by 537 shares, 11,429 shares and 7,200 shares of our common stock, respectively.
As of September 7, 2018, out of 19,737 shares of our common stock reserved for issuance pursuant to awards under the 2013
Plan, there were 8,983 shares remaining available for future issuance under the 2013 Plan. The proposed Fourth Amendment (i) further
increases the number of shares of common stock available for issuance pursuant to awards under the 2013 Plan by an additional
8,900,000 shares, to a total of 8,919,737 shares of our common stock and (ii) removes the cap on the number of shares of common
stock with respect to which stock options or stock appreciation rights may be granted to certain executive officers of the Company
during any calendar year.
We
believe that operation of the 2013 Plan is a necessary and powerful tool in attracting and retaining the services of key employees,
key contractors, and outside directors in a competitive labor market, which is essential to our long-term growth and success.
We also need to ensure that we can continue to provide an incentive to our current employees, contractors and outside directors,
many of whom hold outstanding options that were previously awarded under the 2013 Plan with exercise prices above the current
fair market value of our common stock. We have strived to use our 2013 Plan resources effectively and maintain an appropriate
balance between stockholder interests and the ability to recruit and retain valuable employees. However, we only have 8,983 shares
remaining available for future issuance under the 2013 Plan and believe that this is an insufficient number to meet our current
and projected needs. In March, April and July of 2018, we closed three public offerings, increasing the number of shares of common
stock outstanding from 1,675,619 shares as of February 22, 2018, to 23,784,784 shares as of September 6, 2018. Additionally, based
on the number of shares of Series B and Series C Preferred Stock and the number of pre-funded warrants outstanding as of September
6, 2018, an aggregate of 20,867,102 shares of common stock are issuable upon conversion of the outstanding shares of Series B
and C Preferred Stock at the conversion price currently in effect and upon exercise of the outstanding pre-funded warrants at
the exercise price currently in effect. As a result of these financings and the resulting increase in the number of shares of
common stock being issuable upon conversion of outstanding shares of preferred stock and upon exercise of outstanding pre-funded
warrants, the number of shares issuable pursuant to the 2013 Plan relative to our fully diluted capitalization is now disproportionately
low, relative to our peer companies Having such a small percentage of our fully diluted capitalization reserved for employees
and directors will impair our ability to both attract and retain key persons going forward. Accordingly, it is the judgment of
our board of directors that increasing the number of shares of common stock available for issuance under the 2013 Plan pursuant
to the Fourth Amendment is in the best interest of the Company and its stockholders. In addition, we believe that the Fourth Amendment
to increase the number of shares of common stock available for issuance pursuant to awards under the 2013 Plan reflects best practices
in our industry.
In
addition, the Fourth Amendment removes the cap on the number of shares of common stock with respect to which stock options or
stock appreciation rights may be granted to certain of our executive officers during any calendar year. Section 162(m) of the
Internal Revenue Code of 1986, as amended (the “Code”), prevents us from deducting compensation of more than $1,000,000
that is paid to certain of our executive officers who are “covered employees” (as defined in Section 162(m) of the
Code). Prior to the enactment of the Tax Cuts and Jobs Act on December 22, 2017 (the “Tax Reform Act”), certain types
of compensation, such as qualified performance-based compensation, were exempt from that $1,000,000 deductibility limit if certain
requirements were met. One such requirement was that the plan that provided for such qualified performance-based compensation
state the maximum number of shares of stock with respect to which stock options or stock appreciation rights may be granted to
an individual during a specified period of time. The Tax Reform Act repealed the qualified performance-based compensation exception
to Section 162(m) of the Code, except with respect to Grandfathered Awards (as defined in the
Million Dollar Deduction Limit
and Other Tax Matters
section below). Consequently, the 2013 Plan is no longer required to contain a limit on the number of
shares of common stock with respect to which stock options or stock appreciation rights may be granted to an individual during
any calendar year, and the Fourth Amendment removes the 2013 Plan’s cap on the number of shares of common stock with respect
to which stock options or stock appreciation rights may be granted to certain of our executive officers during any calendar year.
The removal of that cap is expected to provide us with even greater flexibility in our compensation methods so as to be able to
adapt the compensation of our employees, contractors, and outside directors to a changing business environment, after giving due
consideration to competitive conditions and the impact of U.S. and Israeli tax laws.
A
copy of the Fourth Amendment and the 2013 Plan are included as Annex A and Annex B, respectively, to this Proxy Statement. Described
below is a summary of certain key provisions of the 2013 Plan, which is qualified in its entirety by reference to the full text
of the 2013 Plan.
The
board of directors recommends that the stockholders vote “FOR” the approval of the Plan Amendment Proposal (Proposal
2).
Summary
of the Proposed Fourth Amendment
Our
board of directors adopted the Fourth Amendment on May 23, 2018, subject to stockholder approval, to (i) increase the number of
shares of our common stock available for issuance pursuant to awards under the 2013 Plan by an additional 8,900,000 shares, to
a total of 8,919,737 shares of common stock, and (ii) remove the cap on the number of shares of common stock with respect to which
stock options or stock appreciation rights may be granted to certain executive officers of the Company during any calendar year.
Description
of the 2013 Plan
Purpose
.
The purpose of the 2013 Plan is to enable the Company and its subsidiaries and affiliates (together, the “Group”)
to remain competitive and innovative in our ability to attract, motivate, reward, and retain the services of key employees, key
contractors, and outside directors. The 2013 Plan provides for the granting of incentive stock options, nonqualified stock options,
stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other
awards which may be granted singly, in combination, or in tandem and which may be paid in cash, shares of common stock, or a combination
of cash and shares of common stock. The 2013 Plan is expected to provide flexibility to our compensation methods in order to adapt
the compensation of employees, contractors, and outside directors to a changing business environment, after giving due consideration
to competitive conditions and the impact of U.S. and Israeli tax laws.
The
2013 Plan consists of two components, the primary plan document which governs all awards granted under the 2013 Plan, and one
sub-part appendix: Appendix A, which is the 2013 Employee Stock Incentive Plan (the “Israeli Appendix”), designated
for grants of stock options, restricted stock, and other stock incentive awards to Israeli employees, consultants, officers, directors,
and other service providers and to other non-U.S. employees, consultants, and service providers subject to Israeli income tax.
Effective
Date and Expiration
. The 2013 Plan became effective on October 25, 2013, subject to and conditioned upon stockholder approval
of the 2013 Plan, and will terminate on October 25, 2023. No award may be made under the 2013 Plan after its expiration date,
but awards m ade prior thereto may extend beyond that date in accordance with their terms and conditions.
Share
Authorization
. Subject to certain adjustments, the maximum number of shares of our common stock that may be delivered pursuant
to awards under the 2013 Plan is currently 19,737 shares, 100% of which may be delivered pursuant to incentive stock options.
If the Fourth Amendment is approved, the total number of shares that may be issued pursuant to awards under the 2013 Plan will
be increased to 8,919,737 shares. The 2013 Plan also provides that no more than 10% of the shares of common stock that may be
issued pursuant to an award under the 2013 Plan may be designated as Exempt Shares (as defined in the 2013 Plan). The compensation
committee has greater flexibility to accelerate the vesting for shares designated as Exempt Shares.
Shares
to be issued may be made available from authorized but unissued shares of our common stock, shares held by the Company in its
treasury, or shares purchased by the Company on the open market or otherwise. During the term of the 2013 Plan, we will at all
times reserve and keep enough shares available to satisfy the requirements of the 2013 Plan. If an award under the 2013 Plan is
cancelled, forfeited, or expires, in whole or in part, the shares subject to such forfeited, expired, or cancelled award may again
be awarded under the 2013 Plan. In the event that previously acquired shares are delivered to us in full or partial payment of
the option price for the exercise of a stock option granted under the 2013 Plan, the number of shares available for future awards
under the 2013 Plan shall be reduced only by the net number of shares issued upon the exercise of the stock option or settlement
of an award. Awards that may be satisfied either by the issuance of common stock or by cash or other consideration shall be counted
against the maximum number of shares that may be issued under the 2013 Plan only during the period that the award is outstanding
or to the extent the award is ultimately satisfied by the issuance of shares. An award will not reduce the number of shares that
may be issued pursuant to the 2013 Plan if the settlement of the award will not require the issuance of shares, as, for example,
a stock appreciation right that can be satisfied only by the payment of cash. Only shares forfeited back to the Company; shares
cancelled on account of termination, expiration, or lapse of an award; shares surrendered in payment of the option price of an
option; or shares withheld for payment of applicable employment taxes and/or withholding obligations resulting from the exercise
of a stock option shall again be available for grants of incentive stock options under the 2013 Plan, but shall not increase the
maximum number of shares described above as the maximum number of shares that may be delivered pursuant to incentive stock options.
Administration
.
The 2013 Plan may be administered by our board of directors or a committee of the board of directors consisting of two or more
members. The 2013 Plan is currently administered by the compensation committee of our board of directors. The compensation committee
will determine the persons to whom awards are to be made; determine the type, size, and terms of awards; interpret the 2013 Plan;
establish and revise rules and regulations relating to the 2013 Plan; and make any other determinations that it believes are necessary
for the administration of the 2013 Plan. To assure the viability of awards granted to participants employed in foreign countries,
the compensation committee may provide for such special terms as it may consider necessary or appropriate to accommodate differences
in local law, tax policy, or custom. Moreover, the compensation committee may approve such supplements to, or amendments, restatements,
or alternative versions of, the 2013 Plan as the compensation committee determines is necessary or appropriate for such purposes.
Any such amendment, restatement, or alternative versions that the compensation committee approves for purposes of using the 2013
Plan in a foreign country will not affect the terms of the 2013 Plan for any other country. The compensation committee may delegate
certain duties to one or more officers of the Company as provided in the 2013 Plan.
Eligibility
.
Employees (including any employee who is also a director or an officer), contractors, and outside directors of the Group whose
judgment, initiative and efforts contributed to or may be expected to contribute to the successful performance of the Group are
eligible to participate in the 2013 Plan. As of September 7, 2018, there were approximately 38 employees, directors, and
contractors who would be eligible for awards under the 2013 Plan.
Stock
Options
. For persons subject to U.S. income tax, the compensation committee may grant either incentive stock options (“ISOs”)
qualifying under Section 422 of the Code or nonqualified stock options, provided that only employees of the Company and its subsidiaries
(excluding subsidiaries that are not corporations) are eligible to receive ISOs. Stock options may not be granted with an option
price less than 100% of the fair market value of a share of common stock on the date the stock option is granted. If an ISO is
granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of stock of the
Company (or any parent or subsidiary), the option price shall be at least 110% of the fair market value of a share of common stock
on the date of grant. The compensation committee will determine the terms of each stock option at the time of grant, including,
without limitation, the methods by or forms in which shares will be delivered to participants. The maximum term of each option,
the times at which each option will be exercisable, and provisions requiring forfeiture of unexercised options at or following
termination of employment or service generally are fixed by the compensation committee, except that the compensation committee
may not grant stock options with a term exceeding ten years, or in the case of an ISO granted to an employee who owns or is deemed
to own 10% or more of the combined voting power of all classes of our stock (or any parent or subsidiary), a term exceeding five
years.
Recipients
of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of the Company;
(ii) by delivering to us shares of common stock (including restricted stock) already owned by the participant having a fair market
value equal to the aggregate option price and that the participant has not acquired from us within six months prior to the exercise
date; (iii) by delivering to us or our designated agent an executed irrevocable option exercise form together with irrevocable
instructions from the participant to a broker or dealer, reasonably acceptable to us, to sell certain of the shares purchased
upon the exercise of the option or to pledge such shares to the broker as collateral for a loan from the broker and to deliver
to us the amount of sale or loan proceeds necessary to pay the purchase price; or (iv) by any other form of valid consideration
that is acceptable to the compensation committee in its sole discretion.
Stock
Appreciation Rights
. The compensation committee is authorized to grant stock appreciation rights (“SARs”) as a
stand-alone award, or freestanding SARs, or in conjunction with options granted under the 2013 Plan, or tandem SARs. SARs entitle
a participant to receive an amount, in cash, shares, or a combination of both, equal to the excess of the fair market value of
a share of common stock on the date of exercise over the fair market value of a share of common stock on the date of grant. The
grant price of a SAR cannot be less than 100% of the fair market value of a share of common stock on the date of grant. The compensation
committee will determine the terms of each SAR at the time of the grant, including, without limitation, the methods by or forms
in which shares will be delivered to participants. The maximum term of each SAR, the times at which each SAR will be exercisable,
and provisions requiring forfeiture of unexercised SARs at or following termination of employment or service generally are fixed
by the compensation committee, except that no freestanding SAR may have a term exceeding ten years and no tandem SAR may have
a term exceeding the term of the option granted in conjunction with the tandem SAR. The compensation committee, in its sole discretion,
may place a ceiling on the amount payable upon exercise of a SAR, but any such limitation shall be specified at the time that
the SAR is granted.
Restricted
Stock and Restricted Stock Units
. The compensation committee is authorized to grant restricted stock and restricted stock
units. Restricted stock consists of shares of common stock that may not be sold, transferred, pledged, assigned, hypothecated,
encumbered, or otherwise disposed of, and that may be forfeited in the event of certain terminations of employment or service,
prior to the end of a restricted period as specified by the compensation committee. Restricted stock units are the right to receive
shares of common stock at a future date in accordance with the terms of such grant upon the attainment of certain conditions specified
by the compensation committee, which include a substantial risk of forfeiture and restrictions on their sale or other transfer
by the participant. The compensation committee determines the eligible participants to whom, and the time or times at which, grants
of restricted stock or restricted stock units will be made, the number of shares or units to be granted, the price to be paid,
if any, the time or times within which the shares covered by such grants will be subject to forfeiture, the time or times at which
the restrictions will terminate, and all other terms and conditions of the grants. Restrictions or conditions could include, but
are not limited to, the attainment of performance goals (as described below), continuous service with us, the passage of time,
or other restrictions and conditions.
Dividend
Equivalent Rights
. The compensation committee is authorized to grant a dividend equivalent right to any participant either
as a component of another award or as a separate award, conferring on the participant the right to receive credits based on the
cash dividends that would have been paid on the shares of common stock specified in the grant if such shares were held by the
participant to whom the grant is made. The terms and conditions of the dividend equivalent right shall be specified by the grant.
Dividend equivalents credited to the holder of a dividend equivalent right may be paid currently or may be deemed to be reinvested
in additional shares of common stock. Any such reinvestment shall be at the fair market value at the time thereof. A dividend
equivalent right may be settled in cash, shares, or a combination thereof.
Performance
Awards
. The compensation committee may grant performance awards of cash, shares of common stock, units, or rights based upon,
payable in, or otherwise related to shares of our common stock. Payment will be contingent upon achieving pre-established performance
goals (as described below) by the end of the performance period. The compensation committee will determine the length of the performance
period, the maximum payment value of an award, and the minimum performance goals required before payment will be made, so long
as such provisions are not inconsistent with the terms of the 2013 Plan, and to the extent an award is subject to Section 409A
of the Code, are in compliance with the applicable requirements of Section 409A of the Code and any applicable regulations or
guidance. In addition, to the extent we intended for Section 162(m) of the Code to apply to any Grandfathered Awards, no participant
has received in any calendar year Grandfathered Awards with respect to more than 1,000,000 shares of common stock. In certain
circumstances, the compensation committee may, in its discretion, determine that the amount payable with respect to certain performance
awards will be reduced from the amount of any potential awards. However, the compensation committee may not, in any event, increase
the amount of compensation payable to an individual upon the attainment of a performance goal intended to satisfy the requirements
of Section 162(m) of the Code. With respect to a performance award that is not intended to satisfy the requirements of Section
162(m) of the Code, if the compensation committee determines, in its sole discretion, that the established performance measures
or objectives are no longer suitable because of a change in our business, operations, corporate structure, or for other reasons
that the compensation committee deemed satisfactory, the compensation committee may modify the performance measures or objectives
and/or the performance period.
Performance
Goals
. Awards of restricted stock, restricted stock units, performance awards, and other awards (whether relating to cash
or shares of common stock) under the 2013 Plan may be made subject to the attainment of performance goals relating to one or more
business criteria which, where applicable, shall be within the meaning of Section 162(m) of the Code and consist of one or more
or any combination of the following criteria (“Performance Criteria”): cash flow; cost; revenues; sales; ratio of
debt to debt plus equity; net borrowing, credit quality or debt ratings; profit before tax; economic profit; earnings before interest
and taxes; earnings before interest, taxes, depreciation and amortization; gross margin; earnings per share (whether on a pre-tax,
after-tax, operational or other basis); operating earnings; capital expenditures; expenses or expense levels; economic value added;
ratio of operating earnings to capital spending or any other operating ratios; free cash flow; net profit; net sales; net asset
value per share; the accomplishment of mergers, acquisitions, dispositions, public offerings or similar extraordinary business
transactions; sales growth; price of our common stock; return on assets, equity or stockholders’ equity; market share; inventory
levels, inventory turn or shrinkage; or total return to stockholders. Any Performance Criteria may be used to measure our performance
as a whole or any business unit of the Company and may be measured relative to a peer group or index. Any Performance Criteria
may include or exclude (i) extraordinary, unusual, and/or non-recurring items of gain or loss; (ii) gains or losses on the disposition
of a business; (iii) changes in tax or accounting regulations or laws; (iv) the effect of a merger or acquisition, as identified
in our quarterly and annual earnings releases; or (v) other similar occurrences. In all other respects, Performance Criteria shall
be calculated in accordance with our financial statements, under generally accepted accounting principles, or under a methodology
established by the compensation committee prior to the issuance of an award. However, to the extent Section 162(m) of the Code
is applicable, the compensation committee may not in any event increase the amount of compensation payable to an individual upon
the attainment of a Performance Goal.
Other
Awards
. The compensation committee may grant other forms of awards, based upon, payable in, or otherwise related to, in whole
or in part, shares of our common stock, if the compensation committee determines that such other form of award is consistent with
the purpose and restrictions of the 2013 Plan. The terms and conditions of such other form of award shall be specified by the
grant. Such other awards may be granted for no cash consideration, for such minimum consideration as may be required by applicable
law, or for such other consideration as may be specified by the grant.
Israeli
Awards
. For persons subject to the Israeli Income Tax Ordinance (the “Ordinance”), the compensation committee
is authorized to grant stock options pursuant to the terms of the Israeli Appendix. The compensation committee may grant (i) options
under Section 102 of the Ordinance (“Section 102 Options”) to employees, officers, and directors (excluding Controlling
Members, as defined below) and (ii) options under Section 3(i) of the Ordinance (“Section 3(i) Options”) to controlling
members as defined in the Ordinance (holding more than 10% of the Company’s outstanding voting shares of common stock) (the
“Controlling Members”), consultants and other service providers with no employer/employee relationship with the Group
and who are not office holders. The compensation committee may designate Section 102 Options as “Approved 102 Options,”
for which the options and shares upon exercise must be held in trust and granted through a trustee, and as “Unapproved 102
Options,” for which the options and shares upon exercise do not have to be held in trust. As described further below, the
determination of the compensation committee as to the taxation route of the incentive, the type of option, and the duration of
time the option and shares upon exercise are held in trust will determine the tax consequences to the participant. Of the Approved
102 Options, the compensation committee may grant options as “Work Income Options,” for which the options and shares
upon exercise must be held in trust for 12 months from the date of grant, or as “Capital Gain Options,” for which
the options and shares upon exercise must be held in trust for 24 months from the date of grant. If the requirements of the Approved
102 Options are not met, the options are regarded as Unapproved 102 Options. Section 3(i) Options and the shares upon exercise
may be held in trust as well, depending upon the agreement between the compensation committee, optionee, and the trustee of the
trust.
Israeli
participants can be granted other type of options under the 2013 Plan, but some of them will require a pre-ruling from the Israeli
Tax Authorities in order to be deemed Approved 102 Options. In addition, the compensation committee is authorized to grant restricted
stock and other stock incentives subject to restrictions as specified by the compensation committee. The compensation committee
may grant such incentives under (i) Section 102 of the Ordinance (“Section 102 Incentives”) to employees, officers,
and directors (excluding Controlling Members) and (ii) under Section 3(i) of the Ordinance (“Section 3(i) Incentives”)
to Controlling Members, consultants and other service providers with no employer/employee relationship with the Group and who
are not office holders.
Vesting,
Forfeiture, Assignment
. The compensation committee, in its sole discretion, may determine that an award will be immediately
vested in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent to its date of grant,
or until the occurrence of one or more specified events, subject in any case to the terms of the 2013 Plan. If the compensation
committee imposes conditions upon vesting, then, except as otherwise provided below, subsequent to the date of grant, the compensation
committee may, in its sole discretion, accelerate the date on which all or any portion of the award may be vested. “Full
Value Awards” (
i.e.,
restricted stock or restricted stock units) that constitute performance awards must vest no
earlier than one year after the date of grant, and Full Value Awards that are payable upon the completion of future services must
vest no earlier than over the three year period commencing on the date of grant. Notwithstanding the foregoing, the compensation
committee may, in its sole discretion, accelerate the vesting or waive any applicable restriction period for such Full Value Awards,
provided that the shares of common stock subject to such awards shall be Exempt Shares, unless such acceleration or waiver occurs
by reason of the participant’s death, disability, retirement, or occurrence of a change in control. The number of Exempt
Shares is limited to 10% of the number of shares available for issuance under the 2013 Plan. For stock options granted pursuant
to the Israeli Appendix, unless otherwise provided in an award agreement, the options are subject to the following default vesting
provisions: 1/4 of the optioned shares shall vest annually over a four-year period, beginning with the first anniversary of the
date of grant.
The
compensation committee may impose on any award at the time of grant or thereafter, such additional terms and conditions as the
compensation committee determines, including, without limitation, terms requiring forfeiture of awards in the event of a participant’s
termination of service. The compensation committee will specify the circumstances on which performance awards may be forfeited
in the event of a termination of service by a participant prior to the end of a performance period or settlement of awards. Except
as otherwise determined by the compensation committee, restricted stock will be forfeited upon a participant’s termination
of service during the applicable restriction period. For stock options granted pursuant to the Israeli Appendix, unless otherwise
provided in an award agreement, the options are subject to the following forfeiture provisions: (i) upon any termination of service,
all unvested optioned shares are forfeited; (ii) upon a voluntary termination of service by a participant, vested optioned shares
terminate 30 days following the date of the termination of service; (iii) upon an involuntary termination of service by us other
than for “cause” (as defined in the Israeli Appendix), vested optioned shares terminate 60 days following the date
of the termination of service; (iv) upon a termination of service due to disability or the Participant’s retirement with
our consent, vested optioned shares terminate one year following the date of such termination of service; (v) upon a termination
of service due to death, vested optioned shares terminate two years from the date of death; and (vi) upon an involuntary termination
of service by us for “cause” (as defined in the Israeli Appendix), all optioned shares, including vested optioned
shares, terminate immediately.
Awards
granted under the 2013 Plan generally are not assignable or transferable except by will or by the laws of descent and distribution,
except that the compensation committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers
of nonqualified stock options or SARs to (i) the spouse (or former spouse), children or grandchildren of the participant (“Immediate
Family Members”); (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership
in which the only partners are (1) such Immediate Family Members and/or (2) entities which are controlled by Immediate Family
Members; (iv) an entity exempt from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision; or
(v) a split interest trust or pooled income fund described in Section 2522(c)(2) of the Code or any successor provision, provided
that (x) there shall be no consideration for any such transfer, (y) the applicable award agreement pursuant to which such award
is granted must be approved by the compensation committee and must expressly provide for such transferability and (z) subsequent
transfers of transferred awards shall be prohibited except those by will or the laws of descent and distribution.
Adjustments
Upon Changes in Capitalization
. In the event that any dividend or other distribution (whether in the form of cash, common
stock, other securities, or other property), recapitalization, stock split, reverse stock split, rights offering, reorganization,
merger, consolidation, split-up, spin-off, split-off, combination, subdivision, repurchase, or exchange of shares of common stock
or other securities of the Company, issuance of warrants or other rights to purchase shares of common stock or other securities
of the Company, or other similar corporate transaction or event affects the fair value of an award, then the compensation committee
shall adjust any or all of the following so that the fair value of the award immediately after the transaction or event is equal
to the fair value of the award immediately prior to the transaction or event (i) the number of shares and type of common stock
(or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of common
stock (or other securities or property) subject to outstanding awards; (iii) the number of shares and type of common stock (or
other securities or property) specified as the annual per-participant limitation under the 2013 Plan; (iv) the exercise price
of each outstanding award; (v) the amount, if any, we pay for forfeited shares in accordance with the terms of the 2013 Plan;
and (vi) the number of or exercise price of shares then subject to outstanding SARs previously granted and unexercised under the
2013 Plan to the end that the same proportion of our issued and outstanding shares common stock in each instance shall remain
subject to exercise at the same aggregate exercise price; provided however, that the number of shares of common stock (or other
securities or property) subject to any award shall always be a whole number. Notwithstanding the foregoing, no such adjustment
shall be made or authorized to the extent that such adjustment would cause the 2013 Plan or any stock option to violate Section
422 of the Code or Section 409A of the Code. All such adjustments must be made in accordance with the rules of any securities
exchange, stock market, or stock quotation system to which we are subject.
Amendment
or Discontinuance of the 2013 Plan
. The board of directors may at any time and from time to time, without the consent of the
participants, alter, amend, revise, suspend, or discontinue the 2013 Plan in whole or in part, except that no amendment for which
stockholder approval is required either: (i) by any securities exchange or inter-dealer quotation system on which our common stock
is listed or traded, or (ii) in order for the 2013 Plan and incentives awarded under the 2013 Plan to continue to comply with
Sections 162(m), 421, and 422 of the Code, including any successors to such Sections, or other applicable law, shall be effective
unless such amendment is approved by the requisite vote of our stockholders entitled to vote thereon. Any amendments made shall,
to the extent deemed necessary or advisable by the compensation committee, be applicable to any outstanding awards theretofore
granted under the 2013 Plan, notwithstanding any contrary provisions contained in any award agreement. In the event of any such
amendment to the 2013 Plan, the holder of any award outstanding under the 2013 Plan shall, upon request of the compensation committee
and as a condition to the exercisability thereof, execute a conforming amendment in the form prescribed by the compensation committee
to any award agreement relating thereto. Notwithstanding anything contained in the 2013 Plan to the contrary, unless required
by law, no action regarding amendment or discontinuance shall adversely affect any rights of participants or obligations of the
Company to participants with respect to any awards granted under the 2013 Plan without the consent of the affected participant.
U.S.
Federal Income Tax Consequences
The
following is a brief summary of certain U.S. federal income tax consequences relating to the transactions described under the
2013 Plan as set forth below. This summary does not purport to address all aspects of U.S. federal income taxation and does not
describe state, local, or foreign tax consequences. This discussion is based upon provisions of the Code and the Treasury Regulations
issued thereunder, and judicial and administrative interpretations under the Code and the Treasury Regulations, all as in effect
as of the date hereof, and all of which are subject to change (possibly on a retroactive basis) or different interpretation.
Law
Affecting Deferred Compensation
. In 2004, Section 409A was added to the Code to regulate all types of deferred compensation.
If the requirements of Section 409A of the Code are not satisfied, deferred compensation and earnings thereon will be subject
to tax as it vests, plus an interest charge at the underpayment rate plus 1% and a 20% penalty tax. Certain performance awards,
stock options, SARs, restricted stock units, and certain types of restricted stock are subject to Section 409A of the Code.
Incentive
Stock Options
. A participant will not recognize income at the time an ISO is granted. When a participant exercises an ISO,
a participant also generally will not be required to recognize income (either as ordinary income or capital gain). However, to
the extent that the fair market value (determined as of the date of grant) of the shares with respect to which the participant’s
ISOs are exercisable for the first time during any year exceeds $100,000, the ISOs for the shares over $100,000 will be treated
as nonqualified stock options, and not ISOs, for federal tax purposes, and the participant will recognize income as if the ISOs
were nonqualified stock options. In addition to the foregoing, if the fair market value of the shares received upon exercise of
an ISO exceeds the exercise price, then the excess may be deemed a tax preference adjustment for purposes of the federal alternative
minimum tax calculation. The federal alternative minimum tax may produce significant tax repercussions depending upon the participant’s
particular tax status.
The
tax treatment of any shares acquired by exercise of an ISO will depend upon whether the participant disposes of his or her shares
prior to two years after the date the ISO was granted or one year after the shares were transferred to the participant (referred
to as, the “Holding Period”). If a participant disposes of shares acquired by exercise of an ISO after the expiration
of the Holding Period, any amount received in excess of the participant’s tax basis for such shares will be treated as short-term
or long-term capital gain, depending upon how long the participant has held the shares. If the amount received is less than the
participant’s tax basis for such shares, the loss will be treated as short-term or long-term capital loss, depending upon
how long the participant has held the shares.
If
the participant disposes of shares acquired by exercise of an ISO prior to the expiration of the Holding Period, the disposition
will be considered a “disqualifying disposition.” If the amount received for the shares is greater than the fair market
value of the shares on the exercise date, then the difference between the ISO’s exercise price and the fair market value
of the shares at the time of exercise will be treated as ordinary income for the tax year in which the “disqualifying disposition”
occurs. The participant’s basis in the shares will be increased by an amount equal to the amount treated as ordinary income
due to such “disqualifying disposition.” In addition, the amount received in such “disqualifying disposition”
over the participant’s increased basis in the shares will be treated as capital gain. However, if the price received for
shares acquired by exercise of an ISO is less than the fair market value of the shares on the exercise date and the disposition
is a transaction in which the participant sustains a loss which otherwise would be recognizable under the Code, then the amount
of ordinary income that the participant will recognize is the excess, if any, of the amount realized on the “disqualifying
disposition” over the basis of the shares.
Nonqualified
Stock Options
. A participant generally will not recognize income at the time a nonqualified stock option is granted. When
a participant exercises a nonqualified stock option, the difference between the option price and any higher market value of the
shares of common stock on the date of exercise will be treated as compensation taxable as ordinary income to the participant.
The participant’s tax basis for the shares acquired under a nonqualified stock option will be equal to the option price
paid for such shares, plus any amounts included in the participant’s income as compensation. When a participant disposes
of shares acquired by exercise of a nonqualified stock option, any amount received in excess of the participant’s tax basis
for such shares will be treated as short-term or long-term capital gain, depending upon how long the participant has held the
shares. If the amount received is less than the participant’s tax basis for such shares, the loss will be treated as short-term
or long-term capital loss, depending upon how long the participant has held the shares.
Special
Rule if Option Price is Paid for in Shares
. If a participant pays the option price of a nonqualified stock option with previously-owned
shares of our common stock and the transaction is not a disqualifying disposition of shares previously acquired under an ISO,
the shares received equal to the number of shares surrendered are treated as having been received in a tax-free exchange. The
participant’s tax basis and holding period for these shares received will be equal to the participant’s tax basis
and holding period for the shares surrendered. The shares received in excess of the number of shares surrendered will be treated
as compensation taxable as ordinary income to the participant to the extent of such shares’ fair market value. The participant’s
tax basis in such shares will be equal to their fair market value on the date of exercise, and the participant’s holding
period for such shares will begin on the date of exercise.
If
the use of previously acquired shares to pay the exercise price of a nonqualified stock option constitutes a disqualifying disposition
of shares previously acquired under an ISO, the participant will have ordinary income as a result of the disqualifying disposition
in an amount equal to the excess of the fair market value of the shares surrendered, determined at the time such shares were originally
acquired on exercise of the ISO, over the aggregate option price paid for such shares. As discussed above, a disqualifying disposition
of shares previously acquired under an ISO occurs when the participant disposes of such shares before the end of the Holding Period.
The other tax results from paying the exercise price with previously-owned shares are as described above, except that the participant’s
tax basis in the shares that are treated as having been received in a tax-free exchange will be increased by the amount of ordinary
income recognized by the participant as a result of the disqualifying disposition.
Restricted
Stock
. A participant who receives a grant of restricted stock generally will recognize as ordinary income the excess, if any,
of the fair market value of the shares granted as restricted stock at such time as the shares are no longer subject to forfeiture
or restrictions, over the amount paid, if any, by the participant for such shares. However, a participant who receives restricted
stock may make an election under Section 83(b) of the Code within 30 days of the date of transfer of the shares to recognize ordinary
income on the date of transfer of the shares equal to the excess of the fair market value of such shares (determined without regard
to the restrictions on such shares) over the purchase price, if any, of such shares. If a participant does not make an election
under Section 83(b) of the Code, then the participant will recognize as ordinary income any dividends received with respect to
such shares. At the time of the sale of such shares, any gain or loss realized by the participant will be treated as either short-term
or long-term capital gain (or loss) depending on the holding period. For purposes of determining any gain or loss realized, the
participant’s tax basis will be the amount previously taxable as ordinary income, plus the purchase price paid by the participant,
if any, for such shares.
Stock
Appreciation Rights
. Generally, a participant who receives a stand-alone SAR will not recognize taxable income at the time
the stand-alone SAR is granted, provided that the SAR is exempt from or complies with Section 409A of the Code. If an employee
receives the appreciation inherent in the SARs in cash, the cash will be taxed as ordinary income to the recipient at the time
it is received. If a recipient receives the appreciation inherent in the SARs in stock, the spread between the then current market
value and the grant price, if any, will be taxed as ordinary income to the employee at the time it is received. In general, there
will be no U.S. federal income tax deduction allowed to us upon the grant or termination of SARs. However, upon the exercise of
a SAR, we will be entitled to a deduction equal to the amount of ordinary income the recipient is required to recognize as a result
of the exercise.
Other
Awards
. In the case of an award of restricted stock units, performance awards, dividend equivalent rights, or other stock
or cash awards, the recipient will generally recognize ordinary income in an amount equal to any cash received and the fair market
value of any shares received on the date of payment or delivery, provided that the award is exempt from or complies with Section
409A of the Code. In that taxable year, we will receive a U.S. federal income tax deduction in an amount equal to the ordinary
income which the participant has recognized.
U.S.
Federal Tax Withholding
. Any ordinary income realized by a participant upon the exercise of an award under the 2013 Plan is
subject to withholding of U.S. federal, state, and local income tax and to withholding of the participant’s share of tax
under the Federal Insurance Contribution Act and the Federal Unemployment Tax Act. To satisfy federal income tax withholding requirements,
we will have the right to require that, as a condition to delivery of any certificate for shares of common stock or the registration
of the shares in the participant’s name, the participant remit to us an amount sufficient to satisfy the withholding requirements.
Such payment may be made by (i) the delivery of cash to us in an amount that equals or exceeds (to avoid the issuance of fractional
shares under (iii) below) the required tax withholding payment; (ii) if we, in our sole discretion, so consent in writing, the
actual delivery by the participant to us of shares of common stock that the participant has not acquired from us within six months
prior to the date of exercise, which shares so delivered have an aggregate fair market value that equals or exceeds (to avoid
the issuance of fractional shares under (iii) below) the required tax withholding payment; (iii) if we, in our sole discretion,
so consent in writing, our withholding of a number of shares to be delivered upon the exercise of a stock option, which shares
so withheld have an aggregate fair market value that equals (but does not exceed) the required tax withholding payment; or (iv)
any combination of (i), (ii), or (iii). We also may, in our sole discretion, withhold any such taxes from any other cash remuneration
otherwise paid by us to the participant.
Withholding
does not represent an increase in the participant’s total income tax obligation, since it is fully credited toward his or
her tax liability for the year. Additionally, withholding does not affect the participant’s tax basis in the shares. Compensation
income realized and tax withheld will be reflected on Forms W-2 supplied by us to employees by January 31 of the succeeding year.
Deferred compensation that is subject to Section 409A of the Code will be subject to certain federal income tax withholding and
reporting requirements.
Tax
Consequences to the Company
. To the extent that a participant recognizes ordinary income in the circumstances described above,
we will be entitled to a corresponding deduction provided that, among other things, the income meets the test of reasonableness,
is an ordinary and necessary business expense, is not an “excess parachute payment” within the meaning of Section
280G of the Code, and is not disallowed by the $1,000,000 limitation on certain executive compensation under Section 162(m) of
the Code.
Million
Dollar Deduction Limit and Other Tax Matters
. We may not deduct compensation of more than $1,000,000 that is paid to “covered
employees” (as defined in Section 162(m) of the Code), which include (i) an individual (or, in certain circumstances, his
or her beneficiaries) who, at any time during the taxable year, is either our principal executive officer or principal financial
officer; (ii) an individual who is among our three highest compensated officers for the taxable year (other than an individual
who was either our principal executive officer or principal financial officer at any time during the taxable year); or (iii) anyone
who was a covered employee for purposes of Section 162(m) of the Code for any tax year beginning on or after January 1, 2017.
This limitation on deductions (x) only applies to compensation paid by a publicly-traded corporation (and not compensation paid
by non-corporate entities) and (z) may not apply to certain types of compensation, such as qualified performance-based compensation
that is payable pursuant to a written, binding contract that was in effect as of November 2, 2017 (each, a “Grandfathered
Award”), so long as the contract is not materially modified after that date. To the extent that compensation is payable
pursuant to a Grandfathered Award, and if we determine that Section 162(m) of the Code will apply to such Grandfathered Award,
the Company intends to interpret and operate the 2013 Plan so that the terms of the Grandfathered Award will not be materially
modified and will be constructed so as to constitute qualified performance-based compensation and, as such, will be exempt from
the $1,000,000 limitation on deductible compensation.
If
an individual’s rights under the 2013 Plan are accelerated as a result of a change in control and the individual is a “disqualified
individual” under Section 280G of the Code, the value of any such accelerated rights received by such individual may be
included in determining whether or not such individual has received an “excess parachute payment” under Section 280G
of the Code, which could result in (i) the imposition of a 20% federal excise tax (in addition to federal income tax) payable
by the individual on the value of such accelerated rights; and (ii) the loss by us of a compensation deduction.
Israeli
Income Tax Consequences
The
following description of the Israel income tax consequences of awards under the Israeli Appendix of the 2013 Plan is general and
does not purport to be complete.
Pursuant
to the current Section 102 of the Ordinance, which came into effect on January 1, 2003, options, shares and other securities (including
restricted shares) (together “Options”) may be granted through a trustee (
i.e.
, Approved 102 Options) or not
through a trustee (
i.e.
, Unapproved 102 Options). The following is a brief discussion of the tax consequences applicable
to both types of Section 102 Options.
Grant
Through a Trustee.
Options granted through a trustee and held in trust are made either through the capital gains tax track
(
i.e.
, Capital Gains Options) or the compensation income tax track (
i.e.
, Work Income Options). Capital Gains Options
and Work Income Options can be granted only through a trustee. Under the capital gains tax track, the Capital Gains Options and
the underlying shares have to be held in trust for at least 24 months from their date of grant. Any gain made on the sale of shares
following the 24 month period is subject to a capital gains tax at a current rate of 25%; the amount of gain is the difference
between the sales proceeds from the sale of shares and the exercise price paid for such shares. Generally, Capital Gains Options
are not taxed on their date of grant. However, in the event that the exercise price of the options is less than the fair market
value of our common stock on the date of grant, a portion of the gain will be deemed compensation income, taxable at the personal
marginal tax rate of the participant. The payment of such tax is made at the time of exercise of the Capital Gains Options. The
portion of the gain that is deemed compensation income is the difference between the average value of the shares as listed on
the stock exchange during the 30-day period prior to the date of grant and the exercise price of the option. If the Capital Gains
Options or the underlying shares of such options are sold by the trustee or transferred from the trustee to the beneficiary before
the end of the 24 month period, any resulting income (cash or equivalent) is taxed as compensation income. If the options have
not been exercised and transferred from the trustee to the beneficiary, the taxable amount of income is the value of the option.
If the options have been exercised, the taxable amount of income is the difference between the aggregate fair market value of
the shares at the time of such sale or transfer and the aggregate exercise price paid for such shares.
Under
the compensation income tax track, the Work Income Options and the underlying shares have to be held in trust for at least 12
months from their date of grant. Any gain made on the sale of shares is subject to compensation income tax at the personal marginal
tax rate of the respective participant; the amount of gain is the difference between the sales proceeds from the sale of shares
and the exercise price paid for such shares. Work Income Options are not taxed on their date of grant, but rather when the options
or the underlying shares of such options are sold by the trustee or transferred from the trustee to the beneficiary. At such time,
if the options have not been exercised, the taxable amount of income is the value of the option. If the options have been exercised,
the taxable amount of income is the difference between the aggregate fair market value of the shares at the time of such sale
or transfer and the aggregate exercise price paid for such shares.
A
corporate tax deduction is available for the employer in the tax year in which tax is withheld. The deductible amount is equal
to any amount included by a participant as compensation income, except when a participant is granted Capital Gains Options, including
in the event that such Capital Gains Options or the underlying shares of such options are sold by the trustee or transferred from
the trustee to the beneficiary before the end of the applicable 24 month period. In such event, any resulting income to the participant
is deemed to be compensation income for tax purposes, but there would be no corresponding corporate tax deduction available to
the employer.
Grant
Not Through a Trustee.
In the case of options not made through a trustee, if the shares are non-marketable securities, the
option will not be subject to tax at the date of grant of the option or the exercise of the option. However, ordinary income tax
will be payable upon the sale of the shares acquired upon exercise of the option. The taxable amount will be the sales proceeds
less the aggregate exercise price paid by the participant. If the shares covered by the option have a market value, then the value
of the option is treated as compensation income, and subject to tax at the date of grant. There is no tax upon the exercise of
the option. However, capital gains tax will be payable on the sale of the shares upon exercise of the option. The taxable amount
will be the sales proceeds, less the value that was taxed at the date of grant and the aggregate exercise price paid by the participant.
Grant
of Section 3(i) Options.
Options under Section 3(i) of the Ordinance may be granted to Controlling Members, consultants, service
providers and controlling stockholders (which are excluded from the term employees under Section 102 of the Ordinance). Grants
of options for shares which are non-marketable are not taxed under the income tax rules on the date of grant, but such event creates
VAT liability. However, they are subject to tax at the time of exercise at the ordinary income tax rate, and at the day such shares
or sold at the capital gains tax rate. The difference between the fair market value of the shares at the time of exercise and
the exercise price is taxed at the ordinary income tax rate. Any gain above such value at the time of sale of the shares is taxed
at the capital gains rate. Grants of options for shares which have a market value are subject to tax on the date of grant, exercise
of the option, and the sale of the shares. The value of the option is taxed on the date of grant at the ordinary income tax rate.
The difference between the fair market value of the shares at the time of exercise and the sum of the exercise price and the amounts
previously taxed at grant, is taxed at the ordinary income tax rate. Any gain above such value at the time of sale of the shares
is taxed at the capital gains rate.
Restricted
Stock
. In the event that restricted stock is issued under Section 102 of the Ordinance and held with a trustee, the tax treatment
to the stockholder will be the same as that of Approved 102 Options. If restricted stock is granted under Section 102 of the Ordinance
without being held by a trustee, or through the Section 3(i) of the Ordinance, the stockholder will have to get a tax ruling from
the Israeli Tax Authority for the postponement of the tax event arising from the issuance of the restricted stock, from the restricted
stock issuance date to the date when the restriction on the restricted stock is removed, otherwise it might cause an immediate
tax event to the stockholder with an immediate withholding tax obligation of the Company.
Other
Stock Incentives
. All other incentives under the Israeli Plan need a tax ruling from the Israeli Tax Authority for the postponement
of the tax event arising from the issuance thereof. Otherwise there is an immediate tax event.
Interest
of Directors and Executive Officers
All
members of our board of directors and all of our executive officers are eligible for awards under the 2013 Plan and, thus, have
a personal interest in the approval of the Fourth Amendment.
New
Plan Benefits
With
respect to the increased number of shares reserved under the 2013 Plan pursuant to the Fourth Amendment, we cannot currently determine
the benefits or number of shares subject to awards that may be granted in the future to eligible participants under the 2013 Plan
because the grant of awards and terms of such awards are to be determined in the sole discretion of the compensation committee.
The
market value of our common stock is $[ ] per share based on the closing price of our common stock on September 6, 2018.
Vote
Required
Pursuant
to Section 711 of the NYSE American Company Guide, the Plan Amendment Proposal (Proposal 2) must be approved by a majority of
the votes cast on such proposal with abstentions counting as votes cast. Therefore, the affirmative vote of the holders of a majority
of the shares of our voting securities represented in person or by proxy at the Annual Meeting entitled to vote on such proposal
that cast a vote for, against or abstain from such proposal is required for the approval of the Plan Amendment Proposal (Proposal
2).
|
The
board of directors recommends a vote
FOR
the approval of the Plan Amendment Proposal (Proposal 2).
|
|
PROPOSAL
3: ADVISORY VOTE ON EXECUTIVE COMPENSATION
The
Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, enables our stockholders to approve,
on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with
the SEC’s rules. The proposal, commonly known as a “say-on-pay” proposal, is required under Section 14A of the
Securities Exchange Act of 1934, as amended (which was put in place by the Dodd-Frank Act) and gives our stockholders the opportunity
to express their views on the Company’s executive compensation. Because this vote is an advisory vote, this proposal is
not binding upon the Company, our board of directors or the compensation committee; however, the compensation committee, which
is responsible for designing and administering the Company’s executive compensation program, values the opinions expressed
by stockholders in their vote on this proposal. To the extent there is any significant vote against the compensation of our named
executive officers as disclosed in this Proxy Statement, we will consider our stockholders’ concerns and the compensation
committee will evaluate whether any actions are necessary to address these concerns.
As
described in detail under the heading “Compensation Philosophy and Process,” the goals of our compensation program
are to ensure that executive compensation rewards management for helping us achieve our financial goals (increased sales, profitability,
etc.) and meet our clinical trial milestones and align management’s overall goals and objectives with those of our stockholders.
To achieve these goals, our board of directors and, going forward, our compensation committee, aims to:
|
●
|
provide
a competitive compensation package that enables us to attract and retain superior management personnel;
|
|
|
|
|
●
|
provide
incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value
and facilitate executive retention;
|
|
|
|
|
●
|
reward
our officers fairly for their role in our achievements; and
|
|
|
|
|
●
|
align
executives’ interests with those of stockholders through long-term incentives linked to specific performance.
|
We
are asking our stockholders to indicate their support for our named executive officer compensation program as described in this
Proxy Statement in accordance with the compensation disclosure rules of the SEC. This vote is not intended to address any specific
item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices
described in this Proxy Statement. Accordingly, we ask our stockholders to vote “FOR” the following resolution at
the Annual Meeting:
“RESOLVED,
that the stockholders approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed
in the Compensation Philosophy and Process, the accompanying compensation tables, and the related narrative disclosure in the
Company’s proxy statement for the 2015 annual meeting.”
At
our 2012 Annual Meeting of Stockholders, the stockholders voted to hold a say-on-pay vote once every three years. In light of
such outcome, we held an advisory vote on executive compensation every three years (including this year). As further described
in “Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation,” the board of directors
is asking the Company’s stockholders in to vote at the Annual Meeting on a proposal regarding the frequency of the vote
on future Say-on-Pay proposals as required by Section 14A. Subject to adoption by the board of directors of a different frequency
for an advisory vote on executive compensation in accordance with the recommendation of the Company’s stockholders pursuant
to “Proposal No. 4 - Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation” or otherwise,
we currently expects to hold future advisory votes on executive compensation every three years, and the next “say-on-pay”
vote is expected to occur at the annual meeting of our stockholders in 2021.
Vote
Required
The
affirmative vote of the holders of a majority of the shares of our voting securities represented in person or by proxy at the
Annual Meeting entitled to vote on such proposal that vote for or against such proposal is required to approve the advisory vote
on executive compensation. This is a non-binding advisory vote.
The
board of directors recommends a vote
FOR
the advisory vote on executive compensation disclosed in the Compensation Philosophy
and Process, the accompanying compensation tables, and the related narrative disclosure.
PROPOSAL
4: ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTE ON EXECUTIVE COMPENSATION
The
Dodd-Frank Act also provides that stockholders must be given the opportunity to vote, on a non-binding, advisory basis, for their
preference as to how frequently we should seek future advisory votes on the compensation of our named executive officers as disclosed
in accordance with the compensation disclosure rules of the SEC, which we refer to as an advisory vote on executive compensation.
By voting with respect to this proposal, stockholders may indicate whether they would prefer that we conduct future advisory votes
on executive compensation once every one, two, or three years. Stockholders also may, if they wish, abstain from casting a vote
on this proposal.
The
board of directors believes that a frequency of “every three years” for the advisory vote on executive compensation
is the optimal interval for conducting and responding to a “say on pay” vote. In determining to recommend that stockholders
vote for a frequency of once every three years, the board considered how an advisory vote at this frequency will provide our stockholders
with sufficient time to evaluate the effectiveness of our overall compensation philosophy, policies and practices in the context
of our long-term business results for the corresponding period, while avoiding over-emphasis on short-term variations in compensation
and business results. An advisory vote occurring once every three years will also permit our stockholders to observe and evaluate
the impact of any changes to our executive compensation policies and practices that have occurred since the last advisory vote
on executive compensation, including changes made in response to the outcome of a prior advisory vote on executive compensation.
We will continue to engage with our stockholders regarding our executive compensation program during the period between advisory
votes on executive compensation. Stockholders who have concerns about executive compensation during the interval between “say
on pay” votes are welcome to bring their specific concerns to the attention of the board of directors. Please refer to “Corporate
Governance—Communications with the Board of Directors” in this Proxy Statement for information about communicating
with the board.
Although
this advisory vote on the frequency of the “say on pay” vote is non-binding, the board of directors and the compensation
committee will take into account the outcome of the vote when considering the frequency of future advisory votes on executive
compensation.
Vote
Required
For
the advisory vote on how frequently our stockholders should vote on the compensation of our named executive officers, the number
of years (1, 2 or 3) that receives the highest number of votes will be deemed to be preferred by our stockholders. This is a non-binding
advisory vote.
The
board of directors recommends a vote FOR the option of “every three years” for future advisory votes on executive
compensation.
PROPOSAL
5: RATIFICATION OF
APPOINTMENT OF Kesselman & Kesselman, Certified Public Accountants,
a member of PricewaterhouseCoopers International Limited, AS OUR
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The
audit committee of our board of directors has appointed Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers
International Limited (“Kesselman”), a member of PricewaterhouseCoopers International Limited, as the independent
registered public accounting firm for the year ending December 31, 2018, subject to stockholder ratification.
Kesselman
served as our independent registered public accounting firm for the years ended December 31, 2017 and 2016. Representatives of
Kesselman will not be present at the Annual Meeting, will not have the opportunity to make a statement if they so desire and will
not be available to respond to appropriate questions.
The
fees billed for professional services provided to us by Kesselman for the years ended December 31, 2017 and 2016 are described
below.
Audit
Fees
Kesselman
billed us audit fees in the aggregate amount of $119,000 for the years ended December 31, 2017 and 2016. These fees relate to
the audit of our annual financial statements and the review of our interim quarterly financial statements.
Audit-Related
Fees
Kesselman
billed us audit-related fees in the aggregate amount of $52,000 and $109,000 for the year ended December 31, 2017 and 2016, respectively.
The fees for the year ended December 31, 2017 mostly related to our prospectus supplements filed with the SEC on March 10, 2017.
The
fees for the year ended December 31, 2016 mostly related to our prospectus supplement filed with the SEC on March 16, 2016 and
July 1, 2016.
Tax
Fees
Kesselman
billed us tax fees in the aggregate amount of $38,675 for the year ended December 31, 2017 and 2016, respectively. These fees
relate to professional services rendered for tax compliance, tax advice and tax planning.
All
Other Fees
Kesselman
did not bill us for any other fees for the year ended December 31, 2017 and 2016.
Pre-Approval
of Independent Registered Public Accounting Firm Fees and Services Policy
Our
audit committee pre-approves all auditing services, internal control-related services and permitted non-audit services (including
the fees and terms thereof) to be performed for us by our independent auditor, except for de minimis non-audit services that are
approved by the audit committee prior to the completion of the audit. The audit committee may form and delegate authority to subcommittees
consisting of one or more members when appropriate, including the authority to grant pre-approvals of audit and permitted non-audit
services, provided that decisions of such subcommittee to grant pre-approvals is presented to the full audit committee at its
next scheduled meeting. The Audit Committee pre-approved all of the fees set forth above.
Approval
of Independent Registered Public Accounting Firm Services and Fees
The
board of directors requests that stockholders ratify the appointment of Kesselman as the independent registered public accounting
firm to conduct the audit of our financial statements for the year ending December 31, 2018. In the event that the stockholders
fail to ratify the selection, the audit committee will reconsider whether or not to continue to retain that firm. Even if the
selection is ratified, the audit committee, in its discretion, may direct the appointment of a different independent registered
public accounting firm at any time during the fiscal year if the audit committee determines that such a change could be in the
best interest of our stockholders.
Vote
Required
The
affirmative vote of the holders of a majority of the shares of our voting securities represented in person or by proxy at the
Annual Meeting entitled to vote on such proposal that vote for or against such proposal is required to adopt the proposal to ratify
the appointment of Kesselman as our independent registered public accounting firm for the year ending December 31, 2018.
The
board of directors recommends a vote
FOR
the ratification of the appointment of Kesselman
& Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited.
OTHER
BUSINESS
The
board of directors knows of no other business to be brought before the Annual Meeting. If, however, any other business should
properly come before the Annual Meeting, the persons named in the accompanying proxy will vote the proxy in accordance with applicable
law and as they may deem appropriate in their discretion, unless directed by the proxy to do otherwise.
SUBMISSION
OF FUTURE STOCKHOLDER PROPOSALS
Pursuant
to rules of the SEC, a stockholder who intends to present a proposal at our next annual meeting of stockholders and who wishes
the proposal to be included in the proxy statement for that meeting must submit the proposal to us in writing to the attention
of the Secretary at InspireMD, Inc., 4 Menorat Hamaor St., Tel Aviv, Israel 6744832. The proposal must be received no later than
May 16, 2019, after which date such stockholder proposal will be considered untimely. Stockholders wishing to submit nominations
of persons for election to the board of directors or proposals of business to be presented directly at the annual meeting instead
of for inclusion in next year’s proxy statement must follow the submission criteria and deadlines set forth in our amended
and restated bylaws. To be timely in connection with our next annual meeting, such a stockholder nomination or proposal must be
received by our Secretary at our principal executive offices between June 30, 2019 and July 30, 2019.
A
copy of InspireMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, is available without charge
(except for exhibits, which are available upon payment of a reasonable fee) upon written request to InspireMD, Inc., 4 Menorat
Hamaor St., Tel Aviv, Israel 6744832.
Annex
A
FOURTH
AMENDMENT TO THE
INSPIREMD,
INC. 2013 LONG-TERM INCENTIVE PLAN
This
FOURTH AMENDMENT TO THE INSPIREMD, INC. 2013 LONG-TERM INCENTIVE PLAN (this “
Amendment
”), dated as of
[●], 2018, is made and entered into by InspireMD, Inc., a Delaware corporation (the “
Company
”).
Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed
to such terms in the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “
Plan
”).
RECITALS
WHEREAS
,
Article 9 of the Plan provides that the Company’s Board of Directors (the “
Board
”) may amend the
Plan at any time and from time to time;
WHEREAS
,
the Company previously reserved a total of nine million seven hundred thousand (9,700,000) shares of common stock of the Company,
par value $0.0001 (“
Common Stock
”), to be delivered pursuant to awards under the Plan;
WHEREAS
,
on October 1, 2015, the Company effected a one-for-ten reverse stock split such that, after giving effect to the reverse stock
split, there were nine hundred seventy thousand (970,000) shares of Common Stock reserved for issuance under the Plan;
WHEREAS
,
on April 18, 2016, the Board, and, on May 24, 2016, at the Company’s 2016 annual meeting of stockholders, the stockholders,
approved an amendment to the Plan to increase the number of shares of Common Stock available for issuance pursuant to awards under
the Plan by ten million (10,000,000) shares, to a total of ten million nine hundred seventy thousand (10,970,000) shares of Common
Stock;
WHEREAS
,
on August 4, 2016, the Board, and on September 28, 2016, at the Company’s special meeting of stockholders, the stockholders,
approved an amendment to the Plan to increase the number of shares of Common Stock available for issuance under the Plan by six
million three hundred thousand (6,300,000) shares, to a total of seventeen million two hundred seventy thousand (17,270,000) shares
of Common Stock;
WHEREAS
,
on October 7, 2016, the Company effected a 1-for-25 reverse stock split such that, after giving effect to the reverse stock split,
there were six hundred ninety thousand eight hundred (690,800) shares of Common Stock reserved for issuance pursuant to awards
under the Plan;
WHEREAS
,
on February 7, 2018, the Company effected a 1-for-35 reverse stock split such that, after giving effect to the reverse stock split,
there were nineteen thousand seven hundred thirty-seven (19,737) shares of Common Stock reserved for issuance pursuant to awards
under the Plan;
WHEREAS
,
the Board desires to amend the Plan to (i) increase the number of shares of Common Stock that may be delivered pursuant to awards
under the Plan by an additional eight million nine hundred thousand (8,900,000) shares, for an aggregate maximum total of eight
million nine hundred nineteen thousand seven hundred thirty-seven (8,919,737) shares of Common Stock available for issuance under
the Plan and (ii) remove the cap on the number of shares of Common Stock with respect to which Stock Options or SARs may be granted
to an Executive Officer during any calendar year ; and
WHEREAS
,
the Board intends to submit this Amendment to the Company’s stockholders for approval.
NOW,
THEREFORE
, in accordance with Article 9 of the Plan and subject to stockholder approval, the Plan is hereby amended, effective
as of the date hereof, as follows:
1.
Section 5.1 of the Plan is hereby amended by deleting said section in its entirety and substituting in lieu thereof the following
new Section 5.1:
5.1
Number Available for Awards
. Subject to adjustment as provided in
Articles 11 and 12
, the maximum number of shares
of Common Stock that may be delivered pursuant to Awards granted under the Plan is eight million nine hundred nineteen thousand
seven hundred thirty-seven (8,919,737) shares, of which one hundred percent (100%) may be delivered pursuant to Incentive Stock
Options. Shares to be issued may be made available from authorized but unissued Common Stock, Common Stock held by the Company
in its treasury, or Common Stock purchased by the Company on the open market or otherwise. During the term of this Plan, the Company
will at all times reserve and keep available the number of shares of Common Stock that shall be sufficient to satisfy the requirements
of this Plan.
2.
Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions
thereof.
[
Remainder
of Page Intentionally Left Blank
Signature
Page Follows
.]
IN
WITNESS WHEREOF
, the Company has caused this Amendment to be duly executed as of the date first written above.
|
INSPIREMD,
INC.
|
|
|
|
|
By:
|
|
|
Name:
|
Craig
Shore
|
|
Title:
|
Chief
Financial Officer, Chief Administrative Officer, Treasurer and Secretary
|
Annex
B
INSPIREMD, INC.
2013 LONG-TERM INCENTIVE PLAN
The InspireMD, Inc.
2013 Long-Term Incentive Plan (the “
Plan
”) was adopted by the Board of Directors of InspireMD, Inc.,
a Delaware corporation (the “
Company
”), effective as of October 25, 2013, subject to approval by the
Company’s stockholders.
Article
1
PURPOSE
The purpose of the
Plan is to attract and retain the services of key Employees, key Contractors, and Outside Directors of the Company and its Subsidiaries
(together, the “
Group
”) and to provide such persons with a proprietary interest in the Company through
the granting of Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock
Units, Performance Awards, Dividend Equivalent Rights, and Other Awards, whether granted singly, or in combination, or in tandem,
that will:
(a) increase
the interest of such persons in the Group’s welfare;
(b) furnish
an incentive to such persons to continue their services for the Company or its Subsidiaries; and
(c) provide
a means through which the Group may attract able persons as Employees, Contractors, and Outside Directors.
This Plan is intended
serve as an “umbrella” plan for the Company and the entire Group worldwide. Therefore, if so required, appendices may
be added to the Plan for the various international Subsidiaries in order to accommodate local regulations that do not correspond
to the scope of the Plan, at the discretion of the Board. Any such appendices that the Company approves for purposes of using this
Plan for an international Subsidiary will not affect the terms of this Plan for any other country.
Attached hereto as
Appendix A
is the InspireMD, Inc. 2013 Employee Stock Incentive Plan (the “
Israeli Plan
”), designated
for the purpose of making grants pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance (New Version), 1961 to Israeli
employees and officers of the Group and any other service providers or control holders of the Company who are subject to Israeli
Income Tax.
With respect to Reporting
Participants, the Plan and all transactions under the Plan are intended to comply with all applicable conditions of Rule 16b-3
promulgated under the Exchange Act. To the extent any provision of the Plan or action by the Committee fails to so comply, such
provision or action shall be deemed null and void
ab initio
, to the extent permitted by law and deemed advisable by the
Committee.
Article
2
DEFINITIONS
For the purpose of
the Plan, unless the context requires otherwise, the following terms shall have the meanings indicated:
2.1 “
Applicable
Law
” means all legal requirements relating to the administration of equity incentive plans and the issuance and distribution
of shares of Common Stock, if any, under applicable corporate laws, applicable securities laws, the rules of any exchange or inter-dealer
quotation system upon which the Company’s securities are listed or quoted, the rules of any foreign jurisdiction applicable
to Incentives granted to residents therein, and any other applicable law, rule or restriction.
2.2 “
Award
”
means the grant of any Incentive Stock Option, Nonqualified Stock Option, Restricted Stock, SAR, Restricted Stock Units, Performance
Award, Dividend Equivalent Right or Other Award, whether granted singly or in combination or in tandem (each individually referred
to herein as an “
Incentive
”).
2.3 “
Award
Agreement
” means a written agreement between a Participant and the Company which sets out the terms of the grant
of an Award.
2.4 “
Award
Period
” means the period set forth in the Award Agreement during which one or more Incentives granted under an Award
may be exercised.
2.5 “
Board
”
means the board of directors of the Company.
2.6 “
Change
in Control
” means any of the following, except as otherwise provided herein: (i) any consolidation, merger or share
exchange of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of the
Company’s Common Stock would be converted into cash, securities or other property, other than a consolidation, merger or
share exchange of the Company in which the holders of the Company’s Common Stock immediately prior to such transaction have
the same proportionate ownership of Common Stock of the surviving corporation immediately after such transaction; (ii) any sale,
lease, exchange or other transfer (excluding transfer by way of pledge or hypothecation) in one transaction or a series of related
transactions, of all or substantially all of the assets of the Company; (iii) the stockholders of the Company approve any plan
or proposal for the liquidation or dissolution of the Company; (iv) the cessation of control (by virtue of their not constituting
a majority of directors) of the Board by the individuals (the “
Continuing Directors
”) who (x) at the
date of this Plan were directors or (y) become directors after the date of this Plan and whose election or nomination for election
by the Company’s stockholders was approved by a vote of at least two-thirds (2/3
rds
) of the directors then in
office who were directors at the date of this Plan or whose election or nomination for election was previously so approved; (v)
the acquisition of beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of an aggregate of fifty percent
(50%) or more of the voting power of the Company’s outstanding voting securities by any person or group (as such term is
used in Rule 13d-5 under the Exchange Act) who beneficially owned less than fifty percent (50%) of the voting power of the Company’s
outstanding voting securities on the date of this Plan;
provided
,
however
, that notwithstanding the foregoing, an
acquisition shall not constitute a Change in Control hereunder if the acquirer is (x) a trustee or other fiduciary holding securities
under an employee benefit plan of the Company and acting in such capacity, (y) a Subsidiary of the Company or a corporation owned,
directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of voting securities
of the Company or (z) any other person whose acquisition of shares of voting securities is approved in advance by a majority of
the Continuing Directors; or (vi) in a Title 11 bankruptcy proceeding, the appointment of a trustee or the conversion of a case
involving the Company to a case under Chapter 7.
Notwithstanding the
foregoing provisions of this
Section 2.6
, if an Award issued under the Plan is subject to Section 409A of the Code, then
an event shall not constitute a Change in Control for purposes of such Award under the Plan unless such event also constitutes
a change in the Company’s ownership, its effective control or the ownership of a substantial portion of its assets within
the meaning of Section 409A of the Code.
2.7 “
Code
”
means the United States Internal Revenue Code of 1986, as amended.
2.8 “
Committee
”
means the committee appointed or designated by the Board to administer the Plan in accordance with
Article 3
of this Plan.
2.9 “
Common
Stock
” means the common stock, par value $0.0001 per share, which the Company is currently authorized to issue or
may in the future be authorized to issue, or any securities into which or for which the common stock of the Company may be converted
or exchanged, as the case may be, pursuant to the terms of this Plan.
2.10 “
Company
”
means InspireMD, Inc., a Delaware corporation, and any successor entity.
2.11 “
Contractor”
means any natural person, who is not an Employee, rendering
bona fide
services to the Company or a Subsidiary, with compensation,
pursuant to a written independent contractor agreement between such person (or any entity employing such person) and the Company
or a Subsidiary, provided that such services are not rendered in connection with the offer or sale of securities in a capital raising
transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.
2.12 “
Corporation
”
means any entity that (i) is defined as a corporation under Section 7701 of the Code and (ii) is the Company or is in an unbroken
chain of corporations (other than the Company) beginning with the Company, if each of the corporations other than the last corporation
in the unbroken chain owns stock possessing a majority of the total combined voting power of all classes of stock in one of the
other corporations in the chain. For purposes of clause (ii) hereof, an entity shall be treated as a “corporation”
if it satisfies the definition of a corporation under Section 7701 of the Code.
2.13 “
Date
of Grant
” means the effective date on which an Award is made to a Participant as set forth in the applicable Award
Agreement; provided, however, that solely for purposes of Section 16 of the Exchange Act and the rules and regulations promulgated
thereunder, the Date of Grant of an Award shall be the date of stockholder approval of the Plan if such date is later than the
effective date of such Award as set forth in the Award Agreement.
2.14 “
Dividend
Equivalent Right
” means the right of the holder thereof to receive credits based on the cash dividends that would
have been paid on the shares of Common Stock specified in the Award if such shares were held by the Participant to whom the Award
is made.
2.15 “
Employee
”
means a common law employee (as defined in accordance with the Regulations and Revenue Rulings then applicable under Section 3401(c)
of the Code) of the Company or any Subsidiary of the Company;
provided
,
however
, in the case of individuals whose
employment status, by virtue of their employer or residence, is not determined under Section 3401(c) of the Code, “Employee”
shall mean an individual treated as an employee for local payroll tax or employment purposes by the applicable employer under Applicable
Law for the relevant period.
2.16 “
Exchange
Act
” means the United States Securities Exchange Act of 1934, as amended.
2.17 “
Executive
Officer
” means an officer of the Company or a Subsidiary subject to Section 16 of the Exchange Act or a “covered
employee” as defined in Section 162(m)(3) of the Code.
2.18 “
Fair
Market Value
”
means, as of a particular date, (a) if the shares of Common Stock are listed
on any established national securities exchange, the closing sales price per share of Common Stock on the consolidated transaction
reporting system for the principal securities exchange for the Common Stock on that date, or, if there shall have been no such
sale so reported on that date, on the last preceding date on which such a sale was so reported; (b) if the shares of Common Stock
are not so listed, but are quoted on an automated quotation system, the closing sales price per share of Common Stock reported
on the automated quotation system on that date, or, if there shall have been no such sale so reported on that date, on the last
preceding date on which such a sale was so reported; (c) if the Common Stock is not so listed or quoted, the mean between the closing
bid and asked price on that date, or, if there are no quotations available for such date, on the last preceding date on which such
quotations shall be available, as reported by
the OTC Bulletin Board operated by the Financial Industry Regulation Authority,
Inc. or the OTC Markets Group Inc., formerly known as Pink OTC Markets Inc.
; or (d) if none of the above
is applicable, such amount as may be determined by the Committee (acting on the advice of an Independent Third Party, should the
Committee elect in its sole discretion to utilize an Independent Third Party for this purpose), in good faith, to be the fair market
value per share of Common Stock.
The determination of Fair Market Value shall, where applicable, be in compliance with Section
409A of the Code.
2.19 “
Incentive
”
is defined in
Section 2.2
hereof.
2.20 “
Incentive
Stock Option
” means an incentive stock option within the meaning of Section 422 of the Code, granted pursuant to
this Plan.
2.21 “
Independent
Third Party
” means an individual or entity independent of the Company having experience in providing investment banking
or similar appraisal or valuation services and with expertise generally in the valuation of securities or other property for purposes
of this Plan. The Committee may utilize one or more Independent Third Parties.
2.22 “
Nonqualified
Stock Option
” means a nonqualified stock option, granted pursuant to this Plan, which is not an Incentive Stock Option.
2.23 “
Option
Price
” means the price which must be paid by a Participant upon exercise of a Stock Option to purchase a share of
Common Stock.
2.24 “
Other
Award
” means an Award issued pursuant to
Section 6.9
hereof.
2.25 “
Outside
Director
” means a director of the Company who is not an Employee or a Contractor.
2.26 “
Participant
”
means an Employee or Contractor of the Company or a Subsidiary or an Outside Director to whom an Award is granted under this Plan.
2.27 “
Performance
Award
” means an Award hereunder of cash, shares of Common Stock, units or rights based upon, payable in, or otherwise
related to, Common Stock pursuant to
Section 6.7
hereof.
2.28 “
Performance
Goal
” means any of the goals set forth in
Section 6.10
hereof.
2.29 “
Plan
”
means this InspireMD, Inc. 2013 Long-Term Incentive Plan, as amended from time to time.
2.30 “
Reporting
Participant
” means a Participant who is subject to the reporting requirements of Section 16 of the Exchange Act.
2.31 “
Restricted
Stock
” means shares of Common Stock issued or transferred to a Participant pursuant to
Section 6.4
of this
Plan which are subject to restrictions or limitations set forth in this Plan and in the related Award Agreement.
2.32 “
Restricted
Stock Units
” means units awarded to Participants pursuant to
Section 6.6
hereof, which are convertible into
Common Stock at such time as such units are no longer subject to restrictions as established by the Committee.
2.33 “
Retirement
”
means any Termination of Service solely due to retirement upon or after attainment of age sixty-five (65), or permitted early retirement
as determined by the Committee;
provided
,
however
, in the case of Participants who reside in the European Economic
Area, “Retirement” shall mean any Termination of Service as of a date they are eligible for mandatory retirement benefits
under local law, without regard to age.
2.34 “
SAR
”
or “
S
tock Appreciation Right
” means the right to receive an amount, in cash and/or Common Stock, equal
to the excess of the Fair Market Value of a specified number of shares of Common Stock as of the date the SAR is exercised (or,
as provided in the Award Agreement, converted) over the SAR Price for such shares.
2.35 “
SAR
Price
” means the exercise price or conversion price of each share of Common Stock covered by a SAR, determined on
the Date of Grant of the SAR.
2.36 “
Stock
Option
” means a Nonqualified Stock Option or an Incentive Stock Option.
2.37 “
Subsidiary
”
means (i) any corporation in an unbroken chain of corporations beginning with the Company, if each of the corporations other than
the last corporation in the unbroken chain owns stock possessing a majority of the total combined voting power of all classes of
stock in one of the other corporations in the chain, (ii) any limited partnership, if the Company or any corporation described
in item (i) above owns a majority of the general partnership interest and a majority of the limited partnership interests entitled
to vote on the removal and replacement of the general partner, and (iii) any partnership or limited liability company, if the partners
or members thereof are composed only of the Company, any corporation listed in item (i) above or any limited partnership listed
in item (ii) above. “
Subsidiaries
” means more than one of any such corporations, limited partnerships,
partnerships or limited liability companies.
2.38 “
Termination
of Service
” occurs when a Participant who is (i) an Employee of the Company or any Subsidiary ceases to serve as
an Employee of the Company and its Subsidiaries, for any reason; (ii) an Outside Director of the Company or a Subsidiary ceases
to serve as a director of the Company and its Subsidiaries for any reason; or (iii) a Contractor of the Company or a Subsidiary
ceases to serve as a Contractor of the Company and its Subsidiaries for any reason. Except as may be necessary or desirable to
comply with applicable federal or state law, a “Termination of Service” shall not be deemed to have occurred when a
Participant who is an Employee becomes an Outside Director or Contractor or vice versa. If, however, a Participant who is an Employee
and who has an Incentive Stock Option ceases to be an Employee but does not suffer a Termination of Service, and if that Participant
does not exercise the Incentive Stock Option within the time required under Section 422 of the Code upon ceasing to be an Employee,
the Incentive Stock Option shall thereafter become a Nonqualified Stock Option. Notwithstanding the foregoing provisions of this
Section 2.38
, in the event an Award issued under the Plan is subject to Section 409A of the Code, then, in lieu of the foregoing
definition and to the extent necessary to comply with the requirements of Section 409A of the Code, the definition of “Termination
of Service” for purposes of such Award shall be the definition of “separation from service” provided for under
Section 409A of the Code and the regulations or other guidance issued thereunder.
2.39 “
Total
and Permanent Disability
” means a Participant is qualified for long-term disability benefits under the Company’s
or Subsidiary’s disability plan or insurance policy; or, if no such plan or policy is then in existence or if the Participant
is not eligible to participate in such plan or policy, that the Participant, because of a physical or mental condition resulting
from bodily injury, disease, or mental disorder, is unable to perform his or her duties of employment for a period of six (6) continuous
months, as determined in good faith by the Committee, based upon medical reports or other evidence satisfactory to the Committee;
provided
that
, with respect to any Incentive Stock Option, Total and Permanent Disability shall have the meaning
given it under the rules governing Incentive Stock Options under the Code. Notwithstanding the foregoing provisions of this
Section
2.39
, in the event an Award issued under the Plan is subject to Section 409A of the Code, then, in lieu of the foregoing definition
and to the extent necessary to comply with the requirements of Section 409A of the Code, the definition of “Total and Permanent
Disability” for purposes of such Award shall be the definition of “disability” provided for under Section 409A
of the Code and the regulations or other guidance issued thereunder.
Article
3
ADMINISTRATION
3.1
General Administration;
Establishment of Committee.
Subject to the terms of this
Article 3
, the Plan shall be administered by the Board
or such committee of the Board as is designated by the Board to administer the Plan (the “
Committee
”).
The Committee shall consist of not fewer than two persons. Any member of the Committee may be removed at any time, with or without
cause, by resolution of the Board. Any vacancy occurring in the membership of the Committee may be filled by appointment by the
Board. At any time there is no Committee to administer the Plan, any references in this Plan to the Committee shall be deemed to
refer to the Board.
Membership on the Committee
shall be limited to those members of the Board who are “outside directors” under Section 162(m) of the Code and “non-employee
directors” as defined in Rule 16b-3 promulgated under the Exchange Act. The Committee shall select one of its members to
act as its Chairman. A majority of the Committee shall constitute a quorum, and the act of a majority of the members of the Committee
present at a meeting at which a quorum is present shall be the act of the Committee.
3.2
Designation
of Participants and Awards.
(a) The
Committee or the Board shall determine and designate from time to time the eligible persons to whom Awards will be granted and
shall set forth in each related Award Agreement, where applicable, the Award Period, the Date of Grant, and such other terms, provisions,
limitations, and performance requirements, as are approved by the Committee, but not inconsistent with the Plan. The Committee
shall determine whether an Award shall include one type of Incentive or two or more Incentives granted in combination or two or
more Incentives granted in tandem (that is, a joint grant where exercise of one Incentive results in cancellation of all or a portion
of the other Incentive). Although the members of the Committee shall be eligible to receive Awards, all decisions with respect
to any Award, and the terms and conditions thereof, to be granted under the Plan to any member of the Committee shall be made solely
and exclusively by the other members of the Committee, or if such member is the only member of the Committee, by the Board.
(b) Notwithstanding
Section 3.2(a)
, to the extent permitted by Applicable Law, the Board may, in its discretion and by a resolution adopted
by the Board, authorize one or more officers of the Company (an “
Authorized Officer
”) to (i) designate
one or more Employees as eligible persons to whom Awards will be granted under the Plan, and (ii) determine the number of shares
of Common Stock that will be subject to such Awards;
provided
,
however
, that the resolution of the Board granting
such authority shall (x) specify the total number of shares of Common Stock that may be made subject to the Awards, (y) set forth
the price or prices (or a formula by which such price or prices may be determined) to be paid for the purchase of the Common Stock
subject to such Awards, and (z) not authorize an officer to designate himself as a recipient of any Award.
3.3
Authority
of the Committee.
The Committee, in its discretion, shall (i) interpret the Plan and Award Agreements, (ii) prescribe, amend,
and rescind any rules and regulations and sub-plans (including sub-plans for Awards made to Participants who are not resident in
the United States), as necessary or appropriate for the administration of the Plan, (iii) establish performance goals for an Award
and certify the extent of their achievement, and (iv) make such other determinations or certifications and take such other action
as it deems necessary or advisable in the administration of the Plan. Any interpretation, determination, or other action made or
taken by the Committee shall be final, binding, and conclusive on all interested parties. The Committee’s discretion set
forth herein shall not be limited by any provision of the Plan, including any provision which by its terms is applicable notwithstanding
any other provision of the Plan to the contrary.
The Committee may delegate
to officers of the Company, pursuant to a written delegation, the authority to perform specified functions under the Plan. Any
actions taken by any officers of the Company pursuant to such written delegation of authority shall be deemed to have been taken
by the Committee.
With respect to restrictions
in the Plan that are based on the requirements of Rule 16b-3 promulgated under the Exchange Act, Section 422 of the Code, Section
162(m) of the Code, the rules of any exchange or inter-dealer quotation system upon which the Company’s securities are listed
or quoted, or any other Applicable Law, to the extent that any such restrictions are no longer required by Applicable Law, the
Committee shall have the sole discretion and authority to grant Awards that are not subject to such mandated restrictions and/or
to waive any such mandated restrictions with respect to outstanding Awards.
Article
4
ELIGIBILITY
Any Employee (including
an Employee who is also a director or an officer), Contractor or Outside Director of the Company whose judgment, initiative, and
efforts contributed or may be expected to contribute to the successful performance of the Company is eligible to participate in
the Plan; provided that only Employees of a Corporation shall be eligible to receive Incentive Stock Options. The Committee, upon
its own action, may grant, but shall not be required to grant, an Award to any Employee, Contractor or Outside Director. Awards
may be granted by the Committee at any time and from time to time to new Participants, or to then Participants, or to a greater
or lesser number of Participants, and may include or exclude previous Participants, as the Committee shall determine. Except as
required by this Plan, Awards need not contain similar provisions. The Committee’s determinations under the Plan (including
without limitation determinations of which Employees, Contractors or Outside Directors, if any, are to receive Awards, the form,
amount and timing of such Awards, the terms and provisions of such Awards and the agreements evidencing same) need not be uniform
and may be made by it selectively among Participants who receive, or are eligible to receive, Awards under the Plan.
Article
5
SHARES SUBJECT TO PLAN
5.1
Number Available
for Awards.
Subject to adjustment as provided in
Articles 11 and 12
,
the maximum number of shares of Common Stock
that may be delivered pursuant to Awards granted under the Plan is five million (5,000,000) shares, of which one hundred percent
(100%)
may be delivered pursuant to Incentive Stock Options. Subject to adjustment pursuant to
Articles 11 and 12
,
the maximum number of shares of Common Stock with respect to which Stock Options or SARs may be granted to an Executive Officer
during any calendar year is one million (1,000,000) shares of Common Stock. Shares to be issued may be made available from authorized
but unissued Common Stock, Common Stock held by the Company in its treasury, or Common Stock purchased by the Company on the open
market or otherwise. During the term of this Plan, the Company will at all times reserve and keep available the number of shares
of Common Stock that shall be sufficient to satisfy the requirements of this Plan.
5.2
Reuse of
Shares.
To the extent that any Award under this Plan shall be forfeited, shall expire or be canceled, in whole or in part,
then the number of shares of Common Stock covered by the Award or stock option so forfeited, expired or canceled may again be awarded
pursuant to the provisions of this Plan. In the event that previously acquired shares of Common Stock are delivered to the Company
in full or partial payment of the exercise price for the exercise of a Stock Option granted under this Plan, the number of shares
of Common Stock available for future Awards under this Plan shall be reduced only by the net number of shares of Common Stock issued
upon the exercise of the Stock Option. Awards that may be satisfied either by the issuance of shares of Common Stock or by cash
or other consideration shall be counted against the maximum number of shares of Common Stock that may be issued under this Plan
only during the period that the Award is outstanding or to the extent the Award is ultimately satisfied by the issuance of shares
of Common Stock. Awards will not reduce the number of shares of Common Stock that may be issued pursuant to this Plan if the settlement
of the Award will not require the issuance of shares of Common Stock, as, for example, a SAR that can be satisfied only by the
payment of cash. Notwithstanding any provisions of the Plan to the contrary, only shares forfeited back to the Company, shares
canceled on account of termination, expiration or lapse of an Award, shares surrendered in payment of the exercise price of an
option or shares withheld for payment of applicable employment taxes and/or withholding obligations resulting from the exercise
of an option shall again be available for grant of Incentive Stock Options under the Plan, but shall not increase the maximum number
of shares described in
Section 5.1
above as the maximum number of shares of Common Stock that may be delivered pursuant
to Incentive Stock Options.
Article
6
GRANT OF AWARDS
6.1
In General.
(a) The
grant of an Award shall be authorized by the Committee and shall be evidenced by an Award Agreement setting forth the Incentive
or Incentives being granted, the total number of shares of Common Stock subject to the Incentive(s), the Option Price (if applicable),
the Award Period, the Date of Grant, and such other terms, provisions, limitations, and performance objectives, as are approved
by the Committee, but (i) not inconsistent with the Plan, (ii) to the extent an Award issued under the Plan is subject to Section
409A of the Code, in compliance with the applicable requirements of Section 409A of the Code and the regulations or other guidance
issued thereunder, and (iii) to the extent the Committee determines that an Award shall comply with the requirements of Section
162(m) of the Code, in compliance with the applicable requirements of Section 162(m) of the Code and the regulations and other
guidance issued thereunder. The Company shall execute an Award Agreement with a Participant after the Committee approves the issuance
of an Award. Any Award granted pursuant to this Plan must be granted within ten (10) years of the date of adoption of this Plan
by the Board. The Plan shall be submitted to the Company’s stockholders for approval; however, the Committee may grant Awards
under the Plan prior to the time of stockholder approval. Any such Award granted prior to such stockholder approval shall be made
subject to such stockholder approval. The grant of an Award to a Participant shall not be deemed either to entitle the Participant
to, or to disqualify the Participant from, receipt of any other Award under the Plan.
(b) If
the Committee establishes a purchase price for an Award, the Participant must accept such Award within a period of thirty (30)
days (or such shorter period as the Committee may specify) after the Date of Grant by executing the applicable Award Agreement
and paying such purchase price.
(c) Any
Award under this Plan that is settled in whole or in part in cash on a deferred basis may provide for interest equivalents to be
credited with respect to such cash payment. Interest equivalents may be compounded and shall be paid upon such terms and conditions
as may be specified by the grant.
6.2
Option Price.
The Option Price for any share of Common Stock which may be purchased under a Nonqualified Stock Option for any share of Common
Stock may be equal to or greater than the Fair Market Value of the share on the Date of Grant. The Option Price for any share of
Common Stock which may be purchased under an Incentive Stock Option must be at least equal to the Fair Market Value of the share
on the Date of Grant; if an Incentive Stock Option is granted to an Employee who owns or is deemed to own (by reason of the attribution
rules of Section 424(d) of the Code) more than ten percent (10%) of the combined voting power of all classes of stock of the Company
(or any parent or Subsidiary), the Option Price shall be at least one hundred ten percent (110%) of the Fair Market Value of the
Common Stock on the Date of Grant.
6.3
Maximum ISO
Grants.
The Committee may not grant Incentive Stock Options under the Plan to any Employee which would permit the aggregate
Fair Market Value (determined on the Date of Grant) of the Common Stock with respect to which Incentive Stock Options (under this
and any other plan of the Company and its Subsidiaries) are exercisable for the first time by such Employee during any calendar
year to exceed $100,000. To the extent any Stock Option granted under this Plan which is designated as an Incentive Stock Option
exceeds this limit or otherwise fails to qualify as an Incentive Stock Option, such Stock Option (or any such portion thereof)
shall be a Nonqualified Stock Option. In such case, the Committee shall designate which stock will be treated as Incentive Stock
Option stock by causing the issuance of a separate stock certificate and identifying such stock as Incentive Stock Option stock
on the Company’s stock transfer records.
6.4
Restricted
Stock.
If Restricted Stock is granted to or received by a Participant under an Award (including a Stock Option), the Committee
shall set forth in the related Award Agreement: (i) the number of shares of Common Stock awarded, (ii) the price, if any, to be
paid by the Participant for such Restricted Stock and the method of payment of the price, (iii) the time or times within which
such Award may be subject to forfeiture, (iv) specified Performance Goals of the Company, a Subsidiary, any division thereof or
any group of Employees of the Company, or other criteria, which the Committee determines must be met in order to remove any restrictions
(including vesting) on such Award, and (v) all other terms, limitations, restrictions, and conditions of the Restricted Stock,
which shall be consistent with this Plan, to the extent applicable and in the event the Committee determines that an Award shall
comply with the requirements of Section 162(m) of the Code, in compliance with the requirements of Section 162(m) of the Code and
the regulations and other guidance issued thereunder and, to the extent Restricted Stock granted under the Plan is subject to Section
409A of the Code, in compliance with the applicable requirements of Section 409A of the Code and the regulations or other guidance
issued thereunder. The provisions of Restricted Stock need not be the same with respect to each Participant.
(a)
Legend
on Shares.
The Company shall electronically register the Restricted Stock awarded to a Participant in the name of such Participant,
which shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock,
substantially as provided in
Section 15.10
of the Plan. No stock certificate or certificates shall be issued with respect
to such shares of Common Stock, unless, following the expiration of the Restriction Period (as defined in
Section 6.4(b)(i)(a)(i)
)
without forfeiture in respect of such shares of Common Stock, the Participant requests delivery of the certificate or certificates
by submitting a written request to the Committee (or such party designated by the Company) requesting delivery of the certificates.
The Company shall deliver the certificates requested by the Participant to the Participant as soon as administratively practicable
following the Company’s receipt of such request.
(b)
Restrictions
and Conditions.
Shares of Restricted Stock shall be subject to the following restrictions and conditions:
(i) Subject
to the other provisions of this Plan and the terms of the particular Award Agreements, during such period as may be determined
by the Committee commencing on the Date of Grant or the date of exercise of an Award (the “
Restriction Period
”),
the Participant shall not be permitted to sell, transfer, pledge or assign shares of Restricted Stock. Except for these limitations,
the Committee may in its sole discretion, remove any or all of the restrictions on such Restricted Stock whenever it may determine
that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date of the Award, such action
is appropriate.
(ii) Except
as provided in sub-paragraph (i) above or in the applicable Award Agreement, the Participant shall have, with respect to his or
her Restricted Stock, all of the rights of a stockholder of the Company, including the right to vote the shares, and the right
to receive any dividends thereon. Certificates for shares of Common Stock free of restriction under this Plan shall be delivered
to the Participant promptly after, and only after, the Restriction Period shall expire without forfeiture in respect of such shares
of Common Stock or after any other restrictions imposed on such shares of Common Stock by the applicable Award Agreement or other
agreement have expired. Certificates for the shares of Common Stock forfeited under the provisions of the Plan and the applicable
Award Agreement shall be promptly returned to the Company by the forfeiting Participant. Each Award Agreement shall require that
each Participant, in connection with the issuance of a certificate for Restricted Stock, shall endorse such certificate in blank
or execute a stock power in form satisfactory to the Company in blank and deliver such certificate and executed stock power to
the Company.
(iii) The
Restriction Period of Restricted Stock shall commence on the Date of Grant or the date of exercise of an Award, as specified in
the Award Agreement, and, subject to
Article 12
of the Plan, unless otherwise established by the Committee in the Award
Agreement setting forth the terms of the Restricted Stock, shall expire upon satisfaction of the conditions set forth in the Award
Agreement; such conditions may provide for vesting based on such Performance Goals, as may be determined by the Committee in its
sole discretion.
(iv) Except
as otherwise provided in the particular Award Agreement, upon Termination of Service for any reason during the Restriction Period,
the nonvested shares of Restricted Stock shall be forfeited by the Participant. In the event a Participant has paid any consideration
to the Company for such forfeited Restricted Stock, the Committee shall specify in the Award Agreement that either (i) the Company
shall be obligated to, or (ii) the Company may, in its sole discretion, elect to, pay to the Participant, as soon as practicable
after the event causing forfeiture, in cash, an amount equal to the lesser of the total consideration paid by the Participant for
such forfeited shares or the Fair Market Value of such forfeited shares as of the date of Termination of Service, as the Committee,
in its sole discretion shall select. Upon any forfeiture, all rights of a Participant with respect to the forfeited shares of the
Restricted Stock shall cease and terminate, without any further obligation on the part of the Company.
6.5
SARs.
The
Committee may grant SARs to any Participant, either as a separate Award or in connection with a
Stock Option. SARs shall be subject to such terms and conditions as the Committee shall impose, provided that such terms and conditions
are (i) not inconsistent with the Plan, (ii) to the extent a SAR issued under the Plan is subject to Section 409A of the Code,
in compliance with the applicable requirements of Section 409A of the Code and the regulations or other guidance issued thereunder,
and (iii) to the extent the Committee determines that a SAR shall comply with the requirements of Section 162(m) of the Code, in
compliance with the applicable requirements of Section 162(m) and the regulations and other guidance issued thereunder. The grant
of the SAR may provide that the holder may be paid for the value of the SAR either in cash or in shares of Common Stock, or a combination
thereof. In the event of the exercise of a SAR payable in shares of Common Stock, the holder of the SAR shall receive that number
of whole shares of Common Stock having an aggregate Fair Market Value on the date of exercise equal to the value obtained by multiplying
(i) the difference between the Fair Market Value of a share of Common Stock on the date of exercise over the SAR Price as set forth
in such SAR (or other value specified in the agreement granting the SAR), by (ii) the number of shares of Common Stock as to which
the SAR is exercised, with a cash settlement to be made for any fractional shares of Common Stock. The SAR Price for any share
of Common Stock subject to a SAR may be equal to or greater than the Fair Market Value of the share on the Date of Grant. The Committee,
in its sole discretion, may place a ceiling on the amount payable upon exercise of a SAR, but any such limitation shall be specified
at the time that the SAR is granted.
6.6
Restricted
Stock Units.
Restricted Stock Units may be awarded or sold to any Participant under such terms and conditions as shall be established
by the Committee, provided, however, that such terms and conditions are (i) not inconsistent with the Plan, (ii) to the extent
a Restricted Stock Unit issued under the Plan is subject to Section 409A of the Code, in compliance with the applicable requirements
of Section 409A of the Code and the regulations or other guidance issued thereunder, and
(iii) to the
extent the Committee determines that a Restricted Stock Unit award shall comply with the requirements of Section 162(m) of the
Code, in compliance with the applicable requirements of Section 162(m) and the regulations and other guidance issued thereunder.
Restricted Stock Units shall be subject to such restrictions as the Committee determines, including, without limitation, (a) a
prohibition against sale, assignment, transfer, pledge, hypothecation or other encumbrance for a specified period; or (b) a requirement
that the holder forfeit (or in the case of shares of Common Stock or units sold to the Participant, resell to the Company at cost)
such shares or units in the event of Termination of Service during the period of restriction.
6.7
Performance
Awards.
(a) The
Committee may grant Performance Awards to one or more Participants. The terms and conditions of Performance Awards shall be specified
at the time of the grant and may include provisions establishing the performance period, the Performance Goals to be achieved during
a performance period, and the maximum or minimum settlement values,
provided that such terms and conditions
are (i) not inconsistent with the Plan and (ii) to the extent a Performance Award issued under the Plan is subject to Section 409A
of the Code, in compliance with the applicable requirements of Section 409A of the Code and the regulations or other guidance issued
thereunder.
If the Performance Award is to be in shares of Common Stock, the Performance Awards may provide for the issuance
of the shares of Common Stock at the time of the grant of the Performance Award or at the time of the certification by the Committee
that the Performance Goals for the performance period have been met;
provided
,
however
, if shares of Common Stock
are issued at the time of the grant of the Performance Award and if, at the end of the performance period, the Performance Goals
are not certified by the Committee to have been fully satisfied, then, notwithstanding any other provisions of this Plan to the
contrary, the Common Stock shall be forfeited in accordance with the terms of the grant to the extent the Committee determines
that the Performance Goals were not met. The forfeiture of shares of Common Stock issued at the time of the grant of the Performance
Award due to failure to achieve the established Performance Goals shall be separate from and in addition to any other restrictions
provided for in this Plan that may be applicable to such shares of Common Stock. Each Performance Award granted to one or more
Participants shall have its own terms and conditions.
To
the extent the Committee determines that a Performance Award shall comply with the requirements of Section 162(m) of the Code and
the regulations and other guidance issued thereunder, and if
it is determined to be necessary in order to satisfy Section
162(m) of the Code, at the time of the grant of a Performance Award (other than a Stock Option) and to the extent permitted under
Section 162(m) of the Code and the regulations issued thereunder, the Committee shall provide for the manner in which the Performance
Goals shall be reduced to take into account the negative effect on the achievement of specified levels of the Performance Goals
which may result from enumerated corporate transactions, extraordinary events, accounting changes and other similar occurrences
which were unanticipated at the time the Performance Goal was initially established. In no event, however, may the Committee increase
the amount earned under such a Performance Award, unless the reduction in the Performance Goals would reduce or eliminate the amount
to be earned under the Performance Award and the Committee determines not to make such reduction or elimination.
With respect
to a Performance Award that is not intended to satisfy the requirements of Code Section 162(m), if the Committee determines, in
its sole discretion, that the established performance measures or objectives are no longer suitable because of a change in the
Company’s business, operations, corporate structure, or for other reasons that the Committee deemed satisfactory, the Committee
may modify the performance measures or objectives and/or the performance period.
(b) Performance
Awards may be valued by reference to the Fair Market Value of a share of Common Stock or according to any formula or method deemed
appropriate by the Committee, in its sole discretion, including, but not limited to, achievement of Performance Goals or other
specific financial, production, sales or cost performance objectives that the Committee believes to be relevant to the Company’s
business and/or remaining in the employ of the Company or a Subsidiary for a specified period of time. Performance Awards may be
paid in cash, shares of Common Stock, or other consideration, or any combination thereof. If payable in shares of Common Stock,
the consideration for the issuance of such shares may be the achievement of the performance objective established at the time of
the grant of the Performance Award. Performance Awards may be payable in a single payment or in installments and may be payable
at a specified date or dates or upon attaining the performance objective. The extent to which any applicable performance objective
has been achieved shall be conclusively determined by the Committee.
(c) Notwithstanding
the foregoing, in order to comply with the requirements of Section 162(m) of the Code, if applicable, no Participant may receive
in any calendar year Performance Awards intended to comply with the requirements of Section 162(m) of the Code which have an aggregate
value of more than $5,000,000, and if such Performance Awards involve the issuance of shares of Common Stock, said aggregate value
shall be based on the Fair Market Value of such shares on the time of the grant of the Performance Award. In no event, however,
shall any Performance Awards not intended to comply with the requirements of Section 162(m) of the Code be issued contingent upon
the failure to attain the Performance Goals applicable to any Performance Awards granted hereunder that the Committee intends to
comply with the requirements of Section 162(m) of the Code.
6.8
Dividend
Equivalent Rights.
The Committee may grant a Dividend Equivalent Right to any Participant, either as a component of another
Award or as a separate Award. The terms and conditions of the Dividend Equivalent Right shall be specified by the grant. Dividend
equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional
shares of Common Stock (which may thereafter accrue additional dividend equivalents). Any such reinvestment shall be at the Fair
Market Value at the time thereof. Dividend Equivalent Rights may be settled in cash or shares of Common Stock, or a combination
thereof, in a single payment or in installments. A Dividend Equivalent Right granted as a component of another Award may provide
that such Dividend Equivalent Right shall be settled upon exercise, settlement, or payment of, or lapse of restrictions on, such
other Award, and that such Dividend Equivalent Right granted as a component of another Award may also contain terms and conditions
different from such other Award.
6.9
Other Awards.
The Committee may grant to any Participant other forms of Awards, based upon, payable in, or otherwise related to, in whole or
in part, shares of Common Stock, if the Committee determines that such other form of Award is consistent with the purpose and restrictions
of this Plan. The terms and conditions of such other form of Award shall be specified by the grant. Such Other Awards may be granted
for no cash consideration, for such minimum consideration as may be required by Applicable Law, or for such other consideration
as may be specified by the grant.
6.10
Performance
Goals.
Awards of Restricted Stock, Restricted Stock Units, Performance Award and Other Awards (whether relating to cash or
shares of Common Stock) under the Plan may be made subject to the attainment of Performance Goals relating to one or more business
criteria which, where applicable, shall be within the meaning of Section 162(m) of the Code and consist of one or more or any combination
of the following criteria: cash flow; cost; revenues; sales; ratio of debt to debt plus equity; net borrowing, credit quality or
debt ratings; profit before tax; economic profit; earnings before interest and taxes; earnings before interest, taxes, depreciation
and amortization; gross margin; earnings per share (whether on a pre-tax, after-tax, operational or other basis); operating earnings;
capital expenditures; expenses or expense levels; economic value added; ratio of operating earnings to capital spending or any
other operating ratios; free cash flow; net profit; net sales; net asset value per share; the accomplishment of mergers, acquisitions,
dispositions, public offerings or similar extraordinary business transactions; sales growth; price of the Company’s Common
Stock; return on assets, equity or stockholders’ equity; market share; inventory levels, inventory turn or shrinkage; or
total return to stockholders (“
Performance Criteria
”). Any Performance Criteria may be used to measure
the performance of the Company as a whole or any business unit of the Company and may be measured relative to a peer group or index.
Any Performance Criteria may include or exclude (i) extraordinary, unusual and/or non-recurring items of gain or loss, (ii) gains
or losses on the disposition of a business, (iii) changes in tax or accounting regulations or laws, (iv) the effect of a merger
or acquisition, as identified in the Company’s quarterly and annual earnings releases, or (v) other similar occurrences.
In all other respects, Performance Criteria shall be calculated in accordance with the Company’s financial statements, under
generally accepted accounting principles, or under a methodology established by the Committee prior to the issuance of an Award
which is consistently applied and identified in the audited financial statements, including footnotes, or the Compensation Discussion
and Analysis section of the Company’s annual report. However, to the extent Section 162(m) of the Code is applicable, the
Committee may not in any event increase the amount of compensation payable to an individual upon the attainment of a Performance
Goal.
6.11
Tandem Awards.
The Committee may grant two or more Incentives in one Award in the form of a “tandem Award,” so that the right of the
Participant to exercise one Incentive shall be canceled if, and to the extent, the other Incentive is exercised. For example, if
a Stock Option and a SAR are issued in a tandem Award, and the Participant exercises the SAR with respect to one hundred (100)
shares of Common Stock, the right of the Participant to exercise the related Stock Option shall be canceled to the extent of one
hundred (100) shares of Common Stock.
Article
7
AWARD PERIOD; VESTING
7.1
Award Period.
Subject to the other provisions of this Plan, the Committee may, in its discretion, provide that an Incentive may not be exercised
in whole or in part for any period or periods of time or beyond any date specified in the Award Agreement. Except as provided in
the Award Agreement, an Incentive may be exercised in whole or in part at any time during its term. The Award Period for an Incentive
shall be reduced or terminated upon Termination of Service. No Incentive granted under the Plan may be exercised at any time after
the end of its Award Period. No portion of any Incentive may be exercised after the expiration of ten (10) years from its Date
of Grant. However, if an Employee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more
than ten percent (10%) of the combined voting power of all classes of stock of the Company (or any parent or Subsidiary) and an
Incentive Stock Option is granted to such Employee, the term of such Incentive Stock Option (to the extent required by the Code
at the time of grant) shall be no more than five (5) years from the Date of Grant.
7.2
Vesting.
The Committee, in its sole discretion, may determine that an Incentive will be immediately vested in whole or in part, or that
all or any portion may not be vested until a date, or dates, subsequent to its Date of Grant, or until the occurrence of one or
more specified events, subject in any case to the terms of the Plan. If the Committee imposes conditions upon vesting, then, subsequent
to the Date of Grant, the Committee may, in its sole discretion, accelerate the date on which all or any portion of the Incentive
may be vested.
Article
8
EXERCISE OR CONVERSION OF INCENTIVE
8.1
In General.
A vested Incentive may be exercised or converted, during its Award Period, subject to limitations and restrictions set forth in
the Award Agreement.
8.2
Securities
Law and Exchange Restrictions.
In no event may an Incentive be exercised or shares of Common Stock issued pursuant to an Award
if a necessary listing or quotation of the shares of Common Stock on a stock exchange or inter-dealer quotation system or any registration
under state or federal securities laws required under the circumstances has not been accomplished.
8.3
Exercise
of Stock Option.
(a)
In
General.
If a Stock Option is exercisable prior to the time it is vested, the Common Stock obtained on the exercise of the
Stock Option shall be Restricted Stock which is subject to the applicable provisions of the Plan and the Award Agreement. If the
Committee imposes conditions upon exercise, then subsequent to the Date of Grant, the Committee may, in its sole discretion, accelerate
the date on which all or any portion of the Stock Option may be exercised. No Stock Option may be exercised for a fractional share
of Common Stock. The granting of a Stock Option shall impose no obligation upon the Participant to exercise that Stock Option.
(b)
Notice
and Payment.
Subject to such administrative regulations as the Committee may from time to time adopt, a Stock Option may be
exercised by the delivery of written notice to the Committee setting forth the number of shares of Common Stock with respect to
which the Stock Option is to be exercised and the date of exercise thereof (the “
Exercise Date
”) which
shall be at least three (3) days after giving such notice unless an earlier time shall have been mutually agreed upon. On the Exercise
Date, the Participant shall deliver to the Company consideration with a value equal to the total Option Price of the shares to
be purchased, payable as provided in the Award Agreement, which may provide for payment in any one or more of the following ways:
(a) cash or check, bank draft, or money order payable to the order of the Company, (b) Common Stock (including Restricted Stock)
owned by the Participant on the Exercise Date, valued at its Fair Market Value on the Exercise Date, and which the Participant
has not acquired from the Company within six (6) months prior to the Exercise Date, (c) by delivery (including by FAX) to the Company
or its designated agent of an executed irrevocable option exercise form together with irrevocable instructions from the Participant
to a broker or dealer, reasonably acceptable to the Company, to sell certain of the shares of Common Stock purchased upon exercise
of the Stock Option or to pledge such shares as collateral for a loan and promptly deliver to the Company the amount of sale or
loan proceeds necessary to pay such purchase price, and/or (d) in any other form of valid consideration that is acceptable to the
Committee in its sole discretion. In the event that shares of Restricted Stock are tendered as consideration for the exercise of
a Stock Option, a number of shares of Common Stock issued upon the exercise of the Stock Option equal to the number of shares of
Restricted Stock used as consideration therefor shall be subject to the same restrictions and provisions as the Restricted Stock
so tendered.
(c)
Issuance
of Certificate.
Except as otherwise provided in
Section 6.4
hereof (with respect to shares of Restricted Stock) or in
the applicable Award Agreement, upon payment of all amounts due from the Participant, the Company shall cause the Common Stock
then being purchased to be registered in the Participant’s name (or the person exercising the Participant’s Stock Option
in the event of his or her death), but shall not issue certificates for the Common Stock unless the Participant or such other person
requests delivery of the certificates for the Common Stock, in writing in accordance with the procedures established by the Committee.
The Company shall deliver certificates to the Participant (or the person exercising the Participant’s Stock Option in the
event of his or her death) as soon as administratively practicable following the Company’s receipt of a written request from
the Participant or such other person for delivery of the certificates. Notwithstanding the forgoing, if the Participant has exercised
an Incentive Stock Option, the Company may at its option retain physical possession of the certificate evidencing the shares acquired
upon exercise until the expiration of the holding periods described in Section 422(a)(1) of the Code. Any obligation of the Company
to deliver shares of Common Stock shall, however, be subject to the condition that, if at any time the Committee shall determine
in its discretion that the listing, registration, or qualification of the Stock Option or the Common Stock upon any securities
exchange or inter-dealer quotation system or under any state or federal law, or the consent or approval of any governmental regulatory
body, is necessary as a condition of, or in connection with, the Stock Option or the issuance or purchase of shares of Common Stock
thereunder, the Stock Option may not be exercised in whole or in part unless such listing, registration, qualification, consent,
or approval shall have been effected or obtained free of any conditions not reasonably acceptable to the Committee.
(d)
Failure
to Pay.
Except as may otherwise be provided in an Award Agreement, if the Participant fails to pay for any of the Common Stock
specified in such notice or fails to accept delivery thereof, that portion of the Participant’s Stock Option and right to
purchase such Common Stock may be forfeited by the Participant.
8.4
SARs.
Subject
to the conditions of this
Section 8.4
and such administrative regulations as the Committee
may from time to time adopt, a SAR may be exercised by the delivery (including by FAX) of written notice to the Committee setting
forth the number of shares of Common Stock with respect to which the SAR is to be exercised and the date of exercise thereof (the
“
Exercise Date
”) which shall be at least three (3) days after giving such notice unless an earlier time
shall have been mutually agreed upon. Subject to the terms of the Award Agreement and only if permissible under Section 409A of
the Code and the regulations or other guidance issued thereunder (or, if not so permissible, at such time as permitted by Section
409A of the Code and the regulations or other guidance issued thereunder), the Participant shall receive from the Company in exchange
therefor in the discretion of the Committee, and subject to the terms of the Award Agreement:
(a) cash
in an amount equal to the excess (if any) of the Fair Market Value (as of the Exercise Date, or if provided in the Award Agreement,
conversion, of the SAR) per share of Common Stock over the SAR Price per share specified in such SAR, multiplied by the total number
of shares of Common Stock of the SAR being surrendered;
(b) that
number of shares of Common Stock having an aggregate Fair Market Value (as of the Exercise Date, or if provided in the Award Agreement,
conversion, of the SAR) equal to the amount of cash otherwise payable to the Participant, with a cash settlement to be made for
any fractional share interests; or
(c) the
Company may settle such obligation in part with shares of Common Stock and in part with cash.
The distribution of
any cash or Common Stock pursuant to the foregoing sentence shall be made at such time as set forth in the Award Agreement.
8.5
Disqualifying
Disposition of Incentive Stock Option.
If shares of Common Stock acquired upon exercise of an Incentive Stock Option are disposed
of by a Participant prior to the expiration of either two (2) years from the Date of Grant of such Stock Option or one (1) year
from the transfer of shares of Common Stock to the Participant pursuant to the exercise of such Stock Option, or in any other disqualifying
disposition within the meaning of Section 422 of the Code, such Participant shall notify the Company in writing of the date and
terms of such disposition. A disqualifying disposition by a Participant shall not affect the status of any other Stock Option granted
under the Plan as an Incentive Stock Option within the meaning of Section 422 of the Code.
Article
9
AMENDMENT OR DISCONTINUANCE
Subject to the limitations
set forth in this
Article 9
, the Board may at any time and from time to time, without the consent of the Participants, alter,
amend, revise, suspend, or discontinue the Plan in whole or in part; provided, however, that no amendment for which stockholder
approval is required either (i) by any securities exchange or inter-dealer quotation system on which the Common Stock is listed
or traded or (ii) in order for the Plan and Incentives awarded under the Plan to continue to comply with Sections 162(m), 421,
and 422 of the Code, including any successors to such Sections, or other Applicable Law, shall be effective unless such amendment
shall be approved by the requisite vote of the stockholders of the Company entitled to vote thereon. Any such amendment shall,
to the extent deemed necessary or advisable by the Committee, be applicable to any outstanding Incentives theretofore granted under
the Plan, notwithstanding any contrary provisions contained in any Award Agreement. In the event of any such amendment to the Plan,
the holder of any Incentive outstanding under the Plan shall, upon request of the Committee and as a condition to the exercisability
thereof, execute a conforming amendment in the form prescribed by the Committee to any Award Agreement relating thereto. Notwithstanding
anything contained in this Plan to the contrary, unless required by law, no action contemplated or permitted by this
Article
9
shall adversely affect any rights of Participants or obligations of the Company to Participants with respect to any Incentive
theretofore granted under the Plan without the consent of the affected Participant.
Article
10
TERM
The Plan shall be effective
from the date that this Plan is adopted by the Board. Unless sooner terminated by action of the Board, the Plan will terminate
on October 25, 2023, but Incentives granted before that date will continue to be effective in accordance with their terms and conditions.
Article
11
CAPITAL ADJUSTMENTS
In the event that any
dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), recapitalization,
stock split, reverse stock split, rights offering, reorganization, merger, consolidation, split-up, spin-off, split-off, combination,
subdivision, repurchase, or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to
purchase Common Stock or other securities of the Company, or other similar corporate transaction or event affects the fair value
of an Award, then the Committee shall adjust any or all of the following so that the fair value of the Award immediately after
the transaction or event is equal to the fair value of the Award immediately prior to the transaction or event (i) the number of
shares and type of Common Stock (or the securities or property) which thereafter may be made the subject of Awards, (ii) the number
of shares and type of Common Stock (or other securities or property) subject to outstanding Awards, (iii) the number of shares
and type of Common Stock (or other securities or property) specified as the annual per-participant limitation under
Section
5.1
of the Plan, (iv) the Option Price of each outstanding Award, (v) the amount, if any, the Company pays for forfeited shares
of Common Stock in accordance with
Section 6.4
, and (vi) the number of or SAR Price of shares of Common Stock then subject
to outstanding SARs previously granted and unexercised under the Plan, to the end that the same proportion of the Company’s
issued and outstanding shares of Common Stock in each instance shall remain subject to exercise at the same aggregate SAR Price;
provided however, that the number of shares of Common Stock (or other securities or property) subject to any Award shall always
be a whole number. Notwithstanding the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment
would cause the Plan or any Stock Option to violate Section 422 of the Code or Section 409A of the Code. Such adjustments shall
be made in accordance with the rules of any securities exchange, stock market, or stock quotation system to which the Company is
subject.
Upon the occurrence
of any such adjustment, the Company shall provide notice to each affected Participant of its computation of such adjustment which
shall be conclusive and shall be binding upon each such Participant.
Article
12
RECAPITALIZATION, MERGER AND CONSOLIDATION
12.1
No Effect
on Company’s Authority.
The existence of this Plan and Incentives granted hereunder shall not affect in any way the right
or power of the Company or its stockholders to make or authorize any or all adjustments, recapitalizations, reorganizations, or
other changes in the Company’s capital structure and its business, or any Change in Control, or any merger or consolidation
of the Company, or any issuance of bonds, debentures, preferred or preference stocks ranking prior to or otherwise affecting the
Common Stock or the rights thereof (or any rights, options, or warrants to purchase same), or the dissolution or liquidation of
the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether
of a similar character or otherwise.
12.2
Conversion
of Incentives Where Company Survives.
Subject to any required action by the stockholders and except as otherwise provided by
Section 12.4
hereof or as may be required to comply with Section 409A of the Code and the regulations or other guidance
issued thereunder, if the Company shall be the surviving or resulting corporation in any merger, consolidation or share exchange,
any Incentive granted hereunder shall pertain to and apply to the securities or rights (including cash, property, or assets) to
which a holder of the number of shares of Common Stock subject to the Incentive would have been entitled.
12.3
Exchange
or Cancellation of Incentives Where Company Does Not Survive.
Except as otherwise provided by
Section 12.4
hereof or
as may be required to comply with Section 409A of the Code and the regulations or other guidance issued thereunder, in the event
of any merger, consolidation or share exchange pursuant to which the Company is not the surviving or resulting corporation, there
shall be substituted for each share of Common Stock subject to the unexercised portions of outstanding Incentives, that number
of shares of each class of stock or other securities or that amount of cash, property, or assets of the surviving, resulting or
consolidated company which were distributed or distributable to the stockholders of the Company in respect to each share of Common
Stock held by them, such outstanding Incentives to be thereafter exercisable for such stock, securities, cash, or property in accordance
with their terms.
12.4
Cancellation
of Incentives.
Notwithstanding the provisions of
Sections 12.2 and 12.3
hereof, and except as may be required to comply
with Section 409A of the Code and the regulations or other guidance issued thereunder, all Incentives granted hereunder may be
canceled by the Company, in its sole discretion, as of the effective date of any Change in Control, merger, consolidation or share
exchange, or any issuance of bonds, debentures, preferred or preference stocks ranking prior to or otherwise affecting the Common
Stock or the rights thereof (or any rights, options, or warrants to purchase same), or of any proposed sale of all or substantially
all of the assets of the Company, or of any dissolution or liquidation of the Company, by either:
(a) giving
notice to each holder thereof or his personal representative of its intention to cancel those Incentives for which the issuance
of shares of Common Stock involved payment by the Participant for such shares, and permitting the purchase during the thirty (30)
day period next preceding such effective date of any or all of the shares of Common Stock subject to such outstanding Incentives,
including in the Board’s discretion some or all of the shares as to which such Incentives would not otherwise be vested and
exercisable; or
(b) in
the case of Incentives that are either (i) settled only in shares of Common Stock, or (ii) at the election of the Participant,
settled in shares of Common Stock, paying the holder thereof an amount equal to a reasonable estimate of the difference between
the net amount per share payable in such transaction or as a result of such transaction, and the price per share of such Incentive
to be paid by the Participant (hereinafter the “
Spread
”), multiplied by the number of shares subject
to the Incentive. In cases where the shares constitute, or would after exercise, constitute Restricted Stock, the Company, in its
discretion, may include some or all of those shares in the calculation of the amount payable hereunder. In estimating the Spread,
appropriate adjustments to give effect to the existence of the Incentives shall be made, such as deeming the Incentives to have
been exercised, with the Company receiving the exercise price payable thereunder, and treating the shares receivable upon exercise
of the Incentives as being outstanding in determining the net amount per share. In cases where the proposed transaction consists
of the acquisition of assets of the Company, the net amount per share shall be calculated on the basis of the net amount receivable
with respect to shares of Common Stock upon a distribution and liquidation by the Company after giving effect to expenses and charges,
including but not limited to taxes, payable by the Company before such liquidation could be completed.
(c) An
Award that by its terms would be fully vested or exercisable upon a Change in Control will be considered vested or exercisable
for purposes of
Section 12.4(a)
hereof.
Article
13
LIQUIDATION OR DISSOLUTION
Subject to
Section
12.4
hereof, in case the Company shall, at any time while any Incentive under this Plan shall be in force and remain unexpired,
(i) sell all or substantially all of its property, or (ii) dissolve, liquidate, or wind up its affairs, then each Participant shall
be entitled to receive, in lieu of each share of Common Stock of the Company which such Participant would have been entitled to
receive under the Incentive, the same kind and amount of any securities or assets as may be issuable, distributable, or payable
upon any such sale, dissolution, liquidation, or winding up with respect to each share of Common Stock of the Company. If the Company
shall, at any time prior to the expiration of any Incentive, make any partial distribution of its assets, in the nature of a partial
liquidation, whether payable in cash or in kind (but excluding the distribution of a cash dividend payable out of earned surplus
and designated as such) and an adjustment is determined by the Committee to be appropriate to prevent the dilution of the benefits
or potential benefits intended to be made available under the Plan, then the Committee shall, in such manner as it may deem equitable,
make such adjustment in accordance with the provisions of
Article 11
hereof.
Article
14
INCENTIVES IN SUBSTITUTION FOR
INCENTIVES GRANTED BY OTHER ENTITIES
Incentives may be granted
under the Plan from time to time in substitution for similar instruments held by employees, independent contractors or directors
of a corporation, partnership, or limited liability company who become or are about to become Employees, Contractors or Outside
Directors of the Company or any Subsidiary as a result of a merger or consolidation of the employing corporation with the Company,
the acquisition by the Company of equity of the employing entity, or any other similar transaction pursuant to which the Company
becomes the successor employer. The terms and conditions of the substitute Incentives so granted may vary from the terms and conditions
set forth in this Plan to such extent as the Committee at the time of grant may deem appropriate to conform, in whole or in part,
to the provisions of the Incentives in substitution for which they are granted.
Article
15
MISCELLANEOUS PROVISIONS
15.1
Investment
Intent.
The Company may require that there be presented to and filed with it by any Participant under the Plan, such evidence
as it may deem necessary to establish that the Incentives granted or the shares of Common Stock to be purchased or transferred
are being acquired for investment and not with a view to their distribution.
15.2
No Right
to Continued Employment.
Neither the Plan nor any Incentive granted under the Plan shall confer upon any Participant any right
with respect to continuance of employment by the Company or any Subsidiary.
15.3
Indemnification
of Board and Committee.
No member of the Board or the Committee, nor any officer or Employee of the Company acting on behalf
of the Board or the Committee, shall be personally liable for any action, determination, or interpretation taken or made in good
faith with respect to the Plan, and all members of the Board and the Committee, each officer of the Company, and each Employee
of the Company acting on behalf of the Board or the Committee shall, to the extent permitted by law, be fully indemnified and protected
by the Company in respect of any such action, determination, or interpretation.
15.4
Effect of
the Plan.
Neither the adoption of this Plan nor any action of the Board or the Committee shall be deemed to give any person
any right to be granted an Award or any other rights except as may be evidenced by an Award Agreement, or any amendment thereto,
duly authorized by the Committee and executed on behalf of the Company, and then only to the extent and upon the terms and conditions
expressly set forth therein.
15.5
Compliance
With Other Laws and Regulations.
Notwithstanding anything contained herein to the contrary, the Company shall not be required
to sell or issue shares of Common Stock under any Incentive if the issuance thereof would constitute a violation by the Participant
or the Company of any provisions of any law or regulation of any governmental authority or any national securities exchange or
inter-dealer quotation system or other forum in which shares of Common Stock are quoted or traded (including without limitation
Section 16 of the Exchange Act and Section 162(m) of the Code); and, as a condition of any sale or issuance of shares of Common
Stock under an Incentive, the Committee may require such agreements or undertakings, if any, as the Committee may deem necessary
or advisable to assure compliance with any such law or regulation. The Plan, the grant and exercise of Incentives hereunder, and
the obligation of the Company to sell and deliver shares of Common Stock, shall be subject to all applicable federal and state
laws, rules and regulations and to such approvals by any government or regulatory agency as may be required.
15.6
Foreign
Participation.
To assure the viability of Awards granted to Participants employed in foreign countries, the Committee may provide
for such special terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy or custom.
Moreover, the Committee may approve such supplements to, or amendments, restatements or alternative versions of, this Plan as it
determines is necessary or appropriate for such purposes. Any such amendment, restatement or alternative versions that the Committee
approves for purposes of using this Plan in a foreign country will not affect the terms of this Plan for any other country.
15.7
Tax Requirements.
The Company or, if applicable, any Subsidiary (for purposes of this
Section 15.7
, the term “
Company
”
shall be deemed to include any applicable Subsidiary), shall have the right to deduct from all amounts paid in cash or other form
in connection with the Plan, any Federal, state, local, or other taxes required by law to be withheld in connection with an Award
granted under this Plan. The Company may, in its sole discretion, also require the Participant receiving shares of Common Stock
issued under the Plan to pay the Company the amount of any taxes that the Company is required to withhold in connection with the
Participant’s income arising with respect to the Award. Such payments shall be required to be made when requested by Company
and may be required to be made prior to the delivery of any certificate representing shares of Common Stock. Such payment may be
made (i) by the delivery of cash to the Company in an amount that equals or exceeds (to avoid the issuance of fractional shares
under (iii) below) the required tax withholding obligations of the Company; (ii) if the Company, in its sole discretion, so consents
in writing, the actual delivery by the exercising Participant to the Company of shares of Common Stock that the Participant has
not acquired from the Company within six (6) months prior to the date of exercise, which shares so delivered have an aggregate
Fair Market Value that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding
payment; (iii) if the Company, in its sole discretion, so consents in writing, the Company’s withholding of a number of shares
to be delivered upon the exercise of the Stock Option, which shares so withheld have an aggregate fair market value that equals
(but does not exceed) the required tax withholding payment; or (iv) any combination of (i), (ii), or (iii). The Company may, in
its sole discretion, withhold any such taxes from any other cash remuneration otherwise paid by the Company to the Participant.
The Committee may in the Award Agreement impose any additional tax requirements or provisions that the Committee deems necessary
or desirable.
15.8
Assignability.
Incentive Stock Options may not be transferred, assigned, pledged, hypothecated or otherwise conveyed or encumbered other than
by will or the laws of descent and distribution and may be exercised during the lifetime of the Participant only by the Participant
or the Participant’s legally authorized representative, and each Award Agreement in respect of an Incentive Stock Option
shall so provide. The designation by a Participant of a beneficiary will not constitute a transfer of the Stock Option. The Committee
may waive or modify any limitation contained in the preceding sentences of this
Section 15.8
that is not required for compliance
with Section 422 of the Code.
Except as otherwise
provided herein, Nonqualified Stock Options and SARs may not be transferred, assigned, pledged, hypothecated or otherwise conveyed
or encumbered other than by will or the laws of descent and distribution. The Committee may, in its discretion, authorize all or
a portion of a Nonqualified Stock Option or SAR to be granted to a Participant on terms which permit transfer by such Participant
to (i) the spouse (or former spouse), children or grandchildren of the Participant (“
Immediate Family Members
”),
(ii) a trust or trusts for the exclusive benefit of such Immediate Family Members, (iii) a partnership in which the only partners
are (1) such Immediate Family Members and/or (2) entities which are controlled by Immediate Family Members, (iv) an entity exempt
from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision, or (v) a split interest trust or
pooled income fund described in Section 2522(c)(2) of the Code or any successor provision,
provided that
(x) there shall
be no consideration for any such transfer, (y) the Award Agreement pursuant to which such Nonqualified Stock Option or SAR is granted
must be approved by the Committee and must expressly provide for transferability in a manner consistent with this Section, and
(z) subsequent transfers of transferred Nonqualified Stock Options or SARs shall be prohibited except those by will or the laws
of descent and distribution.
Following any transfer,
any such Nonqualified Stock Option and SAR shall continue to be subject to the same terms and conditions as were applicable immediately
prior to transfer, provided that for purposes of
Articles 8, 9, 11, 13 and 15
hereof the term “
Participant
”
shall be deemed to include the transferee. The events of Termination of Service shall continue to be applied with respect to the
original Participant, following which the Nonqualified Stock Options and SARs shall be exercisable or convertible by the transferee
only to the extent and for the periods specified in the Award Agreement. The Committee and the Company shall have no obligation
to inform any transferee of a Nonqualified Stock Option or SAR of any expiration, termination, lapse or acceleration of such Stock
Option or SAR. The Company shall have no obligation to register with any federal or state securities commission or agency any Common
Stock issuable or issued under a Nonqualified Stock Option or SAR that has been transferred by a Participant under this
Section
15.8
.
15.9
Use of Proceeds.
Proceeds from the sale of shares of Common Stock pursuant to Incentives granted under this Plan shall constitute general funds
of the Company.
15.10
Legend.
Each certificate representing shares of Restricted Stock issued to a Participant shall bear the following legend, or a similar
legend deemed by the Company to constitute an appropriate notice of the provisions hereof (any such certificate not having such
legend shall be surrendered upon demand by the Company and so endorsed):
On the face of the certificate:
“Transfer of this stock
is restricted in accordance with conditions printed on the reverse of this certificate.”
On the reverse:
“The shares of stock evidenced
by this certificate are subject to and transferable only in accordance with that certain InspireMD, Inc. 2013 Long-Term Incentive
Plan, a copy of which is on file at the principal office of the Company in Boston, Massachusetts. No transfer or pledge of the
shares evidenced hereby may be made except in accordance with and subject to the provisions of said Plan. By acceptance of this
certificate, any holder, transferee or pledgee hereof agrees to be bound by all of the provisions of said Plan.”
The following legend
shall be inserted on a certificate evidencing Common Stock issued under the Plan if the shares were not issued in a transaction
registered under the applicable federal and state securities laws:
“Shares of stock represented
by this certificate have been acquired by the holder for investment and not for resale, transfer or distribution, have been issued
pursuant to exemptions from the registration requirements of applicable state and federal securities laws, and may not be offered
for sale, sold or transferred other than pursuant to effective registration under such laws, or in transactions otherwise in compliance
with such laws, and upon evidence satisfactory to the Company of compliance with such laws, as to which the Company may rely upon
an opinion of counsel satisfactory to the Company.”
Article
16
ACCELERATION OF AWARD VESTING
16.1
Application.
The provisions of this
Article 16
shall apply notwithstanding any provisions of this Plan to the contrary.
16.2
Definitions.
(a) “
Exempt
Shares
” means shares of Common Stock designated as “Exempt Shares” pursuant to
Section 16.3
.
(b) “
Full
Value Award
” means any Award with a net benefit to the Participant, without regard to any restrictions such as those
described in
Section 6.4(b)
, equal to the aggregate Fair Market Value of the total shares of Common Stock subject to the
Award. Full Value Awards include Restricted Stock and Restricted Stock Units, but do not include Stock Options and SARs.
(c) “
Tenure
Award”
means an Award hereunder of cash, shares of Common Stock, units or rights based upon, payable in, or otherwise
related to, Common Stock that vests over time based upon the Participant’s continued employment with or service to the Company
or its Subsidiaries.
16.3
Number of
Shares Available for Awards.
No more than ten percent (10%) of the shares of Common Stock that may be delivered pursuant to
Awards under
Section 5.1
may be shares designated as “Exempt Shares.”
16.4
Full Value
Award Vesting.
Except as otherwise provided herein, the Committee must grant all Full Value Awards in accordance with the following
provisions:
(a) All
Full Value Awards granted by the Committee that constitute Performance Awards must vest no earlier than one (1) year after the
Date of Grant.
(b) All
Full Value Awards granted by the Committee that constitute Tenure Awards must vest no earlier than over the three (3) year period
commencing on the Date of Grant on a pro rata basis.
(c) The
Committee may not accelerate the date on which all or any portion of a Full Value Award may be vested or waive the Restriction
Period on a Full Value Award except upon the Participant's death, Total and Permanent Disability or Retirement or the occurrence
of a Change in Control.
Notwithstanding the
foregoing, the Committee may, in its sole discretion, grant Full Value Awards with more favorable vesting provisions than set forth
in this
Section 16.4
or accelerate the vesting or waive the Restriction Period for Full Value Awards at any time, provided
that the shares of Common Stock subject to such Awards shall be Exempt Shares.
A copy of this Plan
shall be kept on file in the principal office of the Company in Boston, Massachusetts.
***************
IN WITNESS WHEREOF,
the Company has caused this instrument to be executed as of October 25, 2013, by its Chief Executive Officer and Secretary pursuant
to prior action taken by the Board.
|
INSPIREMD, INC.
|
|
|
|
By:
|
/s/ Alan Milinazzo
|
|
Name:
|
Alan Milinazzo
|
|
Title:
|
Chief Executive Officer
|
Attest:
By:
|
/s/ Craig Shore
|
|
Name:
|
Craig Shore
|
|
Title:
|
Secretary
|
|
APPENDIX A
INSPIREMD, INC.
2013 Employee Stock Incentive Plan
Designated for the Israeli Income Tax
Ordinance
ARTICLE I
Purpose
|
1.
|
The purpose of this 2013 Employee Stock Incentive Plan (the “
Israeli Plan
”)
shall be as defined in the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “
Incentive Plan
”), and
is intended to harmonize the terms and conditions of the Incentive Plan with applicable Israeli law and provide specific provisions
regarding Participants (as defined in the Incentive Plan) who are subject to the Ordinance (as defined below). Unless expressly
provided in this Israeli Plan, the provisions of the Incentive Plan shall apply. Capitalized terms not expressly defined in this
Israeli Plan shall have the meaning ascribed to them under the Incentive Plan.
|
|
2.
|
This Israeli Plan is intended to promote the interests of InspireMD, Inc. (the “
Company
”)
and its Affiliates, if any, (the “
Group Companies
”) by providing present and future officers of the Group
Companies, other employees of the Group Companies (including directors of the Group Companies) and consultants of the Group Companies
with an incentive to enter into and continue in the employ of the Group Companies and to acquire a proprietary interest in the
long-term success of the Group Companies.
|
|
3.
|
The word “
Affiliate
”,
when used in the Israeli Plan, shall mean any “employer company”
within the meaning of Section 102(a) of the Israeli Income Tax Ordinance
(New Version), 5721-1961 (the “
Ordinance
”).
1
|
ARTICLE II
Administration
|
4.
|
The Israeli Plan shall be administered by the Board or the Committee (the “
Administrator
”)
as shall be resolved by the Board. The Administrator shall have the authority in its sole discretion, subject and not inconsistent
with the express provisions of the Israeli Plan, to administer the Israeli Plan and to exercise all the powers and authorities
specifically granted to it under the Israeli Plan as necessary and advisable in the administration of the Israeli Plan, including,
without limitation:
|
1
s. 102 (a) of the Ordinance: “
employer company” – any of the following: (1) an employer that
is an Israeli resident company or a foreign resident company with a permanent enterprise or a research and development center
in Israel, if the Commissioner so approved (for this purpose: the employer), (2) a company that is a controlling member of the
employer or of which the employer is a controlling member, or (3) a company controlled by a person if the same person controls
the employer
.
|
a.
|
To determine which of the eligible,
officers, employees, directors, and consultants of the Group Companies
or other person shall be granted options to purchase Common Stock
(each an “
Option
”), as that term is defined
below, or other Awards, provided however, that (a) employees, officers
and directors (excluding controlling members as defined in Section
32(9) of the Ordinance
2
) (“
Employees
”,
and each an “
Employee
”) may only be granted
Awards, pursuant to Section 102 of the Ordinance and the rules and
regulations promulgated thereunder, including the Income Tax Regulations
(Tax Relief for Issue of Shares to Employees), 5763 -2003, (“
Section
102 Incentives
”); and (b) those who have no employee/employer
relationship with the Group Companies and are not ‘office holders’
(such as consultants and service providers), and Controlling Members
(“
Consultants
”, and each a “
Consultant
”),
may only be granted Incentives pursuant to Section 3(i) of the Ordinance
(“
Section 3(i) Incentives
”);
|
|
b.
|
To determine the type of Incentives to be granted,
i.e.
Section 102 Incentives or Section
3(i) Incentives , or any other type of Incentive provided in
Section 6
of the Incentive Plan, and their Date of Grant;
|
|
c.
|
To determine the number of shares of Common Stock, to which an Incentive may relate, the terms,
conditions and restrictions of each Award and Incentive, the exercise price of each Option (the “
Option Exercise Price
”),
the date on which each Option or other Incentives becomes exercisable or free of any restrictions (the “
Exercise Date
”),
the Award Period and any other restrictions on (i) the exercise of Options issued hereunder, or (ii) other Incentives;
|
|
d.
|
To determine the form or forms of the award agreements under the Israeli Plan (the “
Award
Agreement
”) (which forms shall be consistent with the terms of the Incentive Plan but need not be identical), any
other instruments that constitute or contain a Company obligation to grant an Incentive under the Israeli Plan (each, a “
Grant
Instrument
”), as that term is defined below, and ancillary documentation;
|
|
e.
|
To determine whether, to what extent, and under what circumstances, an Incentive may be settled,
canceled, forfeited, exchanged or surrendered;
|
|
f.
|
To construe and interpret the Israeli Plan, Award Agreements, any Incentive, Grant Instruments
and ancillary documentation and to make all other determinations deemed necessary or advisable for the administration of the Israeli
Plan; and
|
|
g.
|
To prescribe, amend and rescind rules and regulations relating to the Israeli Plan.
|
|
5.
|
All decisions, determinations and interpretations of the Administrator shall be final and binding
on all Participants, unless otherwise determined by the Board of Directors.
|
2
s. 32(9) of the Ordinance: “
controlling member” –
a person who holds, directly or indirectly, alone or with a relative, one of the following: (a) at least 10% of the issued share
capital or at least 10% of the voting power; the right to hold at least 10% of the issued share capital or at least 10% of the
voting power, or a right to acquire either; (c) the right to receive at least 10% of the profits; (d) the right to appoint a director.
|
6.
|
Insofar as the Board is entitled by law to delegate all and any of its powers and authority granted
it under this Israeli Plan to a Committee, the Board shall be entitled to do so. The Committee’s authorities shall be as
provided in the Incentive Plan. Any action may be taken by a written document (in lieu of meeting) signed by the Committee, and
action so taken shall be fully as effective as if it had been taken by a vote of the majority of the members at a meeting duly
called and held. The Committee may appoint a Secretary who shall keep records of its meetings, and shall make such rules and regulations
for the conduct of its business as it shall determine.
|
|
7.
|
No member or former member of the Administrator shall be liable for any action, failure to act,
or determination made in good faith with respect to the Israeli Plan or any right granted thereunder.
|
|
8.
|
The Administrator may designate Incentives granted pursuant to Section 102 as (1) “
Approved
102 Incentives
” (i.e. Incentives granted pursuant to Section 102(b) of the Ordinance and held in trust by a trustee
for the benefit of the Participant); or (2) “
Unapproved 102 Incentives
” (
i.e.
Incentives granted
pursuant to Section 102(c) of the Ordinance and not held in trust by a trustee).
|
|
9.
|
The Administrator may elect for Approved 102 Incentives to be classified as either (1) “
Work
Income Incentives
” that qualify for tax treatment in accordance with the provisions of Section 102(b)(1) of the Ordinance;
or (2) “
Capital Gain Incentives
” that qualify for tax treatment in accordance with the provisions of
Section 102(b)(2) of the Ordinance (the “
Election
”).
|
|
10.
|
Unapproved 102 Incentives may be granted until the Administrator’s Election has been appropriately
filed with the Israeli tax authorities, which election must be made at least thirty days before the date of the first grant of
an Approved 102 Incentive under this Israeli Plan or according to the instructions published by the Israeli tax authorities from
time to time. The Election shall remain in effect until the end of the subsequent year following the year during which the Administrator
first granted such Approved 102 Incentives. During the period indicated in the sentence above, the Administrator may grant only
the type of Approved 102 Incentive it has elected, which Election shall apply to all Participants who were granted Approved 102
Incentives during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Ordinance, as amended.
For the avoidance of doubt, such Election shall not prevent the Administrator from granting, at all times, Unapproved 102 Incentives
to Employees or Section 3(i) Incentives to Consultants.
|
ARTICLE III
Incentive Shares
|
11.
|
The shares to be issued under the Israeli Plan (the “
Incentive
Shares
”)
shall be authorized but unissued Common Stock (the “
Shares
”). The total number of Shares reserved for
issuance under the Israeli Plan shall be equal to the total number of Shares reserved under
Section 5.1
of the Incentive
Plan, subject to any adjustments and reductions made pursuant to the Incentive Plan. Such Shares are reserved out of the total
number of Shares reserved under
Section 5.1
of the Incentive Plan.
|
|
12.
|
The number of Shares available for grant of Incentives under the Israeli Plan shall be decreased
by the sum of the number of Shares with respect to which Incentives have been issued and are then outstanding and the number of
Shares issued upon exercise of Options. In the event that any outstanding Incentive under the Israeli Plan for any reason expires,
is terminated, or is canceled, the Shares covered by the unexercised portion of such Incentive may again be subject to Awards under
the Israeli Plan.
|
|
13.
|
The Company shall at all times during the term of the Israeli Plan reserve and keep available such
number of Shares as will be sufficient to satisfy the requirements of the Incentives granted according to this Israeli Plan, shall
pay all original issue taxes (which shall not include income taxes of the Participant), if any, with respect to the issuance of
Shares pursuant hereto and all other fees and expenses necessarily incurred by the Company in connection therewith, and shall,
from time to time, use its best efforts to comply with all laws and regulations which, in the opinion of counsel for the Company,
shall be applicable thereto.
|
ARTICLE IV
Incentive
Price
|
14.
|
Each Award Agreement and Grant Instrument with respect to an Award shall set forth the amount (the
“
Incentive Price
”) which will be paid by the Participant to the Company upon exercise of the Options
or allocation of other Incentives. Payment shall be made in cash, or by certified check in the manner prescribed in Article VI
(Exercise of Options, Termination) hereof.
|
ARTICLE V
Terms of Awards
|
15.
|
The Administrator shall determine the dates after which, or circumstances in which, Options may
be exercised or other Incentives may be released of any restriction thereto, in whole or in part. If Incentives are exercisable
in installments, then the installments or portions thereof which are exercisable and not exercised shall remain exercisable until
such Incentives expire or terminate in accordance with the provisions herein.
|
|
16.
|
Notwithstanding any other provision of the Israeli Plan but subject to
Section 7.1
of the
Incentive Plan, no Incentive shall be exercisable or otherwise valid after a date ten years from the date of grant of such Award
(the “
Expiration Date
”).
|
|
17.
|
Unless determined otherwise by the Administrator with regard to all or any of the Participants
or the Options and subject to
Section 7.2
of the Incentive Plan, the Options will be exercisable into Shares, as follows:
|
|
a.
|
One fourth (1/4
th
) of the optioned Shares shall vest and that portion of the Option
shall become exercisable upon the expiration of twelve (12) months after their Date of Grant (the “
First Vesting Date
”),
provided
,
that
the Participant is continuously employed or engaged by a Group Company from the Date of Grant until
the end of First Vesting Date;
|
|
b.
|
an additional one fourth (
1
/
4
th
) of the optioned Shares shall
vest and that portion of the Option shall become exercisable upon the expiration of twenty four (24) months after their Date of
Grant (the “
Second Vesting Date
”),
provided
,
that
that the Participant is continuously
employed or engaged by a Group Company from the First Vesting Date until the end of Second Vesting Date;
|
|
c.
|
an additional one fourth (
1
/
4
th
) of the optioned Shares shall
vest and that portion of the Option shall become exercisable upon the expiration of thirty six (36) months after their Date of
Grant the Award (the “
Third Vesting Date
”),
provided
,
that
the Participant is continuously
employed or engaged by a Group Company from the Second Vesting Date until the end of Third Vesting Date; and
|
|
d.
|
an additional one fourth (
1
/
4
th
) of the optioned Shares shall
vest and that portion of the Option shall become exercisable upon the expiration of forty eight (48) months after their Date of
Grant (the “
Fourth Vesting Date
”),
provided
,
that
the Participant is continuously employed
or engaged by a Group Company from the Third Vesting Date until the end of Forth Vesting Date.
|
ARTICLE VI
Exercise of Options, Termination
|
18.
|
Subject to Article X (Trustee) below and as more fully provided in
Section 8.3
of the Incentive
Plan, the exercise of any Option shall be effected by a Participant signing and returning to the Company at its principal office
a notice of exercise in the form prescribed from time to time by the Company or the Committee (a “
Notice of Exercise
”),
along with payment for the Incentive Shares purchased thereby. Such payment will be made in dollars or shekels in accordance with
the terms of the specific Award Agreement.
|
|
19.
|
Subject to Article X (Trustee) below, the Company shall issue Incentive Shares, in the name of
the respective Participant, and deliver to him a certificate or certificates, as the case may be, representing such Shares as soon
as practicable after a Notice of Exercise and payment for the Shares shall be received. If Article X (Trustee) applies, then exercise
of the Incentives will be subject to the agreement with the Trustee, as that term is defined below, and in accordance with Section
102 of the Ordinance.
|
|
20.
|
The Company may, if required under any Applicable Law, require that an Participant deposit with
the Company, in cash, at the time of exercise, such amount as the Company deems necessary to satisfy its obligations to withhold
taxes or other amounts incurred by reason of the exercise or the transfer of Shares thereupon.
|
|
21.
|
All Shares purchased upon the exercise of an Option or other grant of an Incentive as provided
herein shall be fully paid and non-assessable.
|
|
22.
|
In the event that an Option is exercised by any person or persons other than the Participant, pursuant
to Article VII (Non-Transferability of Incentive Rights), such Notice of Exercise shall be accompanied by appropriate proof of
the right of such person or persons to exercise the Option.
|
|
23.
|
If the Participant shall cease to be employed or engaged by a Group Company, as the result of his
resignation, then the Participant shall have the right to exercise the Options, but only to the extent that the Options are exercisable
as of the date Participant resigns (according to the provisions of Article V (Terms of Awards)), within thirty (30) days as of
the Termination Date.
|
|
24.
|
If the Participant shall cease to be employed or engaged by a Group Company, as the result of his
dismissal without Cause, then the Participant shall have the right to exercise the Options, but only to the extent that the Options
are exercisable on the date of Participant’s dismissal (according to the provisions of Article V (Terms of Awards)), within
sixty (60) days after the Termination Date.
|
|
25.
|
If the Participant shall cease to be employed or engaged by a Group Company as the result of his
disability or retirement with the consent of the Group Company, then the Option, to the extent that it is exercisable by him at
the time he ceases to be employed or engaged by the Group Company, and only to the extent that the Option is exercisable as of
such time as defined in Article V (Terms of Awards), may be exercised by him within one (1) year, after the Termination Date.
|
|
26.
|
If the Participant shall die while employed or engaged by a Group Company, his estate, personal
representative, or beneficiary shall have the right, subject to the provisions of Article V (Terms of Options), to exercise the
Option (to the extent that the Participant would have been entitled to do so at the time of his death) at any time within two (2)
years from the date of his death.
|
|
27.
|
If the Participants shall be terminated for Cause, then, all Options, whether exercisable or not
on the date that the Group Company delivers to the employee a termination notice, will expire and may not be further exercised.
|
|
28.
|
For the purpose of this Israeli Plan, “
Cause
” shall exist if the Participant
(i) breaches any of the material terms or conditions of his employment agreement, or agreement to provide services to the Group
Company, including, without limitation, the breach of any duty of non-disclosure or non-competition; (ii) engages in willful misconduct
or acts in bad faith with respect to any Group Company in connection with his employment or other agreement with a Group Company;
or (iii) is convicted of a felony.
|
|
29.
|
In the event of the institution of any legal proceedings directed to the validity of the Israeli
Plan or any Option, the Company may, in its sole discretion, and without incurring any liability therefore to the Participant,
terminate the Option.
|
|
30.
|
All terms and conditions herein are subject to any Applicable Law.
|
|
31.
|
For purposes of this Article VI, “
Termination Date
” shall mean the date
on which Participant’s employment or engagement with a Group Company is terminated.
|
ARTICLE VII
Non-Transferability of Incentive Rights
|
32.
|
An Incentive that is granted hereunder shall not be transferable otherwise than by will or the
laws of descent and distribution. To the extent provided in Article VI (Exercise of Options, Termination), an Option may be exercised,
during the lifetime of the Participant, only by the Participant. More particularly (but without limiting the generality of the
foregoing), the Option may not be assigned, transferred (except as provided above), pledged or hypothecated in any way, shall not
be assignable by operation of law, and shall not be subject to execution, attachment or similar process. Any attempted assignment,
transfer, pledge, hypothecation or other disposition of an Incentive contrary to the provisions of the AwardAgreement or the Israeli
Plan, and the levy of any execution, attachment, or similar process upon the Incentive, shall be null and void and without effect;
provided, however, that if the Participant shall die while in the employ of the Company or any subsidiary, his estate, personal
representative, or beneficiary shall have the right to exercise the Option to the extent exercisable in accordance with Article
VI (Exercise of Options, Termination).
|
ARTICLE VIII
Adjustments
|
33.
|
Except as otherwise provided by
Section 12.4
of the Incentive Plan, upon the occurrence
of any of the following events (each a “
Transaction
”):
|
|
a.
|
a merger or consolidation of the Company (a “
Merger
”) with or into any
company (the “
Successor Company
”) resulting in the Successor Company being the surviving entity; or
|
|
b.
|
an acquisition of: (i) all or substantially all of the shares or assets of the Company in one or
more related transactions to another party (a “
Share Sale
”), or (ii) all or substantially all of the
assets of the Company, in one or more related transactions to another party, in each case such acquirer of shares or assets is
referred to herein as the “
Acquiring Company
”;
|
for any unexercised Incentive
remain outstanding under the Israeli Plan (the “
Unexercised Incentive
”), there shall be substituted for
the Shares subject to the Unexercised Incentive an appropriate number of shares of such class of shares or other securities of
the Successor Company or the Acquiring Company, as the case may be (or, if such company is not an operating company, of the first
operating company in the ownership chain of such company) (the “
Substitute Shares
”). Appropriate equitable
adjustments shall be made in the purchase price per share of the Substitute Shares subject to the Unexercised Incentive, and all
other terms and conditions of the Award Agreements, such as the vesting dates, shall remain in force, all as will be determined
by the Board whose determination shall be final.
|
34.
|
The Committee shall have full authority to determine any provisions regarding the acceleration
of the vesting period of any Incentive or the cancellation of all or any portion of any outstanding restrictions with respect to
any Incentive upon certain events or occurrences, and to include such provisions in the Award Agreement on such terms and conditions
as the Committee shall deem appropriate.
|
|
35.
|
Subject to Applicable Law, the Committee shall have full authority to, at any time and from time
to time, without the approval of the stockholders of the Company, (i) grant in its discretion to the holder of an outstanding Incentive,
in exchange for the surrender and cancellation of such Incentive, a new Incentive having an exercise price or purchase price, as
the case may be, lower than provided in the Award (and related Award Agreement) so surrendered and canceled and containing such
other terms and conditions as the Committee may prescribe in accordance with the provisions of the Israeli Plan and any Applicable
Law, or (ii) effectuate a decrease in the Incentive Price of outstanding Incentives
.
At the
full discretion of the Administrator,
such actions may be brought before the stockholders of the Company for their approval.
|
|
36.
|
In the event of a Share Sale or a Merger, each Participant shall participate in the Share Sale
or the Merger and sell or exchange, as the case may be, all of his or her Shares and Incentives in the Company,
provided
,
however
, that each such Share or Incentive shall be sold or exchanged at a price or ratio (as the case may be) equal to
that of any other share sold or exchanged under the Share Sale or the Merger (minus the applicable exercise price), while accounting
for changes in such price or ratio due to the respective terms of any such Award.
|
|
37.
|
With respect to Incentive Shares held in trust the following procedure will be applied: the Trustee
(as defined below) will transfer the Incentive Shares held in trust and sign any document in order to effectuate the transfer of
Incentive Shares, including share transfer deeds,
provided
,
however
, that the Trustee receives a notice from the
Board, specifying that: (i) all or substantially all of the issued outstanding share capital of the Company is to be sold or exchanged,
and therefore the Trustee is obligated to transfer the Incentive Shares held in trust; (ii) the Company is obligated to withhold
at the source all taxes required to be paid upon release of the Incentive Shares from the trust and to provide the Trustee with
evidence, satisfactory to the Trustee, that such taxes indeed have been paid; (iii) the Company is obligated to transfer the consideration
for the Incentive Shares directly to the Participant.
|
ARTICLE IX
Changes in Capitalization
|
38.
|
In case of any change in capitalization event as provided in
Article 11
of the Incentive
Plan, appropriate equitable adjustments shall be made by the Board, whose determination shall be final, to the number of Shares
which may be purchased under the Israeli Plan, the number of Shares subject to Awards, and the Incentive Price per Share which
may be purchased under outstanding Award Agreements, all as in accordance with
Article 11
of the Incentive Plan.
|
ARTICLE X
Trustee
|
39.
|
Approved 102 Incentives granted under the Israeli Plan and any Shares allocated or issued upon
exercise of such Approved 102 Incentives, including all rights attaching to such shares, and other shares received subsequently
following any realization of rights (including bonus shares), will be allocated or issued to a trustee nominated by the Board (the
“
Trustee
”) and approved in accordance with the provisions of Section 102 of the Ordinance, and will be
held by the Trustee for the benefit of the Participants.
|
|
40.
|
Approved 102 Incentives and any Shares received following exercise of Approved 102 Incentives,
including all rights attached to such Shares, and other Shares received subsequently following any realization of rights (including
bonus Shares), will be held by the Trustee for a period of (i) at least twenty four (24) months from the Date of Grant of the Capital
Gain Incentives , or (ii) at least twelve (12) months from the Date of Grant of the Work Income Incentives (the “
Trust
Period
”). If the requirements for Approved 102 Incentives are not met, then the Approved 102 Incentives will be
regarded as Unapproved 102 Incentives. Notwithstanding the aforesaid, Shares received upon the exercise of Incentives may be sold
or transferred, and the Trustee may release such Shares (or Approved 102 Incentives) from trust, prior to the lapse of the Trust
Period, provided, however, that tax is paid or withheld in accordance with Section 102(b)(4) of the Ordinance and Section 7 of
the Income Tax Rules (Tax Relief in Issuance of Shares to Employees), 2003. However, the Administrator may, in its sole discretion,
require a Participant not to sell the Shares or transfer the Incentives in the Participant’s name prior to the lapse of the
Trust Period.
|
|
41.
|
All rights attaching to any Shares received following exercise of Approved 102 Incentives, and
other shares received subsequently following any realization of rights (including bonus Shares), will be subject to the same taxation
treatment applicable to such received Shares.
|
|
42.
|
Section 3(i) Incentives granted under the Israeli Plan and any Shares allocated or issued upon
exercise of such Section 3(i) Incentives and other Shares received following any realization of rights, in the Administrator’s
discretion, may be allocated or issued to a Trustee and will be held by the Trustee until all of the terms required for release
thereof, as set forth herein and in the applicable Award agreement with the Participant, are fulfilled, including payment of the
required taxes. Anything to the contrary notwithstanding, the Trustee shall not transfer to a Participant any Section 3(i) Incentives
which were not already exercised into Shares by the Participant.
|
|
43.
|
The Trustee shall not transfer to the Participant any Shares allocated or issued upon exercise
of Incentives prior to the full payment of the Participant’s tax liabilities arising from or relating to Incentives, which
were granted to the Participant or any Shares allocated or issued upon exercise of such Incentives.
|
ARTICLE XI
No Obligation to Exercise Incentive
|
44.
|
Granting of an Incentive shall impose no obligation on the recipient to exercise such Incentive.
|
ARTICLE XII
Use of Proceeds
|
45.
|
The proceeds received from the issuance of Shares upon exercise of Incentives pursuant to the Israeli
Plan shall be used for general corporate purposes.
|
ARTICLE XIII
Rights of a Stockholder; Voting Rights
|
46.
|
The Participant shall have no rights of a stockholder with respect to Shares to be acquired by
the exercise of an Incentive until a certificate or certificates representing such Shares are issued to him following exercise
of those Incentives which are fully vested and exercisable. Upon issuance of a certificate or certificates, the Participant shall
have the rights of a stockholder attaching to Shares subject to any restrictions or legends under any law, this Israeli Plan or
the Incentive Plan.
|
ARTICLE XIV
Employment Rights
|
47.
|
Nothing in the Israeli Plan or in any Approved 102 Incentive granted hereunder shall confer on
any Participant who is an employee or service provider any right to continue in the employ of the Company or a Group Company, or
to interfere in any way with the right of the Company or a Group Company to terminate the Participant’s employment or engagement
at any time.
|
ARTICLE XV
Compliance with the Law
|
48.
|
The Company and each of its Affiliates shall be relieved from any liability for the non-issuance
or non-transfer or any delay in issuance or transfer of any Shares subject to Incentives under the Israeli Plan which results from
the inability of the Company or its Affiliates to obtain, or from any delay in obtaining, from any regulatory body having jurisdiction,
all requisite authority to issue or transfer the Shares upon exercise of the Incentives under the Israeli Plan, if counsel for
the Company deems such authority necessary for lawful issuance or transfer of any such shares. Appropriate legends may be placed
on the stock certificates evidencing shares issued upon exercise of Incentives to reflect such transfer restrictions.
|
ARTICLE XVI
Transfer of Shares
|
49.
|
Any issued Shares shall, unless such shares are registered in accordance with the United States
Securities Act of 1933, as amended (the “
Act
”), be sold only in accordance with exemptions under such
Act. There shall be no exercises, transfers, sales or other dispositions of issued Shares unless such shares are either registered
or exempt from registration, provided, however, that such exercise, transfer or other disposition may be subject to any lock up
provision as agreed by the Company.
|
ARTICLE XVII
Investment Representation
|
50.
|
Each Participant exercising any Incentive under the Israeli Plan acknowledges, by virtue of such
exercise, that the Company has not, as of the date of the approval of this Plan by the Board, registered the Shares covered thereby
under the Act. The Participant shall sign and deliver to the Company, if requested, a separate investment representation, certificate
or such other document as may be required by the Company’s counsel, to such effect;
provided
,
however
, that
such Incentive, representation, certificate or other document may provide that the said investment restriction shall not be operative
as to such Shares as may in the future be registered with the Securities and Exchange Commission pursuant to the Act. Furthermore,
the Company may place a legend on any Shares certificate delivered to the Participant to the effect that such Shares were acquired
pursuant to an investment representation and without registration of the Shares.
|
ARTICLE XVIII
Effectiveness and Term of Plan
|
51.
|
This Israeli Plan was originally adopted by the Board on October 25, 2013. The Israeli Plan shall
expire on October 25, 2023, except as to Incentives outstanding on that date. No Incentive shall be granted pursuant to the Israeli
Plan after its expiration. All Shares reserved for issuance under the Israeli Plan, in respect of which the right of a Participant
to purchase the same shall for any reason terminate, expire or otherwise cease to exist, shall again be available for grant through
Incentives under the Israeli Plan.
|
ARTICLE XIX
Amendment or Discontinuance of Plan
|
52.
|
The Board may, without the consent of the stockholders of the Company or the Participants under
the Israeli Plan, at any time terminate the Israeli Plan entirely and at any time, from time to time, amend or modify the Israeli
Plan, provided that no such action shall adversely affect Incentives granted hereunder without the Participant’s consent,
and provided further that no such action by the Board, without the approval of the stockholders, may increase the total number
of Shares which may be purchased pursuant to Incentives granted under the Israeli Plan.
|
ARTICLE XX
Tax Consequences and Other Requirements
|
53.
|
The exercise of an Incentive that is granted hereunder shall be subject to the condition that if
at any time the Company shall determine in its discretion that the satisfaction of withholding tax or other withholding liabilities,
or that the listing, registration, or qualification of any shares otherwise deliverable upon such exercise upon any securities
exchange or under any national, state or federal law, or that the consent or approval of any regulatory body, is necessary or desirable
as a condition of, or in connection with, such exercise in the delivery or purchase of shares pursuant thereto, then in any such
event, such exercise shall not be effective unless such withholding, listing, registration, qualification, consent or approval
shall have been effected or obtained free of any conditions not acceptable to the Company. Any tax obligations arising from the
grant or exercise of an Incentive, from the payment for the Shares covered thereby or from any other event or act (of the Company
or the Participant) hereunder, shall be borne solely by the Participant. Furthermore, the Participant hereby agrees and undertakes
to indemnify the Company, its directors and officers and any Trustee that holds the Incentives, and hold them harmless against
and from any and all liability for any such tax or interest thereon, including without limitation, liabilities relating to the
necessity to withhold, or to have withheld, any such tax from any payment made to the Participants.
|
ARTICLE XXI
Governing Law
|
54.
|
The Israeli Plan and all instruments issued hereunder shall be governed by and interpreted in accordance
with the laws of the State of Israel.
|
ARTICLE XXII
Notices
|
55.
|
Each notice relating to the Israeli Plan shall be in writing and delivered in person or by first
class mail; postage prepaid, to the address as hereinafter provided. Each notice shall be deemed to have been given on the date
it is received. Each notice to the Company shall be addressed to it at its principal offices. Each notice to the Participant or
other person or persons then entitled to exercise an Incentive shall be addressed to the Participant or such other person or persons
at the Participant’s last known address.
|
ARTICLE XXIII
Interpretation
|
56.
|
The interpretation and construction of any terms or conditions of the Israeli Plan, or of the Award
Agreement or other matters related to the Israeli Plan by the Administrator shall be final and conclusive.
|
***************
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024